documents incorporated reference specified portions registrants proxy statement filed commission pursuant regulation connection registrants annual meeting stockholders held may incorporated reference part iii report based closing price per share june excludes shares registrants common stock held executive officers directors stockholders whose ownership exceeds registrants common stock outstanding june exclusion shares construed indicate person possesses power direct indirect direct cause direction management policies registrant person controlled common control registranttable contents gilead sciences inc annual report table contents part item business item risk factors item b unresolved staff comments item properties item legal proceedings item mine safety disclosures part ii item market registrants common equity related stockholder matters issuer purchases equity securities item selected financial data item managements discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data item changes disagreements accountants accounting financial disclosure item controls procedures item b information part iii item directors executive officers corporate governance item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions director independence item principal accountant fees services part iv item exhibits financial statement schedules signatures rights various trademarks copyrights trade names used business including following gilead gilead sciences truvada viread hepsera ambisome emtriva complera eviplera vistide letairis volibris ranexa cayston rapiscan atripla registered trademark belonging bristolmyers squibb gilead sciences llc lexiscan registered trademark belonging astellas us llc macugen registered trademark belonging eyetech inc sustiva registered trademark bristolmyers squibb pharma company tamiflu registered trademark belonging hoffmannla roche inc report also includes trademarks service marks trade names companiestable contents annual report including section entitled managements discussion analysis financial condition results operations contains forwardlooking statements regarding future events future results subject safe harbors created securities act amended securities act securities exchange act amended exchange act words expect anticipate target goal project hope intend plan believe seek estimate continue may could might variations words similar expressions intended identify forwardlooking statements addition statements statements historical fact forward looking statements including statements regarding overall trends operating cost revenue trends liquidity capital needs statements expectations beliefs future plans strategies anticipated events trends similar expressions based forwardlooking statements current expectations future events statements guarantees future performance involve risks uncertainties assumptions difficult predict actual results may differ materially suggested forwardlooking statements various reasons including identified risk factors beginning given risks uncertainties cautioned place undue reliance forward looking statements forwardlooking statements included report made date hereof except required federal securities laws rules regulations securities exchange commission sec undertake specifically decline obligation update statements publicly announce results revisions forwardlooking statements distribution report whether result new information future events changes assumptions otherwise table contents part item business overview gilead sciences inc gilead us incorporated delaware june researchbased biopharmaceutical company discovers develops commercializes innovative medicines areas unmet medical need new discovery experimental drug candidate seek improve care patients suffering lifethreatening diseases around world gileads primary areas focus include human immunodeficiency virus hivaids liver diseases hepatitis b c serious cardiovascularmetabolic respiratory conditions headquartered foster city california operations north america europe asia pacific continue seek add existing portfolio products internal discovery clinical development programs product acquisition inlicensing strategy past year executed philosophy strategy bring bestinclass drugs market keeping strategy completed several acquisitions licensing transactions enhance pipeline also expanded singletablet regimen product offerings treatment hiv launch compleraeviplera emtricitabinerilpivirinetenofovir disoproxil fumarate anticipated launch quad combines four hiv medicines oncedaily singletablet regimen pending food drug administration fda approval largest transaction acquisition pharmasset inc january billion several years focused large proportion research development effort discovering advancing directacting antivirals treatment chronic hepatitis c virus hcv hcv therapeutic market continues vastly underserved due limitations available therapies small fraction individuals infected hcv diagnosed even smaller fraction patients treated prior may first protease inhibitors approved half patients responded standard care combination pegylated interferon ribavirin addition protease inhibitors standard care resulted incremental response rates patients genotype infection however regimen causes substantial side effects fatigue bone marrow suppression potentially debilitating rash anemia neuropsychiatric effects discontinuation rates triple therapy combinations significantly increased last two years progressed several early stage hcv molecules various mechanisms action clinical development field hcv research evolved rapidly became clear hcv portfolio oral antiviral development compounds would difficulty competing behind development programs many competitors acquisition pharmasset gained ownership gs advanced date potent nucleotide analog acts inhibit replication hcv limited safety resistance concerns detected thus far compound studied extensively phase studies genotype infected patients combination ribavirin without pegylated interferon currently studied genotype infected patients first two phase trials known fission evaluating gs genotype patients currently enrolling second phase study genotype patients scheduled begin enrolling next weeks phase data genotype patients consistent data phase trials would expect file new drug application nda treatment genotype patients potential approval late early two thirds hcvinfected individuals united states europe infected hcv genotype conducting phase studies determine efficacy gs plus ribavirin population results studies available next several months expect first data evaluating gs plus ribavirin weeks genotype treatmentnave patients arm quantum study patients available end first quarter expect followed second quarter data arm electron study involving treatmentnave patients treated weeks early third quarter data gs ribavirin treatment weeks arm quantum study become available table contents february announced majority hcv genotype patients prior null response interferoncontaining regimen enrolled arm ongoing electron study experienced viral relapse within four weeks completing weeks treatment gs plus ribavirin ten patients randomized arm electron study data available eight ten patients time announcement among eight patients six experienced viral relapse two patients relapsed however reached two week posttreatment time point data indicate treatment genotype patients classified null responders gs plus ribavirin weeks sufficient cure disease regulatory authorities require patients sustained viral response weeks cessation therapy considered cured disease extent data electron quantum studies indicate genotype treatmentnave patients effectively treated using gs ribavirin larger phase studies genotype patients expected commence able commence phase trials timeline results trials positive expect file nda includes data genotype patients potential approval gs ribavirin sufficiently effective treating genotype treatmentnave patients would need explore combination therapy using gs direct acting antiviral compounds others portfolios would delay development approval gs use genotype treatmentnave patients expect begin clinical studies evaluating gs combination gs nsa inhibitor genotype treatmentnave patients second quarter see risk factor entitled public announcement data clinical studies evaluating gs hcvinfected patients likely cause significant volatility stock price products hivaids atripla efavirenz mg emtricitabine mg tenofovir disoproxil fumarate mg oral formulation dosed day treatment hiv infection adults atripla first oncedaily singletablet regimen hiv intended stand alone therapy combination antiretrovirals fixeddose combination antiretroviral medications viread tenofovir disoproxil fumarate emtriva emtricitabine bristol myerssquibb companys bms nonnucleoside reverse transcriptase inhibitor sustiva efavirenz truvada emtricitabine tenofovir disoproxil fumarate oral formulation dosed day part combination therapy treat hiv infection adults fixeddose combination antiretroviral medications viread emtriva viread oral formulation nucleotide analog reverse transcriptase inhibitor dosed day part combination therapy treat hiv infection patients years age older viread also approved treatment chronic hepatitis b adults compleraeviplera oral formulation dosed day treatment hiv infection treatmentnave adults product marketed united states complera europe eviplera second complete singletablet regimen treatment hiv fixeddose combination antiretroviral medications viread emtriva tibotec pharmaceuticals nonnucleoside reverse transcriptase inhibitor edurant rilpivirine emtriva oral formulation nucleoside analog reverse transcriptase inhibitor dosed day part combination therapy treat hiv infection adults united states europe emtriva also available oral solution approved part combination therapy treat hiv infection children liver disease viread oral formulation nucleotide analog reverse transcriptase inhibitor dosed day treatment chronic hepatitis b adults compensated decompensated liver disease table contents licensed glaxosmithkline inc gsk rights commercialize viread treatment chronic hepatitis b asia certain territories noted viread also approved treatment hiv infection patients years age older combination antiretroviral agents hepsera adefovir dipivoxil oral formulation nucleotide analog polymerase inhibitor dosed day treat chronic hepatitis b patients years age older licensed gsk rights commercialize hepsera treatment chronic hepatitis b asia latin america certain territories cardiovascular letairis ambrisentan oral formulation endothelin receptor antagonist era indicated treatment pulmonary arterial hypertension pah group patients class ii iii symptoms improve exercise capacity delay clinical worsening sublicensed gsk rights ambrisentan marketed gsk volibris ambrisentan pah territories outside united states ranexa ranolazine extendedrelease tablet treatment chronic angina licensed menarini international operations luxembourg sa rights ranexa territories outside united states lexiscanrapiscan regadenoson injection indicated use pharmacologic stress agent radionuclide myocardial perfusion imaging mpi test detects characterizes coronary artery disease patients unable undergo adequate exercise stress astellas us llc exclusive rights manufacture sell regadenoson name lexiscan united states subject obligations pay us royalties based sales lexiscan united states rapidscan pharma solutions inc rps holds exclusive right manufacture sell regadenoson name rapiscan europe certain territories outside united states receive royalties astellas rps sales territories respiratory cayston aztreonam inhalation solution inhaled antibiotic treatment respiratory systems cystic fibrosis cf patients years age older pseudomonas aeruginosa p aeruginosa tamiflu oseltamivir phosphate oral antiviral available capsule form treatment prevention influenza b tamiflu approved treatment influenza children adults countries including united states japan european union tamiflu also approved prevention influenza children adults united states japan european union developed tamiflu f hoffmannla roche ltd together hoffmannla roche inc roche roche exclusive right manufacture sell tamiflu worldwide subject obligation pay us royalties based percentage net sales tamiflu ambisome amphotericin b liposome injection proprietary liposomal formulation amphotericin b antifungal agent treat serious invasive fungal infections caused various fungal species adults corporate partner astellas pharma us inc promotes sells ambisome united states canada promote sell ambisome europe australia new zealand vistide cidofovir injection antiviral injection treatment cytomegalovirus retinitis adult patients aids macugen pegaptanib sodium injection intravitreal injection antiangiogenic oligonucleotide treatment neovascular agerelated macular degeneration macugen table contents developed eyetech inc eyetech using technology licensed us promoted united states eyetech eyetech holds exclusive rights manufacture sell macugen united states pfizer inc pfizer holds exclusive right manufacture sell macugen rest world receive royalties eyetech based sales macugen worldwide following table lists aggregate product sales major products thousands total total total product product product sales sales sales antiviral products atripla truvada viread hepsera compleraeviplera emtriva total antiviral products ambisome letairis ranexa total product sales see item note consolidated financial statements included annual report total revenues geographic area commercialization distribution us international commercial sales operations marketing subsidiaries australia austria belgium canada denmark finland france germany greece hong kong ireland italy netherlands new zealand norway poland portugal south korea spain sweden switzerland turkey united kingdom united states products marketed commercial teams andor conjunction thirdparty distributors corporate partners commercial teams promote products direct field contact physicians hospitals clinics healthcare providers generally grant thirdparty distributors exclusive right promote product territory specified period time agreements distributors provide collaborative efforts distributor gilead obtaining maintaining regulatory approval product specified territory sell distribute atripla truvada viread hepsera complera emtriva ranexa vistide united states exclusively wholesale channel product sales three large wholesalers cardinal health inc mckesson corp amerisourcebergen corp accounted total revenues years ended december combined basis wholesalers accounted approximately product sales united states approximately total worldwide revenues letairis cayston distributed exclusively specialty pharmacies specialty pharmacies dispense medications complex chronic conditions require high level patient education ongoing counseling sell distribute atripla truvada viread hepsera emtriva compleraeviplera ambisome asia australia canada europe latin america middle east new zealand either commercial teams thirdparty distributors corporate partners table contents also rely corporate partners help promote sell products collaboration agreements example bms rights promote atripla united states bms also rights promote atripla majority countries europe limited number central eastern european countries either gilead bms thirdparty distributor sole promoting selling distributing company agreement merck co inc merck promote distribute atripla countries latin america asia pacific either merck existing thirdparty distributors licensed gsk right promote sell viread hepsera treatment hepatitis b certain countries outside united states licensed rights manufacture sell tamiflu macugen lexiscanrapiscan worldwide third parties subject corporate partners obligation pay us royalties based percentage sales products access developing world gilead access program established certain hiv products available substantially reduced prices countries developing world developed system tiered pricing reflects economic status using gross national income per capita gni hiv prevalence approach allows us price therapies based countrys ability pay also support many clinical studies donation products help define best treatment strategies developing world countries example donated tenofovir centre aids programme research south africa caprisa microbicide trial assessed effectiveness safety tenofovirbased microbicide gel prevention hiv infection south african women also provide drugs number innovative international studies investigating whether viread truvada prevent hiv transmission among atrisk uninfected adults potential hiv prevention strategy called preexposure prophylaxis prep december announced submission supplemental nda snda fda approval oncedaily truvada prep reduce risk hiv infection among uninfected adults snda approved truvada would first agent indicated uninfected individuals reduce risk acquiring hiv sex also work closely world health organization nongovernmental organizations provide ambisome treatment leishmaniasis parasitic disease preferential price resource limited settings support numerous clinical studies investigating role ambisome treat visceral cutaneous leishmaniasis developing countries collaborations organizations drugs neglected diseases initiative mdecins sans frontires also support clinical research studies aimed identifying best treatment course visceral leishmaniasis donated ambisome support clinical studies assessing combination therapies costeffectiveness multiple visceral leishmaniasis treatment interventions december signed partnership agreement world health organization donate vials ambisome five years donation used treat patients resourcelimited countries also entered number collaborations related access products developing world include pharmachem technologies grand bahama ltd pharmachem pharmachem one commercial manufacturing partners established facility bahamas manufacture tenofovir disoproxil fumarate active pharmaceutical ingredient viread one active pharmaceutical ingredients atripla truvada resource limited countries cooperative effort pharmachem grand bahama port authority partnership increases manufacturing capacity hiv medicines improve delivery efficiency since medicines produced near markets needed aspen pharmacare holdings ltd aspen entered nonexclusive manufacturing distribution agreement aspen providing manufacture distribution viread truvada treatment hiv infection certain developing world countries included gilead access program amended agreement aspen amended table contents agreement aspen retained right manufacture distribute viread truvada treatment hiv infection developing world countries aspen right purchase viread truvada unlabeled bottles us distribution countries also right manufacture viread truvada using active pharmaceutical ingredient purchased aspen suppliers approved us aspen also granted right manufacture distribute generic versions emtricitabine tenofovir disoproxil fumarate including versions tenofovir disoproxil fumarate combination emtricitabine treatment hiv infection aspen required pay us royalties net sales viread truvada well royalties net sales generic versions tenofovir disoproxil fumarate including versions tenofovir disoproxil fumarate combination generic versions emtricitabine manufactured distributed aspen licenses generic manufacturers entered nonexclusive license agreements thirteen indian generic manufacturers granting rights produce distribute generic versions tenofovir disoproxil fumarate treatment hiv infection low income countries around world includes india many low income countries gilead access program agreements require generic manufacturers meet certain national international regulatory standards include technology transfers enable expeditious production large volumes high quality generic versions tenofovir disoproxil fumarate addition agreements allow manufacture commercial quantities active pharmaceutical ingredient finished product expanded nonexclusive license agreements increase number countries included license also include rights future pipeline products elvitegravir investigational integrase inhibitor cobicistat investigational antiretroviral boosting agent quad combines four hiv medicines oncedaily singletablet regimen pending fda approval expand access viread treatment hepatitis b treatment developing countries also included nonexclusive license agreements ability manufacture distribute generic versions tenofovir disoproxil fumarate treatment hepatitis b countries authorized sell generic versions tenofovir disoproxil fumarate hiv merck entered agreement affiliate merck pursuant gilead merck provide atripla substantially reduced prices hiv infected patients developing countries africa caribbean latin america southeast asia agreement manufacture atripla using efavirenz supplied merck merck handles distribution product countries covered agreement international partnership microbicides ipm conrad entered agreement granted rights ipm conrad cooperating agency us agency international development committed improving reproductive health expanding contraceptive choices women men develop manufacture proven efficacious arrange distribution resource limited countries certain formulations tenofovir use topical microbicide prevent hiv infection medicines patent pool pool entered agreement pool organization established united nations increase global access highquality lowcost antiretroviral therapy sharing patents granted pool nonexclusive license identify generic pharmaceutical manufacturers india specialize highquality production generic medicines grant sublicenses indian manufacturers manufacture distribute generic versions antiretrovirals developing world sublicensees pool free develop combination products pediatric formulations hiv medicines also granted pool right grant sublicenses future pipeline products elvitegravir cobicistat quad generic pharmaceutical manufacturers india distribution developing world tibotec pharmaceuticals tibotec expanded agreement tibotec provide distribution compleraeviplera treatment hiv less developed countries enable commercialization generic versions product table contents competition products target number areas including viral cardiovascular respiratory fungal diseases many commercially available products treatment diseases many companies institutions making substantial investments developing additional products treat diseases products compete available products based primarily efficacy safety tolerability acceptance doctors ease patient compliance patent protection ease use price insurance reimbursement coverage distribution marketing hiv products hiv landscape becoming competitive complex treatment trends continue evolve growing number antihiv drugs currently sold advanced stages clinical development competition current expected competitors may erode revenues receive sales hiv products branded hiv drugs available united states products primarily compete fixeddose combination products nucleotidenucleoside reverse transcriptase inhibitors nrti class including combivir lamivudinezidovudine epzicomkivexa abacavirlamivudine trizivir abacavirlamivudinezidovudine sold joint venture viiv established november gsk pfizer focused hiv therapies hiv products also compete broadly hiv products abbott laboratories inc boehringer ingelheim gmbh merck roche tibotec bmss videx ec didanosine ddi became first generic hiv product united states gsks retrovir zidovudine also faces generic competition united states result launch generic zidovudine bmss zerit stavudine also faces generic competition united states result launch generic stavudine lamivudine marketed viiv competitive emtricitabine active pharmaceutical ingredient emtriva component atripla truvada compleraeviplera may compound patent covering epivir lamivudine expired united states generic lamivudine available united states spain portugal recently received pricing approval italy expect generic versions lamivudine launched countries within european union may generic version combivir lamivudine zidovudine approved recently launched united states addition late generic tenofovir also became available turkey date significant impact generic didanosine zidovudine stavudine lamivudine generic version combivir generic tenofovir turkey price hiv products however price decreases hiv products may result longer term liver disease products hepatitis b virus hbv products viread hepsera face significant competition existing expected therapies treating patients chronic hepatitis b may erode revenues receive sales hbv products hbv products face competition baraclude entecavir oral nucleoside table contents analog developed bms launched united states tyzekasebivo telbivudine oral nucleoside analog developed novartis pharmaceuticals corporation novartis sale united states european union china hbv products also compete epivirhbvzeffix lamivudine developed gsk collaboration shire pharmaceuticals group plc sold major countries throughout north south america europe asia viread hepsera treatment chronic hepatitis b also compete established immunomodulatory therapies including introna interferon alfab sold schering plough corporation major countries throughout north south america europe asia pegasys pegylated interferon alfaa injectable drug similar introna sold roche treatment chronic hepatitis b cardiovascular products letairis competes directly tracleer bosentan sold actelion pharmaceuticals us inc actelion indirectly pah product united therapeutics corporation ranexa competes predominantly generic compounds three distinct classes drugs treatment chronic angina united states including generic andor branded betablockers calcium channel blockers longacting nitrates addition surgical treatments interventions coronary artery bypass grafting percutaneous coronary intervention another option angina patients may perceived healthcare practitioners preferred methods treat cardiovascular disease underlies causes angina numerous marketed generic andor branded pharmacologic stress agents compete lexiscanrapiscan clinical data inc developing apadenoson pharmacologic stress agent mpi currently phase clinical trials stress agents product candidates could also compete lexiscanrapiscan respiratory products cayston competes primarily tobi tobramycin inhalation solution inhaled medication sold novartis treatment cf patients whose lungs contain p aeruginosa tamiflu competes relenza zanamivir antiinfluenza drug sold gsk relenza neuraminidase inhibitor delivered orallyinhaled dry powder generic competitors include amantadine rimantadine oral tablets inhibit replication influenza virus biocryst pharmaceuticals inc developing injectable formulations peramivir influenza neuraminidase inhibitor treatment influenza currently phase clinical trials products ambisome faces strong competition several current expected competitors competition current expected competitors may erode revenues receive sales ambisome ambisome faces competition vfend voriconazole developed pfizer caspofungin product developed merck marketed cancidas united states caspofungin elsewhere ambisome also competes lipidbased amphotericin b products including abelcet amphotericin b lipid complex injection sold enzon pharmaceuticals inc united states canada japan zeneus pharma ltd europe amphotec amphotericin b cholesteryl sulfate complex injection sold three rivers pharmaceuticals llc worldwide anfogen amphotericin b liposomal sold genpharma sa argentina bms numerous generic manufacturers sell conventional amphotericin b also competes ambisome table contents aware least two lipid formulations claim similarity ambisome becoming available outside united states including possible entry one formulation greece formulations may reduce market demand ambisome manufacture lipid formulations amphotericin b complex formulations found unsafe sales ambisome may negatively impacted association vistide competes number drugs also treat cytomegalovirus retinitis including cytovene iv cytovene ganciclovir sold intravenous oral formulations respectively roche ocular implant bausch lomb incorporated valcyte valganciclovir also marketed roche foscavir foscarnet intravenous drug sold astrazeneca plc vitravene fomivirsen drug injected directly eye sold cibavision macugen competes primarily visudyne verteporfin injection sold novartis used connection photodynamic therapy lucentis ranibizumab sold genentech inc united states novartis territories outside united states number companies pursuing development technologies competitive research programs competing companies include specialized pharmaceutical firms large pharmaceutical companies acting either independently together pharmaceutical companies furthermore academic institutions government agencies public private organizations conducting research may seek patent protection may establish collaborative arrangements competitive products programs collaborative relationships part business strategy establish collaborations companies universities medical research institutions assist clinical development andor commercialization certain products product candidates provide support research programs also evaluate opportunities acquiring products rights products technologies complementary business companies universities medical research institutions information regarding certain relationships including ongoing financial accounting impact business found item note consolidated financial statements included annual report commercial collaborations although currently number collaborations corporate partners govern manufacture sale distribution andor marketing products various territories worldwide following commercial collaborations significant us financial statement perspective significant ongoing collaboration activity exists roche entered development license agreement roche develop commercialize therapies treat prevent viral influenza tamiflu antiviral oral formulation treatment prevention influenza codeveloped us roche original agreement roche exclusive right obligation manufacture sell tamiflu worldwide subject obligation pay us percentage net sales roche generated tamiflu sales agreement received upfront payment amount million entitled receive additional milestone payments million upon achievement certain development regulatory objectives received milestone payments roche also made cash payment us amount million related reimbursement certain research preclinical development expenses obligation prosecute maintain certain patents agreement entered first amendment supplement original agreement roche amendment eliminated cost goods adjustments royalty calculation retroactive calendar year future calculations amendment also table contents provided formation joint manufacturing committee review roches manufacturing capacity tamiflu global plans manufacturing tamiflu us commercial committee evaluate commercial plans strategies tamiflu united states joint supervisory committee evaluate roches overall commercial plans tamiflu global basis committees consists representatives roche us amendment option provide specialized sales force supplement roches us marketing efforts tamiflu exercised date agreement roches obligation pay royalties us terminate countrybycountry basis patents providing exclusivity tamiflu countries expire roche may terminate agreement reason case rights tamiflu would revert us either party may terminate agreement response material breach party bms entered collaboration bms develop commercialize singletablet regimen truvada bmss sustiva united states combination approved use united states sold brand name atripla bms structured collaboration joint venture forming limited liability company called bristolmyers squibb gilead sciences llc terms collaboration bms granted royalty free sublicenses joint venture use respective company owned technologies return granted license joint venture use intellectual property results collaboration economic interests joint venture held us bms including share revenues outofpocket expenses based portion net selling price atripla attributable truvada sustiva respectively since net selling price truvada may change time relative net selling price sustiva bmss respective economic interests joint venture may vary annually bms share marketing sales efforts parties providing equivalent sales force efforts levels agreed annually bms gilead since second quarter except limited number activities jointly managed parties longer coordinate detailing promotional activities united states parties begun reduce joint promotional efforts canada launch complera anticipation launch quad parties continue collaborate activities manufacturing regulatory compliance pharmacovigilance daily operations joint venture governed four primary joint committees formed bms gilead responsible accounting financial reporting tax reporting product distribution joint venture bms amended joint ventures collaboration agreement allow joint venture sell atripla canada agreement continue terminated mutual agreement parties addition either party may terminate partys participation collaboration within days launch least one generic version partys single agent products double agent products nonterminating party right continue sell atripla obligated pay terminating party certain royalties threeyear period following effective date termination entered collaboration agreement bms sets forth terms conditions bms commercialize atripla european union iceland liechtenstein norway switzerland either bms thirdparty distributor act selling party countries responsible among things receiving processing customer orders warehousing product collecting receivables handling returns manufacturing atripla coordinated us primarily responsible distribution logistics general parties share revenues outofpocket expenses proportion net selling prices truvada respect us efavirenz respect bms starting except limited number activities jointly managed parties longer coordinate detailing promotional activities region agreement terminate upon expiration lasttoexpire patent affords market exclusivity atripla one components european countries covered agreement prior time either party may terminate agreement reason termination effective december nonterminating party right continue table contents sell atripla obligated pay terminating party certain royalties threeyear period following effective date termination event nonterminating party decides sell atripla effective date termination date atripla withdrawn country date third party assumes distribution atripla whichever earlier gsk sublicensed gsk exclusive rights market ambrisentan active pharmaceutical ingredient letairis name volibris pah territories outside united states license agreement received upfront payment million subject achievement specific milestones eligible receive total additional milestone payments million december received million potential milestone payments addition receive royalties based net sales volibris gsk territories gsk option negotiate us exclusive sublicense additional therapeutic uses volibris gsk territories term license agreement agreement continue conduct bear expense clinical development activities believe required obtain maintain regulatory approvals letairis volibris united states canada european economic area party may conduct additional development activities territories expense parties may agree jointly develop ambrisentan new indications licensed field party pay share external costs associated joint development agreement gsks obligation pay royalties us terminate countrybycountry basis earlier date generic equivalents sold country achieve certain percentage total prescriptions product plus generic equivalents fifteenth anniversary commercial launch country gsk may terminate agreement reason upon termination rights product would revert us either party may terminate agreement response material breach party tibotec entered collaboration agreement tibotec develop commercialize fixeddose combination truvada tibotecs rilpivirine combination approved united states european union sold brand name complera united states eviplera european union agreement tibotec granted us exclusive license compleraeviplera worldwide excluding certain middle income developing world countries japan neither party restricted combining drugs drugs december recorded million approximately million reimbursable rd expenses incurred tibotec development rilpivirine maximum amount reimbursable terms agreement responsible manufacturing compleraeviplera lead role registration distribution commercialization product licensed countries tibotec exercised right codetail combination product countries gilead selling party price product expected sum price truvada price rilpivirine purchased separately cost rilpivirine purchased us tibotec compleraeviplera approximate market price rilpivirine less specified percentage thirty percent july amended collaboration agreement include distribution compleraeviplera rest world distribute product north america europe latin america australia new zealand tibotec distribute product regions including japan russia either party may terminate collaboration agreement compleraeviplera withdrawn market party materially breaches agreement may terminate agreement united states canada expiration last expire patent tenofovir disoproxil fumarate united states may terminate agreement country expiration last expire patent tenofovir disoproxil fumarate country european union tibotec may terminate agreement united states canada expiration table contents last expire patent rilpivirine united states may terminate agreement country expiration last expire patent rilpivirine country european union research collaborations currently number collaborations corporate partners govern research development rd certain compounds drug candidates research collaboration japan tobacco inc japan tobacco collaboration significant us financial statement perspective significant ongoing collaboration activity exists japan tobacco entered licensing agreement japan tobacco japan tobacco granted us exclusive rights develop commercialize elvitegravir novel hiv integrase inhibitor countries world excluding japan japan tobacco would retain rights agreement responsible seeking regulatory approval territories required use diligent efforts commercialize product treatment hiv infection bear costs expenses associated commercialization efforts terms agreement paid upfront license fee million obligated make total potential milestone payments million upon achievement certain clinical regulatory commercial objectives additionally obligated pay royalties based net sales territories market product december made total milestone payments million agreement obligation pay royalties japan tobacco terminate productbyproduct basis patents providing exclusivity product expire later tenth anniversary commercial launch product may terminate agreement reason case license granted japan tobacco us would terminate either party may terminate agreement response material breach party research development research development philosophy strategy develop bestinclass drugs improve safety efficacy unmet medical needs apply expertise drug discovery development target specific medical needs new better treatments needed intend continue committing significant resources research development opportunities business development activity product development efforts cover wide range medical conditions including hivaids liver diseases hepatitis b c cardiovascularmetabolic respiratory inflammationoncology diseases research scientists foster city palo alto san dimas oceanside california branford connecticut princeton new jersey seattle washington engaged discovery development new molecules technologies hope lead new medicines novel formulations existing drugs development product candidates subject various risks uncertainties risks uncertainties include ability enroll patients clinical trials possibility unfavorable results clinical trials need modify delay clinical trials perform additional trials risk failing obtain regulatory approvals result product candidates may never successfully commercialized drug development inherently risky many product candidates fail drug development process table contents summary key product candidates corresponding current stages development additional information development pipeline visit website wwwgileadcom product candidates treatment hiv product candidates description marketing application pending integrase october submitted new drug application nda us food drug administration fda singletablet marketing approval oncedaily singletablet quad regimen elvitegravir cobicistat tenofovir regimen quad disoproxil fumarate emtricitabine december fda accepted nda review set target review date august addition fda indicated panel would convened may timeframe provide expert advice application also december announced submitted marketing authorization application european medicines agency marketing approval singletablet regimen phase cobicistat cobicistat pharmacoenhancer evaluation boosting agent certain hiv medicines treatmentnave patients based positive clinical trial results expect submit nda product second quarter elvitegravir elvitegravir oral integrase inhibitor evaluated part combination therapy hiv treatmentexperienced patients based positive clinical trial results expect submit nda product second quarter phase gs gs nucleotide reverse transcriptase inhibitor evaluated treatment hivaids product candidates treatment liver disease product candidates description phase gs gs nucleotide nsb inhibitor evaluation treatment hcv currently enrolling genotype patients phase clinical program gs ribavirin also evaluating gs combination ribavirin genotype treatmentnave null responder patients null responders patients respond earlier interferonbased therapy february announced majority hcv genotype patients prior null response interferoncontaining regimen enrolled arm ongoing electron study experienced viral relapse within four weeks completing weeks treatment gs plus ribavirin ten patients randomized arm electron study data available eight ten patients time announcement among eight patients six experienced viral relapse two patients relapsed however reached two week post treatment time point data genotype null responder table contents product candidates description arm study presented upcoming scientific conference data indicate treatment genotype patients classified null responders gs plus ribavirin weeks sufficient cure disease expect receive data ongoing studies treatmentnave patients gs ribavirin next several months described overview item business phase gs gs oral nsa inhibitor evaluation treatment hepatitis c gs gs ns oral protease inhibitor evaluated treatment hepatitis c gs gs oral ns protease inhibitor evaluated treatment hepatitis c clinical trials planned time product candidates description tegobuvir gs tegobuvir gs oral nsb nonnucleoside polymerase inhibitor evaluated treatment hepatitis c gs gs monoclonal antibody evaluated treatment liver fibrosis phase gs gs nucleoside reverse transcriptase inhibitor evaluation treatment hepatitis b gs gs oral tlr agonist treatment hepatitis b hepatitis c gs gs nonnucleoside polymerase inhibitor evaluation treatment hepatitis c clinical trials planned time product candidates treatment cardiovascularmetabolic diseases product candidates description phase ranolazine ranolazine late sodium current inhibitor approved treatment chronic angina also evaluated treatment incomplete revascularization postpercutaneous coronary intervention treatment type ii diabetes expect complete phase trial evaluating ranolazine treatment incomplete revascularization postpercutaneous coronary intervention first half phase trial evaluating ranolazine treatment treatment type ii diabetes second half table contents product candidates treatment respiratory diseases product candidates description phase aztreonam inhalation solution aztreonam inhalation solution evaluated treatment bronchiectasis expect complete enrollment two phase trials early phase gs gs monoclonal antibody evaluated treatment idiopathic pulmonary fibrosis product candidates treatment inflammationoncology diseases product candidates description phase gs gs pik delta inhibitor antibody evaluated treatment chronic lymphocytic leukemia expect complete enrollment first phase trial gs treatment chronic lymphocytic leukemia first half phase gs gs pik delta inhibitor antibody evaluated treatment indolent nonhodgkins lymphoma gs gs monoclonal antibody evaluated treatment myelofibrosis colorectal cancer pancreatic cancer phase gs gs syk inhibitor evaluated treatment rheumatoid arthritis total rd expenses billion compared billion million addition internal discovery clinical development programs seek add portfolio products product acquisitions collaborations following table shows recent acquisitions year company therapeutic area cv therapeutics inc cardiovascular disorders cgi pharmaceuticals inc serious inflammatory diseases arresto biosciences inc fibrotic diseases cancer calistoga pharmaceuticals inc cancer inflammatory diseases pharmasset inc chronic hepatitis c virus largest transaction acquisition pharmasset inc january billion pharmasset clinicalstage pharmaceutical company located princeton new jersey committed discovering developing commercializing novel drugs treat viral infections pharmassets primary focus development oral therapeutics treatment hcv infection acquisition pharmasset gained ownership gs advanced date potent nucleotide analog acts inhibit replication hcv limited safety resistance concerns detected thus far see risk factor entitled public announcement data clinical studies evaluating gs hcvinfected patients likely cause significant volatility stock price table contents patents proprietary rights us european patent expiration number us foreign patents patent applications rights patents related compounds products technology certain issued patents enforceable provide adequate protection pending patent applications result issued patents following table shows estimated expiration dates united states europe primary patents patents may issue pending applications phase product candidates phase product candidates patent expiration product candidates treatment hiv us eu cobicistat elvitegravir integrase singletablet regimen quad product candidate treatment liver disease gs product candidate treatment respiratory diseases aztreonam inhalation solution treatment bronchiectasis product candidate treatment cardiovascularmetabolic diseases ranolazine treatment incomplete revascularization postpercutaneous coronary intervention treatment type ii diabetes reflect possible patent term restoration future supplementary protection certificates depending circumstances surrounding regulatory approval product may patents could relevance product finally approved application pending based patent expiration date elvitegravir one components quad following table shows actual estimated expiration dates united states europe primary patents patents may issue pending applications cover compounds marketed products us european patent patent products expiration expiration vistide hepsera letairis ambisome tamiflu macugen viread ranexa lexiscan emtriva truvada atripla cayston compleraeviplera supplementary protection certificate spc protection obtained certain european countries confer auxiliary form patent exclusivity indicated table contents pediatric exclusivity granted extending patent expiration pediatric exclusivity granted extending patent expiration based patent expiration date viread one components truvada based patent expiration date viread one components atripla based patent expiration date edurant one components compleraeviplera patent protection certain challenges patents proprietary rights important business properly designed enforceable patent difficult competitors use technology create competitive products difficult competitors obtain patent prevents us using technology create part business strategy actively seek patent protection united states internationally file additional patent applications appropriate cover improvements compounds products technology also rely trade secrets internal knowhow technological innovations agreements third parties develop maintain protect competitive position ability competitive depend success strategy patents covering active pharmaceutical ingredients atripla truvada viread emtriva compleraeviplera hepsera letairis vistide lexiscan held third parties acquired exclusive rights patents agreements parties patents cover ranolazine active ingredient ranexa instead discovered sustained release formulation ranolazine would achieve therapeutic plasma levels patents obtained formulations characteristic plasma levels achieve patents cover active ingredients ambisome instead hold patents liposomal formulations compound also protect formulations trade secrets addition patent filings china certain asian countries covering forms adefovir dipivoxil active ingredient hepsera asia major market therapies hepatitis b indication hepsera developed may obtain patents certain products many years obtain marketing approval products patents limited life may begin run prior commercial sale related product commercial value patent may limited however may able apply patent term extensions example extensions patents many products granted united states number european countries compensating part delays obtaining marketing approval similar patent term extensions may available products developing certain obtain also important infringe patents proprietary rights others violate agreements grant proprietary rights us infringe patents violate agreements could prevented developing selling products using processes covered patents agreements could required obtain license third parties allow us use technology certain required could obtain license thirdparty technology could obtain one reasonable cost able obtain required license alternative technologies may unable develop commercialize products business could adversely affected example aware body patents may relate operation letairis education access program leap restricted distribution program designed support letairis addition patents claim gs chemical entity metabolites however existence issued patents guarantee right practice patented technology commercialize patented product third parties may obtain rights patents may claim could used prevent attempt prevent us commercializing patented product candidates obtained pharmasset acquisition example aware patents patent applications owned parties might alleged cover use gs parties successful obtaining valid enforceable patents establishing infringement patents could prevented selling gs unless able obtain license patents license needed may available commercially reasonable terms table contents gilead successor pharmasset inc party collaboration agreement roche develop psi prodrugs treatment chronic hcv infection collaborative research efforts agreement ended december roche later asked pharmasset consider whether roche may contributed inventorship gs whether pharmasset complied confidentiality provisions collaboration agreement pharmasset advised us carefully considered issues raised roche believed issues without merit also considered issues reached conclusion however roche successfully assert contributed inventorship gs either independently develop gs file abbreviated new drug application anda market gs roche could point future market product begin competing us prior expiration patents gs marketing activity roche could materially reduce revenues expect receive sale gs could adversely affect results operations patent applications confidential period time patent issued may know competitors filed patent applications technology covered pending applications first invent technology subject patent applications competitors may filed patent applications received patents may obtain additional patents proprietary rights block compete patents competitors file patent applications covering technology may participate interference proceedings litigation determine right patent litigation interference proceedings expensive even ultimately successful results operations may adversely affected participation events patents relating pharmaceutical biopharmaceutical biotechnology products compounds processes cover existing compounds products processes likely file future always provide complete adequate protection future litigation examination proceedings regarding enforcement validity existing patents future patents could invalidate patents substantially reduce protection example public patent foundation filed requests reexamination united states patent trademark office pto challenging four patents related tenofovir disoproxil fumarate active ingredient atripla truvada compleraeviplera viread pto granted requests issued nonfinal rejections four patents step common proceeding initiate reexamination process pto confirmed patentability four patents although successful responding pto actions instance similar organizations may still challenge patents us foreign jurisdictions example april brazilian health ministry citing us patent reexamination proceedings grounds rejection requested brazilian patent authority issue decision supportive patent application tenofovir disoproxil fumarate brazil august examiner brazilian patent authority issued final rejection fumarate salt patent application patent application tenofovir disoproxil fumarate filed brazil filed appeal within patent authority responding questions raised rejection july brazilian patent authority rejected application highest level appeal available us within brazilian patent authority filed civil action brazilian federal court appeal action brazilian patent authority currently patent brazil brazilian government purchased supply tenofovir disoproxil fumarate generic manufacturers result sell hiv products brazil another example indian civil procedure several parties filed oppositions grant patent applications covering tenofovir disoproxil tenofovir disoproxil fumarate august indian patent office announced decided actions us would therefore allow patents granted filed appeal within indian patent office intellectual property appellate board applications predict outcome proceedings unsuccessful appeal decisions appeals pursued indian court system may ultimately prove unsuccessful meantime competitor able sell generic tenofovir disoproxil fumarate india table contents addition unsuccessful appealing negative decisions indian patent office indian courts competitors would able continue sell generic tenofovir disoproxil fumarate pending patent applications patent applications filed collaborative partners may result issuance patents may result patents provide adequate protection result may able prevent third parties developing compounds products closely related developed developing addition certain countries africa asia including china provide effective enforcement patents thirdparty manufacturers able sell generic versions products countries abbreviated new drug applications filed generic manufacturers part approval process products fda granted exclusivity period manufacturers applications approval generic versions product granted generic manufacturers often wait challenge patents protecting products granted exclusivity one year prior end exclusivity period time time received notices manufacturers indicating intend import chemical intermediates possibly use making products generic manufacturers sought may continue seek fda approval similar identical drug anda application form typically used manufacturers seeking approval generic drug example november received notice teva pharmaceuticals teva submitted anda fda requesting permission manufacture market generic version truvada notice teva alleges two patents associated emtricitabine invalid unenforceable andor infringed tevas manufacture use sale generic version truvada december filed lawsuit teva infringement two emtricitabine patents march received notice teva submitted anda fda requesting permission manufacture market generic version atripla notice teva challenged two emtricitabine patents may filed another lawsuit teva infringement two emtricitabine patents lawsuit consolidated lawsuit filed december january received notice teva submitted anda fda requesting permission manufacture market generic version viread notice teva challenged four tenofovir disoproxil fumarate patents protecting viread january also received notices teva amending andas related atripla truvada notice related truvada teva challenged four patents related tenofovir disoproxil fumarate two additional patents related emtricitabine notice related atripla teva challenged four patents related tenofovir disoproxil fumarate two additional patents related emtricitabine two patents related efavirenz march filed lawsuit teva infringement four viread patents two additional emtricitabine patents march bms merck filed lawsuit teva infringement patents related efavirenz june received notice lupin limited lupin submitted anda fda requesting permission manufacture market generic version ranexa notice lupin alleges ten patents associated ranexa invalid unenforceable andor infringed lupins manufacture use sale generic version ranexa july filed lawsuit lupin infringement patents ranexa august received notice sigmapharm labs sigmapharm submitted anda fda requesting permission manufacture market generic version hepsera notice sigmapharm alleges patents associated hepsera invalid unenforceable andor infringed sigmapharms manufacture use sale generic version hepsera september filed lawsuit sigmapharm infringement patents hepsera one patents challenged sigmapharm also challenged ranbaxy inc ranbaxy pursuant notice received october patent challenged ranbaxy expires july option filing lawsuit time believe ranbaxy infringing patent table contents february received notice natco pharma limited natco submitted anda fda requesting permission manufacture market generic version tamiflu notice natco alleges one patents associated tamiflu invalid unenforceable andor infringed natcos manufacture use sale generic version tamiflu march roche filed lawsuit natco infringement patent associated tamiflu november received notice teva submitted abbreviated new drug submission ands canadian ministry health requesting permission manufacture market generic version truvada product notice teva alleges three patents associated truvada invalid unenforceable andor infringed tevas manufacture use sale generic version truvada january filed lawsuit teva seeking order prohibition approval ands december received notice teva submitted ands canadian ministry health requesting permission manufacture market generic version atripla product notice teva alleges three patents associated atripla two mercks patents associated atripla invalid unenforceable andor infringed tevas manufacture use sale generic version atripla february filed lawsuit teva seeking order prohibition approval ands predict ultimate outcome actions may spend significant resources enforcing defending patents unsuccessful lawsuits original claims patents may narrowed invalidated patent protection atripla truvada viread hepsera ranexa tamiflu united states atripla truvada canada could substantially shortened patents covering products invalidated fda could approve requests manufacture generic version products prior expiration date patents trade secrets also rely unpatented trade secrets improvements unpatented internal knowhow technological innovation particular great deal liposomal manufacturing expertise key component liposomal technology covered patents instead protected trade secret protect rights mainly confidentiality agreements corporate partners employees consultants vendors agreements provide confidential information developed made known individual course relationship us kept confidential used disclosed third parties except specified circumstances case employees agreements provide inventions made individual employed us exclusive property certain parties comply confidentiality agreements adequate remedies breach trade secrets otherwise become known independently discovered competitors rd agreements inventions become jointly owned us corporate partner cases become exclusive property one party certain circumstances difficult determine owns particular invention disputes could arise regarding inventions manufacturing raw materials manufacturing strategy contract third parties manufacture majority active pharmaceutical ingredients solid dose products also rely corporate partners manufacture certain products additionally lease manufacturing facilities san dimas california edmonton alberta canada cork ireland oceanside california manufacture certain products active pharmaceutical ingredients clinical commercial uses table contents manufacturing products contract third parties manufacture certain products clinical commercial purposes including atripla truvada viread hepsera compleraeviplera emtriva ranexa vistide use multiple thirdparty contract manufacturers manufacture tenofovir disoproxil fumarate active pharmaceutical ingredient viread one active pharmaceutical ingredients atripla truvada compleraeviplera emtricitabine active pharmaceutical ingredient emtriva one active pharmaceutical ingredients atripla truvada compleraeviplera rely single thirdparty manufacturer manufacture active pharmaceutical ingredients ranexa cayston exclusive manufacturer active pharmaceutical ingredients hepsera letairis vistide also rely thirdparty contract manufacturers tablet capsulate products example use multiple thirdparty contract manufacturers tablet atripla truvada viread hepsera compleraeviplera ranexa emtriva encapsulation also completed thirdparty contract manufacturers rely single thirdparty supplier manufacture letairis tablets also manufacturing agreements many corporate partners roche third parties responsible manufacturing tamiflu agreement roche joint manufacturing committee composed representatives roche us opportunity review roches existing manufacturing capacity tamiflu global plans manufacturing tamiflu astellas us llc corporate partner lexiscan united states responsible commercial manufacture supply product united states dependent single supplier active pharmaceutical ingredient lexiscan pari pharma gmbh responsible manufacturing device required administer cayston lungs patients device made single supplier single site future products continue develop additional manufacturing capabilities establish additional thirdparty suppliers manufacture sufficient quantities product candidates undertake clinical trials manufacture sufficient quantities product approved commercial sale unable develop manufacturing capabilities internally contract large scale manufacturing third parties acceptable terms future products ability conduct large scale clinical trials meet customer demand commercial products adversely affected manufacturing facilities san dimas facility manufacture fill package products currently manufacture cayston exclusively san dimas california manufacturing facility due unexpected delays qualifying two new external sites expanding cayston manufacturing san dimas supply enough cayston fulfill projected demand february suspended access patients new prescriptions cayston subject certain exceptions specific medical need exists patients may use alternative treatment options able resolve supply shortage result inability manufacture sufficient cayston meet demand amount revenues expect receive sale cayston reduced single supplier ambisome san dimas facility depend single supplier high quality cholesterol used manufacture ambisome fill finish macugen exclusively facilities san dimas manufacturing agreements eyetech pfizer eyetech currently provides us pegaptanib sodium active pharmaceutical ingredient macugen also fill package solid dosage form products including atripla truvada viread compleraeviplera emtriva ranexa finished forms label hepsera facilities san dimas event disaster including earthquake equipment failure difficulty may unable replace manufacturing capacity timely manner may unable manufacture ambisome macugen meet market needs fill package drug product atripla truvada viread cayston finished forms label hepsera emtriva facilities cork ireland also perform quality control testing final labeling table contents packaging ambisome final release many products european union elsewhere facility utilize cork ireland facility primarily solid dose tablet manufacturing certain antiviral products well product packaging activities distribute products european union international markets dublin ireland site edmonton facility carry process research scaleup clinical development candidates manufacture active pharmaceutical ingredients investigational commercial products conduct chemical development activities improve existing commercial manufacturing processes also manufacture active pharmaceutical ingredients hepsera letairis vistide exclusively edmonton site although another supplier qualified make active pharmaceutical ingredient letairis oceanside facility acquired designed equipped produce biologic compounds toxicological phase phase clinical studies use facility process development manufacture gs investigational monoclonal antibody candidate development treatment certain cancers fibrotic diseases another antibody currently preclinical testing thirdparty manufacturers thirdparty manufacturers corporate partners independent entities subject unique operational financial risks control thirdparty manufacturers corporate partners fail perform required could impair ability deliver products timely basis receive royalties cause delays clinical trials applications regulatory approval extent risks materialize affect performance obligations us financial results may adversely affected believe technology use manufacture products proprietary products manufactured thirdparty contract manufacturers disclosed necessary aspects technology enable manufacture products us agreements thirdparty manufacturers intended restrict manufacturers using revealing technology certain thirdparty manufacturers comply restrictions addition thirdparty manufacturers could develop technology related work perform us may need manufacture products could required enter additional agreements thirdparty manufacturers want use technology allow another manufacturer use technology thirdparty manufacturer could refuse allow us use technology could demand terms use technology acceptable us regulation manufacturing process manufacturing process pharmaceutical products highly regulated regulators may shut manufacturing facilities believe comply regulations thirdparty manufacturers corporate partners subject current good manufacturing practices extensive regulations governing manufacturing processes stability testing record keeping quality standards defined fda european medicines agency similar regulations effect countries manufacturing operations subject routine inspections regulatory agencies example january february fda conducted routine inspection san dimas california manufacturing distribution facility manufacture ambisome cayston fill finish macugen package solid dosage form products conclusion inspection fda issued form inspectional observations stating concerns maintenance aseptic processing conditions manufacturing suite ambisome product environmental maintenance issues san dimas warehousing facility batch sampling timeliness completion annual product quality reports september san dimas manufacturing facility received warning letter fda table contents detailing fdas concerns ambisome manufacturing environment including control systems monitoring procedures prevent microbiological contamination preventative cleaning equipment maintenance referencing certain viread lots letter also stated concerns connected quality procedures controls investigation procedures generalized concern effectiveness san dimas quality unit carrying responsibilities november december fda reinspected san dimas facility reinspection closed additional form observations august fda notified us resolved issues raised fda warning letter access supplies materials need access certain supplies products manufacture products delivery material suppliers interrupted reason unable purchase sufficient quantities raw materials used manufacture products may unable ship certain products commercial supply supply product candidates development clinical trials example significant portion raw materials intermediates used manufacture hiv products atripla truvada viread emtriva compleraeviplera supplied chinesebased companies result international trade dispute china united states actions chinese government would limit prevent chinese companies supplying materials would adversely affect ability manufacture supply hiv products meet market needs material adverse effect operating results seasonal operations backlog worldwide product sales reflect significant degree seasonality however royalty revenues represented approximately total revenues consisted primarily tamiflu royalties affected seasonality royalty revenue recognize roches sales tamiflu impacted severity flu seasons product delivery response influenza pandemics part operate markets characterized short lead times absence significant backlogs believe backlog information material business whole government regulation operations activities subject extensive regulation numerous government authorities united states countries united states drugs subject rigorous fda regulation federal food drug cosmetic act federal state statutes regulations govern testing manufacture safety efficacy labeling storage record keeping approval advertising promotion products result regulations product development product approval processes expensive time consuming fda must approve drug sold united states general process approval follows preclinical testing test drug candidate humans must study drug laboratory experiments animals generate data support drug candidates potential benefits safety submit data fda investigational new drug ind application seeking approval test compound humans table contents clinical trials fda accepts investigational new drug application drug candidate studied human clinical trials determine drug candidate safe effective clinical trials involve three separate phases often overlap take many years expensive three phases subject considerable regulation follows phase drug candidate given small number healthy human control subjects patients suffering indicated disease test safety dose tolerance pharmacokinetics metabolism distribution excretion phase drug candidate given limited patient population determine effect drug candidate treating disease best dose drug candidate possible side effects safety risks drug candidate uncommon drug candidate appears promising phase clinical trials fail rigorous phase clinical trials phase drug candidate appears effective safe phase clinical trials phase clinical trials commenced confirm results phase clinical trials conducted longer term involve significantly larger population conducted numerous sites different geographic regions carefully designed provide reliable conclusive data regarding safety benefits drug candidate uncommon drug candidate appears promising phase clinical trials fail rigorous extensive phase clinical trials fda approval process believe data phase clinical trials show adequate level safety efficacy submit appropriate filing usually form new drug application nda supplemental nda fda seeking approval sell drug candidate particular use fda may hold public hearing independent advisory committee expert advisors asks additional questions makes recommendations regarding drug candidate committee makes recommendation fda binding generally followed fda fda agrees compound met required level safety efficacy particular use allow us sell drug candidate united states use unusual however fda reject application believes drug candidate safe enough efficacious enough believe data submitted reliable conclusive point process development drug candidate stopped number reasons including safety concerns lack treatment benefit certain clinical trials currently conducting conduct future completed successfully within specified time period may choose fda may require us delay suspend clinical trials time appears patients exposed unacceptable health risk drug candidate appear sufficient treatment benefit fda may also require phase nonregistrational studies explore scientific questions characterize safety efficacy commercial use drug fda may also require us provide additional data information improve manufacturing processes procedures facilities may require extensive surveillance monitor safety benefits product candidates determines filing contain adequate evidence safety benefits drug addition even fda approves drug could limit uses drug fda withdraw approvals believe complying regulatory standards problems uncovered occur approval addition obtaining fda approval drug obtain fda approval manufacturing facilities drug sell including companies manufacture drugs us facilities subject periodic inspections fda fda must also approve foreign establishments manufacture products sold united states facilities subject periodic regulatory table contents inspection manufacturing facilities located california including san dimas facilities also must licensed state california compliance local regulatory requirements manufacturing facilities located canada including edmonton alberta facility facilities located near dublin cork ireland also must obtain local licenses permits compliance local regulatory requirements drugs treat serious life threatening diseases conditions adequately addressed existing drugs development program designed address unmet medical need may designated fast track candidates fda may eligible accelerated priority review drugs treatment hiv infection designated use us presidents emergency plan aids relief may also qualify expedited priority review atripla truvada viread complera received accelerated approval priority reviews drugs receiving accelerated approval must monitored postmarketing clinical trials order confirm safety benefits drug drugs also subject extensive regulation outside united states european union centralized approval procedure authorizes marketing product countries european union includes major countries europe centralized approval procedure used approval one country european union used obtain approval another country european union one two simplified application processes mutual recognition procedure decentralized procedure rely principle mutual recognition receiving regulatory approval european registration procedures separate pricing reimbursement approvals also required countries pricing reimbursement successful commercialization products depends part availability governmental thirdparty payer reimbursement cost products related treatments government health administration authorities private health insurers organizations generally provide reimbursement united states european union significant potentially significant markets products product candidates government authorities thirdparty payers increasingly attempting limit regulate price medical products services particularly new innovative products therapies resulted lower average selling prices significant portion sales majority products subject significant discounts list price rebate obligations united states state aids drug assistance programs adaps purchase significant portion hiv products rely federal supplemental federal state funding help fund purchases products given current economic downturn experienced shift payer mix patients previously covered private insurance move public reimbursement programs require rebates discounts us patients previously covered one public reimbursement program move another public reimbursement program requires greater rebates discounts us result shift revenue growth may lower prescription growth federal state funds available amounts sufficient support number patients rely adaps sales hiv products could negatively impacted would reduce revenues example first quarter state budget crisis florida led temporary movement patients previously covered floridas adap industrysupported patient assistance programs due insufficiency federal state funds many states reduced eligibility criteria also seen may continue see increase number patients state adap wait lists patients enrolled adap generally receive product industrysupported patient assistance programs unable access treatment increased emphasis managed healthcare united states country regional pricing reimbursement controls european union put additional pressure product pricing reimbursement usage may adversely affect product sales profitability pressures arise rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid healthcare reform pharmaceutical reimbursement policies pricing general table contents europe success commercialized products product candidates may develop depend largely obtaining maintaining government reimbursement many european countries patients unlikely use prescription drugs reimbursed governments addition negotiating prices governmental authorities delay commercialization months reimbursement policies may adversely affect ability sell products profitable basis many international markets governments control prices prescription pharmaceuticals including implementation reference pricing price cuts rebates revenuerelated taxes profit control expect prices prescription pharmaceuticals decline life product volumes increase recently many countries european union increased amount discounts required products efforts could continue countries attempt manage healthcare expenditures especially light severe fiscal debt crises experienced many countries european union example june spain imposed incremental discount branded drugs august germany increased rebate prescription pharmaceuticals generic drugs come market may face price decreases products countries european union government agencies also issue regulations guidelines directly applicable us products addition time time professional societies practice management groups private healthscience foundations organizations publish guidelines recommendations directed certain health care patient communities recommendations guidelines may relate matters product usage dosage route administration use related competing therapies consequently result increased decreased usage products example recent hiv treatment guidelines united states abroad endorsed earlier diagnosis treatment united states healthcare reform march healthcare reform legislation adopted united states result required rebate discount products reimbursed paid various public payers including medicaid entities eligible purchase discounted products b drug pricing program public health service act adaps discounts rebates fees legislation impacted us include minimum base rebate amount owed medicaid products reimbursed medicaid increased discounts rebates owe adaps public health service entities reimburse purchase products also increased required extend rebates patients receiving products medicaid managed care organizations required provide discount products sold patients medicare part donut hole along pharmaceutical manufacturers branded drug products required pay portion new industry fee also known pharmaceutical excise tax billion calculated based select government sales calendar year percentage total industry government sales amount industry fee imposed pharmaceutical industry whole increase billion additional increases next several years peak billion per year decrease billion thereafter amount industry fee increases product sales increase drug patents expire major drugs lipitor expect portion excise tax increase well estimate impact pharmaceutical excise tax approximately million compared approximately million excise tax tax deductible even though addressed healthcare reform legislation discussions continue federal level legislation would either allow require federal government directly negotiate price concessions pharmaceutical manufacturers set minimum requirements medicare part pricing table contents addition state medicaid programs could request additional supplemental rebates products result increase federal base medicaid rebate private insurers could also use enactment increased rebates exert pricing pressure products extent private insurers managed care programs follow medicaid coverage payment developments adverse effects may magnified private insurers adopting lower payment schedules health care fraud abuse laws antibribery laws subject various federal state laws pertaining health care fraud abuse including antikickback laws false claims laws antikickback laws make illegal prescription drug manufacturer solicit offer receive pay remuneration exchange induce referral business including purchase prescription particular drug due breadth statutory provisions increasing attention given law enforcement authorities possible certain practices may challenged antikickback similar laws false claims laws prohibit anyone knowingly willingly presenting causing presented payment thirdparty payers including medicare medicaid claims reimbursed drugs services false fraudulent claims items services provided claimed claims medically unnecessary items services sales marketing activities may subject scrutiny laws addition us foreign corrupt practices act similar worldwide antibribery laws generally prohibit companies intermediaries making improper payments nonus officials purpose obtaining retaining business policies mandate compliance antibribery laws operate parts world experienced governmental corruption degree certain circumstances strict compliance antibribery laws may conflict local customs practices may require us interact doctors hospitals may state controlled manner different us despite training compliance program internal control policies procedures may protect us reckless criminal acts committed employees agents violations fraud abuse laws antibribery laws may punishable criminal andor civil sanctions including fines civil monetary penalties well possibility exclusion federal health care programs including medicare medicaid government allege convict us violating laws could disruption business material adverse effect results operations compulsory licenses number developing countries government officials interested groups suggested pharmaceutical companies make drugs hiv infection available low cost alternatively governments developing countries could require grant compulsory licenses allow competitors manufacture sell versions products thereby reducing product sales example past certain offices government brazil expressed concern affordability hiv products declared considering issuing compulsory licenses permit manufacture otherwise patented products hiv infection including viread july brazilian patent authority rejected patent application tenofovir disoproxil fumarate active pharmaceutical ingredient viread highest level appeal available us within brazilian patent authority filed civil action brazilian federal court appeal action brazilian patent authority currently patent brazil brazilian government purchased supply tenofovir disoproxil fumarate generic manufacturers result sell hiv products brazil addition concerns cost availability tamiflu related potential avian flu pandemic hn influenza generated international discussions compulsory licensing tamiflu patents example canadian government considered allowing canadian manufacturers manufacture export active ingredient tamiflu eligible developing least developed countries canadas access medicines regime furthermore roche issued voluntary licenses permit thirdparty manufacturing tamiflu example roche granted sublicense shanghai pharmaceutical group co ltd china table contents sublicense indias hetero drugs limited india certain developing countries one compulsory licenses issued permitting generic manufacturing override tamiflu patents roche issue additional voluntary licenses permit thirdparty manufacturing tamiflu developments could reduce royalties receive roches sales tamiflu certain countries permit enforcement patents thirdparty manufacturers able sell generic versions products countries compulsory licenses sales generic versions products could significantly reduce sales adversely affect results operations particularly generic versions products imported territories existing commercial sales employees january approximately fulltime employees believe good relations employees environment health safety voluntarily assessing publicly reporting greenhouse gas emissions water usage begun take action reduce emissions usage example established employee commuter programs evaluated energy efficiency buildings installed lowflow water fixtures various laws regulations implemented consideration mitigate effects climate change caused greenhouse gas emissions example california air resources board process drafting regulations meet state emissions targets based current information subject finalization proposed regulations believe primary risk related climate change risk increased energy costs however energy intensive business anticipate subject cap trade system mitigation measures would likely material capital expenditures results operations competitive position also subject federal state local regulations regarding workplace safety protection environment use hazardous materials chemicals viruses various radioactive compounds rd activities eliminate risk accidental contamination injury materials certain misuse accidents involving materials could lead significant litigation fines penalties implemented proactive programs reduce minimize risk hazardous materials incidents information subject information requirements exchange act therefore file periodic reports proxy statements information sec reports proxy statements information may obtained visiting public reference room sec f street ne washington dc calling sec sec sending electronic message sec publicinfosecgov sending fax sec addition sec maintains website wwwsecgov contains reports proxy information statements information regarding issuers file electronically mailing address headquarters lakeside drive foster city california telephone number location website wwwgileadcom link investors section website sec filings financial information section make available following filings soon reasonably practicable electronically filed furnished sec annual reports quarterly reports form q current reports form k amendments reports filed furnished pursuant section exchange act filings available free charge upon request table contents item risk factors evaluating business carefully consider following risks addition information annual report manifestation following risks could materially adversely affect business results operations financial condition note factors investors permitted private securities litigation reform act possible predict identify factors therefore consider following risks complete statement potential risks uncertainties face public announcement data clinical studies evaluating gs hcvinfected patients likely cause significant volatility stock price expect receive significant amount data clinical trials evaluating gs investigational nucleotide analog acquired purchase pharmasset hcvinfected individuals across genotypes currently conducting phase studies genotype infected hcv patients determine efficacy gs plus ribavirin population results studies available next several months expect first data evaluating gs plus ribavirin weeks genotype treatmentnave patients arm quantum study patients available end first quarter expect followed second quarter data arm electron study involving treatmentnave patients treated weeks early third quarter data gs ribavirin treatment weeks arm quantum study become available february announced majority hcv genotype patients prior null response interferoncontaining regimen enrolled ongoing electron study experienced viral relapse within four weeks completing weeks treatment gs plus ribavirin ten patients randomized arm electron study data available eight ten patients time announcement among eight patients six experienced viral relapse two patients relapsed however reached two week posttreatment time point data indicate treatment genotype patients classified null responders gs plus ribavirin weeks sufficient cure disease addition phase studies described recently began enrolling patients phase study evaluating gs ribavirin genotype infected patients second phase study genotype patients scheduled begin enrolling next weeks data phase studies indicate smaller anticipated number patients achieved sustained viral response weeks posttreatment stock price may decline significantly results could also delay approval gs treatment genotype andor patients could delay andor reduce revenues expected sale gs developing drugs treatment hcv competitive field significant number drugs development depending length delay development gs companies developing competitive compounds hcv may able progress development timelines potentially bring compounds market gs shortly thereafter substantial portion revenues derived sales hiv products particularly atripla truvada unable maintain continue increasing sales products results operations may adversely affected currently dependent sales products treatment hiv infection particularly atripla truvada support existing operations hiv products contain tenofovir disoproxil fumarate andor emtricitabine belong nucleoside class antiviral therapeutics treatment paradigm hiv change causing nucleosidebased therapeutics fall favor unable maintain continue increasing hiv product sales results operations would likely suffer would likely need table contents scale back operations including spending research development rd efforts year ended december atripla truvada product sales together billion total revenues may able sustain increase growth rate sales hiv products especially atripla truvada number reasons including limited following hiv products used longer period time many patients combination products additional studies conducted new issues respect safety resistance interactions drugs may arise could cause us provide additional warnings contraindications labels narrow approved indications halt sales product could reduce revenues hiv products mature private insurers government payers often reduce amount reimburse patients products increases pressure us reduce prices large part market hiv products consists patients already taking hiv drugs successful encouraging physicians change patients regimens include hiv products sales hiv products limited generic hiv products introduced major markets ability maintain pricing market share may affected fail commercialize new products expand indications existing products prospects future revenues may adversely affected introduce new products market increase sales existing products able increase maintain total revenues continue expand rd efforts drug development inherently risky many product candidates fail drug development process example january announced decision terminate phase clinical trial ambrisentan patients idiopathic pulmonary fibrosis ipf april announced decision terminate phase clinical trial aztreonam inhalation solution treatment cystic fibrosis cf patients burkholderia spp addition marketing applications singletablet quad regimen elvitegravir cobicistat tenofovir disoproxil fumarate emtricitabine treatment hiv treatmentnave patients may approved fda european medicines agency even marketing approval granted may significant limitations use may unable file marketing applications elvitegravir cobicistat currently anticipated timelines marketing approval products may granted results operations adversely affected current potential future healthcare reforms legislative regulatory changes government prescription drug procurement reimbursement programs occur relatively frequently united states foreign jurisdictions march healthcare reform legislation adopted united states result required rebate discount products reimbursed paid various public payers including medicaid entities eligible purchase discounted products b drug pricing program public health service act aids drug assistance programs adaps discounts rebates fees legislation impacted us include minimum base rebate amount owed medicaid products reimbursed medicaid increased discounts rebates owe adaps public health service entities reimburse purchase products also increased required extend rebates patients receiving products medicaid managed care organizations required provide discount products sold patients medicare part donut hole table contents along pharmaceutical manufacturers branded drug products required pay portion new industry fee also known pharmaceutical excise tax billion calculated based select government sales calendar year percentage total industry government sales amount industry fee imposed pharmaceutical industry whole increase billion additional increases next several years peak billion per year decrease billion thereafter amount industry fee increases product sales increase drug patents expire major drugs lipitor expect portion excise tax increase well estimate impact pharmaceutical excise tax approximately million compared approximately million excise tax tax deductible even though addressed healthcare reform legislation discussions continue federal level legislation would either allow require federal government directly negotiate price concessions pharmaceutical manufacturers set minimum requirements medicare part pricing addition state medicaid programs could request additional supplemental rebates products result increase federal base medicaid rebate private insurers could also use enactment increased rebates exert pricing pressure products extent private insurers managed care programs follow medicaid coverage payment developments adverse effects may magnified private insurers adopting lower payment schedules existing products subject reimbursement government agencies third parties pharmaceutical pricing reimbursement pressures may reduce profitability successful commercialization products depends part availability governmental thirdparty payer reimbursement cost products related treatments government health administration authorities private health insurers organizations generally provide reimbursement united states european union significant potentially significant markets products product candidates government authorities thirdparty payers increasingly attempting limit regulate price medical products services particularly new innovative products therapies resulted lower average selling prices significant portion sales majority products subject significant discounts list price rebate obligations united states state adaps purchase significant portion hiv products rely federal supplemental federal state funding help fund purchases products given current economic downturn experienced shift payer mix patients previously covered private insurance move public reimbursement programs require rebates discounts us patients previously covered one public reimbursement program move another public reimbursement program requires greater rebates discounts us result shift revenue growth may lower prescription growth federal state funds available amounts sufficient support number patients rely adaps sales hiv products could negatively impacted would reduce revenues example first quarter state budget crisis florida led temporary movement patients previously covered floridas adap industrysupported patient assistance programs due insufficiency federal state funds many states reduced eligibility criteria also seen may continue see increase number patients state adap wait lists patients enrolled adap generally receive product industrysupported patient assistance programs unable access treatment increased emphasis managed healthcare united states country regional pricing reimbursement controls european union put additional pressure product pricing reimbursement usage may adversely affect product sales profitability pressures arise rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid healthcare reform pharmaceutical reimbursement policies pricing general table contents europe success commercialized products product candidates may develop depend largely obtaining maintaining government reimbursement many european countries patients unlikely use prescription drugs reimbursed governments addition negotiating prices governmental authorities delay commercialization months reimbursement policies may adversely affect ability sell products profitable basis many international markets governments control prices prescription pharmaceuticals including implementation reference pricing price cuts rebates revenuerelated taxes profit control expect prices prescription pharmaceuticals decline life product volumes increase recently many countries european union increased amount discounts required products efforts could continue countries attempt manage healthcare expenditures especially light severe fiscal debt crises experienced many countries european union example june spain imposed incremental discount branded drugs august germany increased rebate prescription pharmaceuticals generic drugs come market may face price decreases products countries european union approximately product sales occur outside united states currency fluctuations hedging expenses may cause earnings fluctuate could adversely affect stock price significant percentage product sales denominated foreign currencies primarily euro face exposure adverse movements foreign currency exchange rates us dollar strengthens foreign currencies relative value sales made respective foreign currency decreases conversely us dollar weakens currencies relative value sales increases overall net receiver foreign currencies therefore benefit weaker us dollar adversely affected stronger us dollar relative foreign currencies transact significant amounts business use foreign currency exchange forward option contracts hedge percentage forecasted international sales primarily denominated euro also hedge certain monetary assets liabilities denominated foreign currencies reduces eliminate exposure currency fluctuations date transaction recorded date cash collected paid predict future fluctuations foreign currency exchange rate us dollar us dollar appreciates significantly certain currencies hedging program sufficiently offset effects appreciation results operations adversely affected stock price may decline additionally expenses recognize relation hedging activities also cause earnings fluctuate level hedging expenses recognize particular period impacted changes interest rate spreads foreign currencies hedge us dollar inability accurately estimate demand products well sales fluctuations result inventory levels held wholesalers pharmacies non retail customers make difficult us accurately forecast sales may cause earnings fluctuate could adversely affect financial results stock price approximately product sales united states three wholesalers cardinal health inc mckesson corp amerisourcebergen corp us wholesalers entered inventory management agreements make estimates determine end user demand may completely effective matching inventory levels actual end user demand result changes inventory levels held wholesalers cause operating results fluctuate unexpectedly sales wholesalers match end user demand addition inventory held retail pharmacies nonwholesale locations inventory management agreements control buying patterns adverse changes economic conditions factors may cause retail pharmacies reduce table contents inventories products would reduce orders wholesalers consequently wholesalers orders us even end user demand changed example fourth quarter wholesalers increased inventory levels antiviral products first quarter wholesalers drew inventory inventory levels antiviral products moved lower end contractual boundaries set inventory management agreements inventory distribution channel fluctuates quarter quarter may continue see fluctuations earnings mismatch prescription demand products revenues addition nonretail sector united states includes government institutions including state adaps correctional facilities large health maintenance organizations tends even less consistent terms buying patterns often causes quarter quarter fluctuations necessarily mirror patient demand example first quarter nonretail purchases driven certain state adaps lower percentage federal adap fiscal year purchases compared first quarters believe decrease driven uncertainty regarding amount availability federal adap budget lack sufficient state funding second quarter portion full year federal budget provided adaps resulted conservative purchasing individual state adaps quarter federal state budget pressures well annual grant cycles federal state adap funds may cause adap purchasing patterns reflect patient demand result expect continue experience fluctuations purchasing patterns nonretail customers may result fluctuations product sales revenues earnings future light global economic downturn budget crises faced many european countries observed variations purchasing patterns induced cost containment measures europe believe measures caused purchasers reduce inventory products distribution channels cases even patient level decreased revenues caused fluctuations product sales earnings may continue see trend future face significant competition face significant competition large pharmaceutical biotechnology companies substantially greater resources addition competitors products operated fields compete longer hiv products compete primarily products joint venture established glaxosmithkline inc gsk pfizer inc pfizer markets fixeddose combination products compete atripla truvada compleraeviplera example lamivudine marketed joint venture competitive emtricitabine active pharmaceutical ingredient emtriva component atripla truvada compleraeviplera also face competition generic hiv products may compound patent covering epivir lamivudine expired united states generic lamivudine available united states spain portugal recently received pricing approval italy expect generic versions lamivudine launched countries within european union may generic version combivir lamivudine zidovudine approved recently launched united states addition late generic tenofovir also became available turkey viread hepsera treatment chronic hepatitis b compete primarily products produced gsk bristolmyers squibb company bms novartis pharmaceuticals corporation novartis united states european union china ambisome compete primarily products produced merck co inc merck pfizer addition aware least two lipid formulations claim similarity ambisome becoming available outside united states including possible entry one formulation greece formulations may reduce market demand ambisome furthermore manufacture lipid formulations amphotericin b complex formulations found unsafe sales ambisome may negatively impacted association letairis competes directly table contents product produced actelion pharmaceuticals us inc indirectly pulmonary arterial hypertension products united therapeutics corporation pfizer ranexa competes predominantly generic compounds three distinct classes drugs betablockers calcium channel blockers longacting nitrates treatment chronic angina united states cayston competes product marketed novartis tamiflu competes products sold gsk generic competitors addition number companies pursuing development technologies competitive existing products research programs competing companies include specialized pharmaceutical firms large pharmaceutical companies acting either independently together pharmaceutical companies furthermore academic institutions government agencies public private organizations conducting research may seek patent protection may establish collaborative arrangements competitive products programs significant safety issues arise marketed products product candidates future sales may reduced would adversely affect results operations data supporting marketing approvals products forming basis safety warnings product labels obtained controlled clinical trials limited duration cases postapproval use products used longer periods time many patients underlying health problems taking numerous medicines expect continue find new issues safety resistance drug interaction issues may require us provide additional warnings contraindications labels narrow approved indications could reduce market acceptance products product letairis approved fda june member class compounds called endothelin receptor antagonists eras pose specific risks including serious risks birth defects risks letairis available letairis education access program leap restricted distribution program intended help physicians patients learn risks associated product assure appropriate use product product used additional patients may discover new risks associated letairis may result changes distribution program additional restrictions use letairis may decrease demand product serious safety resistance drug interaction issues arise marketed products sales products could limited halted us regulatory authorities results operations would adversely affected operations depend compliance complex fda comparable international regulations failure obtain broad approvals timely basis maintain compliance could delay halt commercialization products products develop must approved marketing sale regulatory authorities approved subject extensive regulation fda european medicines agency comparable regulatory agencies countries continuing clinical trials atripla truvada viread hepsera compleraeviplera emtriva ambisome letairis ranexa cayston currently approved additional uses anticipate file marketing approval additional countries additional indications products next several years products may fail receive marketing approvals timely basis marketed products manufacture sell products subject extensive regulation review discovery previously unknown problems marketed products problems manufacturing promotional activities may result restrictions products including withdrawal products market fail comply applicable regulatory requirements including related promotion manufacturing could subject penalties including fines suspensions regulatory approvals product recalls seizure products criminal prosecution table contents september president bush signed law food drug administration amendments act significantly expanded fdas authority including among things require sponsors marketed products conduct postapproval clinical studies assess known serious risk signals serious risk identify unexpected serious risk mandate labeling changes products point products lifecycle based new safety information require sponsors implement risk evaluation mitigation strategy product could include medication guide patient package insert communication plan healthcare providers elements fda deems necessary assure safe use drug could include imposing certain restrictions distribution use product failure comply requirements imposed sponsor fda could result significant civil monetary penalties operating results may adversely affected results anticipated timelines clinical trials uncertain may support continued development product pipeline would adversely affect prospects future revenue growth required demonstrate safety efficacy products develop intended use extensive preclinical studies clinical trials results preclinical early clinical studies always accurately predict results later largescale clinical trials even successfully completed largescale clinical trials may result marketable products product candidates fails achieve primary endpoint clinical trials safety issues arise results clinical trials otherwise inadequate support regulatory approval product candidates commercialization product candidate could delayed halted example january announced decision terminate phase clinical trial ambrisentan patients ipf april announced decision terminate phase clinical trial aztreonam inhalation solution treatment cf patients burkholderia spp addition may also face challenges clinical trial protocol design clinical trials product candidates pipeline delayed terminated prospects future revenue growth would adversely impacted example face numerous risks uncertainties product candidates including gs treatment hepatitis c aztreonam inhalation solution treatment bronchiectasis ranolazine treatment incomplete revascularization postpercutaneous coronary intervention type ii diabetes currently phase clinical trials could prevent completion development product candidates risks include ability enroll patients clinical trials possibility unfavorable results clinical trials need modify delay clinical trials perform additional trials risk failing obtain fda regulatory body approvals result product candidates may never successfully commercialized may make strategic decision discontinue development product candidates example believe commercialization difficult relative opportunities pipeline programs others pipeline completed timely basis prospects future revenue growth may adversely impacted addition clinical trials involving commercial products could raise new safety issues existing products could turn decrease revenues harm business due reliance thirdparty contract research organizations conduct clinical trials unable directly control timing conduct expense quality clinical trials extensively outsource clinical trial activities usually perform small portion startup activities inhouse rely independent third party contract research organizations cros perform clinical studies including document preparation site identification screening preparation prestudy visits training program management bioanalytical analysis many important aspects services performed us cros direct control dispute disruption table contents relationship cros clinical trials may delayed moreover regulatory submissions rely quality validity clinical work performed thirdparty cros cros processes methodologies results determined invalid inadequate clinical data results related regulatory approvals could adversely impacted depend relationships companies sales marketing performance development commercialization product candidates revenues failure maintain relationships poor performance companies disputes companies could negatively impact business rely number significant collaborative relationships major pharmaceutical companies sales marketing performance certain territories include collaborations bms atripla united states europe canada f hoffmannla roche ltd together hoffmannla roche inc roche tamiflu worldwide gsk ambrisentan territories outside united states countries rely international distributors sales truvada viread hepsera emtriva ambisome relationships also involve clinical development products partners reliance collaborative relationships poses number risks including risk unable control resources corporate partners devote programs products disputes may arise respect ownership rights technology developed corporate partners disagreements corporate partners could cause delays termination research development commercialization product candidates result litigation arbitration contracts corporate partners may fail provide significant protection may fail effectively enforced one partners fails perform corporate partners considerable discretion electing whether pursue development additional products may pursue alternative technologies products either collaboration competitors corporate partners marketing rights may choose pursue competing technologies devote fewer resources marketing products products development distributors corporate partners may unable pay us particularly light current economic conditions given risks great deal uncertainty regarding success current future collaborative efforts efforts fail product development commercialization new products could delayed revenues products could decline also rely collaborative relationships major pharmaceutical companies development commercialization certain product candidates gilead successor pharmasset inc party collaboration agreement roche develop psi prodrugs treatment chronic hcv infection collaborative research efforts agreement ended december roche later asked pharmasset consider whether roche may contributed inventorship gs whether pharmasset complied confidentiality provisions collaboration agreement pharmasset advised us carefully considered issues raised roche believed issues without merit also considered issues reached conclusion however roche successfully assert contributed inventorship gs either independently develop gs file abbreviated new drug application anda market gs roche could point future market product begin competing us prior expiration patents gs marketing activity roche could materially reduce revenues expect receive sale gs could adversely affect results operations table contents april licensing agreement gsk gave gsk right control clinical regulatory development commercialization hepsera territories asia africa latin america include major markets hepsera china japan taiwan south korea november entered agreement gsk provided gsk exclusive commercialization rights registration responsibilities viread treatment chronic hepatitis b china october granted similar rights gsk japan saudi arabia success hepsera viread treatment chronic hepatitis b territories depends almost entirely efforts gsk regard gsk promotes epivirhbvzeffix product competes hepsera viread treatment chronic hepatitis b consequently gsks marketing strategy hepsera viread treatment chronic hepatitis b may influenced promotion epivirhbvzeffix receive royalties gsk equal percentage gsks net sales hepsera viread treatment chronic hepatitis b well net sales gsks epivirhbvzeffix gsk fails devote sufficient resources succeed developing commercializing hepsera viread treatment chronic hepatitis b territories potential revenues territories may substantially reduced addition cayston letairis distributed thirdparty specialty pharmacies pharmacies specializing dispensing medications complex chronic conditions may require high level patient education ongoing counseling use specialty pharmacies requires significant coordination sales marketing medical affairs regulatory affairs legal finance organizations involves risks including limited risks specialty pharmacies provide us accurate timely information regarding inventories patient data safety complaints effectively sell support cayston letairis devote resources necessary sell cayston letairis volumes within time frames expect able satisfy financial obligations us others cease operations also rely third party administer leap restricted distribution program designed support letairis third party provides information education prescribers patients risks letairis confirms insurance coverage investigates alternative sources reimbursement assistance ensures fulfillment risk management requirements mandated letairis fda coordinates controls dispensing patients third party specialty pharmacies failure third party specialty pharmacies distribute letairis perform expected may result regulatory action fda decreased letairis sales either would harm business cayston may taken patients using specific inhalation device delivers drug lungs patients ongoing distribution cayston entirely reliant upon manufacturer device example manufacturer could encounter issues regulatory agencies related device unable supply sufficient quantities device addition manufacturer may able provide adequate warranty support device distributed patients respect distribution drug device patients reliant capabilities specialty pharmacies example distribution channel drug device complicated requires coordination reimbursement approval processes associated drug device similarly complex device manufacturer unable obtain reimbursement approval receives approval lowerthanexpected price sales cayston may adversely affected previously described issues may limit sales cayston would adversely affect financial results table contents expenses associated clinical trials may cause earnings fluctuate could adversely affect stock price clinical trials required regulatory approval products well clinical trials required conduct approval expensive difficult accurately predict control amount timing expenses quarter quarter fda andor regulatory agencies may require clinical testing originally anticipated uneven unexpected spending programs may cause operating results fluctuate quarter quarter stock price may decline success depend significant degree ability protect patents intellectual property rights domestically internationally may able obtain effective patents protect technologies use competitors patents companies could require us stop using pay use required technology patents proprietary rights important business success depend significant degree ability obtain patents licenses patent rights preserve trade secrets operate without infringing proprietary rights others properly drafted enforceable patent difficult competitors use technology create competitive products difficult competitors obtain patent prevents us using technology create part business strategy actively seek patent protection united states internationally file additional patent applications appropriate cover improvements compounds products technology number us foreign patents patent applications rights patents related compounds products technology certain issued patents enforceable provide adequate protection pending patent applications result issued patents patent applications confidential period time patent issued result may know competitors filed patent applications technology covered pending applications first invent technology subject patent applications competitors may filed patent applications received patents may obtain additional patents proprietary rights block compete products addition competitors file patent applications covering technology may participate interference proceedings litigation determine right patent litigation interference proceedings unpredictable expensive even ultimately successful results operations may adversely affected events time time certain individuals entities may challenge patents example public patent foundation filed requests reexamination united states patent trademark office pto challenging four patents related tenofovir disoproxil fumarate active ingredient atripla truvada viread pto granted requests issued nonfinal rejections four patents step common proceeding initiate reexamination process pto confirmed patentability four patents although successful responding pto actions instance similar organizations may still challenge patents us foreign jurisdictions example april brazilian health ministry citing us patent reexamination proceedings grounds rejection requested brazilian patent authority issue decision supportive patent application tenofovir disoproxil fumarate brazil august examiner brazilian patent authority issued final rejection fumarate salt patent application patent application tenofovir disoproxil fumarate filed brazil table contents filed appeal within patent authority responding questions raised rejection july brazilian patent authority rejected application highest level appeal available us within brazilian patent authority filed civil action brazilian federal court appeal action brazilian patent authority currently patent brazil brazilian government purchased supply tenofovir disoproxil fumarate generic manufacturers result sell hiv products brazil another example indian civil procedure several parties filed oppositions grant patent applications covering tenofovir disoproxil tenofovir disoproxil fumarate august indian patent office announced decided actions us would therefore allow patents granted filed appeal within indian patent office intellectual property appellate board applications predict outcome proceedings unsuccessful appeal decisions appeals pursued indian court system may ultimately prove unsuccessful meantime competitor able sell generic tenofovir disoproxil fumarate india addition unsuccessful appealing negative decisions indian patent office indian courts competitors would able continue sell generic tenofovir disoproxil fumarate patents cover ranolazine compound active ingredient ranexa instead discovered sustained release formulation ranolazine would achieve therapeutic plasma levels patents obtained formulations characteristic plasma levels achieve patents cover active ingredients ambisome addition patent filings china certain asian countries covering forms adefovir dipivoxil active ingredient hepsera asia major market therapies hepatitis b indication hepsera developed may obtain patents certain products many years marketing approval obtained products patents limited life may begin run prior commercial sale related product commercial value patent may limited however may able apply patent term extensions countries part approval process products fda granted exclusivity period manufacturers applications approval generic versions product granted generic manufacturers often wait challenge patents protecting products granted exclusivity one year prior end exclusivity period time time received notices manufacturers indicating intend import chemical intermediates possibly use making products generic manufacturers sought may continue seek fda approval similar identical drug abbreviated new drug application anda application form typically used manufacturers seeking approval generic drug example november received notice teva pharmaceuticals teva submitted anda fda requesting permission manufacture market generic version truvada notice teva alleges two patents associated emtricitabine invalid unenforceable andor infringed tevas manufacture use sale generic version truvada december filed lawsuit teva infringement two emtricitabine patents march received notice teva submitted anda fda requesting permission manufacture market generic version atripla notice teva challenged two emtricitabine patents may filed another lawsuit teva infringement two emtricitabine patents lawsuit consolidated lawsuit filed december january received notice teva submitted anda fda requesting permission manufacture market generic version viread notice teva challenged four tenofovir disoproxil fumarate patents protecting viread january also received notices teva amending andas related atripla truvada notice related truvada teva challenged four patents related tenofovir disoproxil fumarate two additional patents related emtricitabine notice related atripla teva challenged four patents related tenofovir disoproxil fumarate two additional patents table contents related emtricitabine two patents related efavirenz march filed lawsuit teva infringement four viread patents two additional emtricitabine patents march bms merck filed lawsuit teva infringement patents related efavirenz june received notice lupin limited lupin submitted anda fda requesting permission manufacture market generic version ranexa notice lupin alleges ten patents associated ranexa invalid unenforceable andor infringed lupins manufacture use sale generic version ranexa july filed lawsuit lupin infringement patents ranexa august received notice sigmapharm labs sigmapharm submitted anda fda requesting permission manufacture market generic version hepsera notice sigmapharm alleges patents associated hepsera invalid unenforceable andor infringed sigmapharms manufacture use sale generic version hepsera september filed lawsuit sigmapharm infringement patents hepsera one patents challenged sigmapharm also challenged ranbaxy inc ranbaxy pursuant notice received october patent challenged ranbaxy expires july option filing lawsuit time believe ranbaxy infringing patent february received notice natco pharma limited natco submitted anda fda requesting permission manufacture market generic version tamiflu notice natco alleges one patents associated tamiflu invalid unenforceable andor infringed natcos manufacture use sale generic version tamiflu march roche filed lawsuit natco infringement patent associated tamiflu november received notice teva submitted abbreviated new drug submission ands canadian ministry health requesting permission manufacture market generic version truvada product notice teva alleges three patents associated truvada invalid unenforceable andor infringed tevas manufacture use sale generic version truvada january filed lawsuit teva seeking order prohibition approval ands december received notice teva submitted ands canadian ministry health requesting permission manufacture market generic version atripla product notice teva alleges three patents associated atripla two mercks patents associated atripla invalid unenforceable andor infringed tevas manufacture use sale generic version atripla february filed lawsuit teva seeking order prohibition approval ands predict ultimate outcome actions may spend significant resources enforcing defending patents unsuccessful lawsuits original claims patents may narrowed invalidated patent protection atripla truvada viread hepsera ranexa tamiflu united states atripla truvada canada could substantially shortened patents covering products invalidated fda could approve requests manufacture generic version products prior expiration date patents success depends large part ability operate without infringing upon patents proprietary rights third parties infringe patents others may prevented commercializing products may required obtain licenses third parties may able obtain alternative technologies required license reasonable terms fail obtain licenses alternative technologies may unable develop commercialize products example aware body patents may relate operation leap restricted distribution program designed support letairis table contents patents claim gs chemical entity metabolites however existence issued patents guarantee right practice patented technology commercialize patented product third parties may obtain rights patents may claim could used prevent attempt prevent us commercializing patented product candidates obtained pharmasset acquisition example aware patents patent applications owned parties might alleged cover use gs parties successful obtaining valid enforceable patents establishing infringement patents could prevented selling gs unless able obtain license patents license needed may available commercially reasonable terms furthermore use significant proprietary technology rely unpatented trade secrets proprietary knowhow protect certain aspects production technologies trade secrets may become known independently discovered competitors manufacturing problems including thirdparty manufacturers corporate partners could cause inventory shortages delay product shipments regulatory approvals may adversely affect results operations order generate revenue products must able produce sufficient quantities products satisfy demand many products result complex manufacturing processes manufacturing process pharmaceutical products also highly regulated regulators may shut manufacturing facilities believe comply regulations products either manufactured facilities thirdparty manufacturers corporate partners depend third parties perform manufacturing activities effectively timely basis majority solid dose products addition roche either third parties responsible manufacturing tamiflu thirdparty manufacturers corporate partners subject current good manufacturing practices gmp extensive regulations governing manufacturing processes stability testing record keeping quality standards defined fda european medicines agency similar regulations effect countries thirdparty manufacturers corporate partners independent entities subject unique operational financial risks control thirdparty manufacturers corporate partners fail perform required could impair ability deliver products timely basis receive royalties cause delays clinical trials applications regulatory approval extent risks materialize affect performance obligations us financial results may adversely affected addition thirdparty manufacturers corporate partners may able produce products one limited number facilities therefore limited manufacturing capacity certain products example currently manufacture cayston exclusively san dimas california manufacturing facility due unexpected delays qualifying two new external sites expanding cayston manufacturing san dimas supply enough cayston fulfill projected demand february suspended access patients new prescriptions cayston subject certain exceptions specific medical need exists patients may use alternative treatment options able resolve supply shortage result inability manufacture sufficient cayston meet demand amount revenues expect receive sale cayston reduced manufacturing operations subject routine inspections regulatory agencies example january february fda conducted routine inspection san dimas manufacturing facility exclusively manufacture cayston ambisome fill finish macugen conclusion inspection fda issued form inspectional observations stating concerns maintenance table contents aseptic processing conditions manufacturing suite ambisome product environmental maintenance issues san dimas warehousing facility batch sampling timeliness completion annual product quality reports september san dimas manufacturing facility received warning letter fda detailing fdas concerns ambisome manufacturing environment including control systems monitoring procedures prevent microbiological contamination preventative cleaning equipment maintenance referencing certain viread lots letter also stated concerns connected quality procedures controls investigation procedures generalized concern effectiveness san dimas quality unit carrying responsibilities november december fda reinspected san dimas facility reinspection closed additional form observations august fda notified us resolved issues raised fda warning letter ability successfully manufacture commercialize cayston depend upon ability manufacture multiproduct facility aztreonam active pharmaceutical ingredient cayston monobactam gramnegative antibiotic manufacture cayston san dimas california third parties multiproduct manufacturing facilities historically fda permitted manufacture monobactams multiproduct manufacturing facilities however assurance fda continue allow practice currently singleproduct facility dedicated manufacture cayston engaged contract manufacturer singleproduct facility cayston fda prohibits manufacture monobactam antibiotics like aztreonam multiproduct manufacturing facilities future may able procure singleproduct manufacturing facility timely manner would adversely affect commercial supplies cayston anticipated financial results attributable product may able obtain materials supplies necessary conduct clinical trials manufacture sell products would limit ability generate revenues need access certain supplies products conduct clinical trials manufacture products light global economic downturn increased difficulty purchasing certain raw materials used manufacturing process unable purchase sufficient quantities materials find suitable alternate materials timely manner development efforts product candidates may delayed ability manufacture products would limited would limit ability generate revenues suppliers key components materials must named nda filed fda ema regulatory authority product candidate seeking marketing approval significant delays occur qualification new supplier required even manufacturer qualified regulatory authority manufacturer must continue expend time money effort area production quality control ensure full compliance gmp manufacturers subject regular periodic inspections regulatory authorities following initial approval result inspections regulatory authority determines equipment facilities laboratories processes comply applicable regulations conditions product approval regulatory authority may suspend manufacturing operations manufacturing operations single suppliers products suspended may unable generate sufficient quantities commercial clinical supplies product meet market demand would turn decrease revenues harm business addition delivery material suppliers interrupted reason may unable ship certain products commercial supply supply products development clinical trials addition products materials utilize operations made one facility example manufacture ambisome fill finish macugen exclusively facilities san dimas california event disaster including earthquake equipment failure difficulty may unable replace manufacturing capacity timely manner may unable manufacture ambisome macugen meet market needs table contents cayston dependent two different thirdparty singlesource suppliers first aztreonam active pharmaceutical ingredient aztreonam inhalation solution manufactured single supplier single site second administered lungs patients device made single supplier single site disruptions delays single suppliers could adversely affect ability supply cayston sure alternative suppliers identified timely manner see risk factor entitled ability successfully manufacture commercialize cayston depend upon ability manufacture multiproduct facility addition depend single supplier highquality cholesterol used manufacture ambisome also rely single source active pharmaceutical ingredient ranexa hepsera letairis vistide tableting letairis astellas us llc markets lexiscan united states responsible commercial manufacture supply product united states dependent single supplier active pharmaceutical ingredient lexiscan problems single suppliers depend may negatively impact development commercialization efforts significant portion raw materials intermediates used manufacture hiv products atripla truvada viread compleraeviplera emtriva supplied chinesebased companies result international trade dispute china united states actions chinese government would limit prevent chinese companies supplying materials would adversely affect ability manufacture supply hiv products meet market needs material adverse effect operating results face credit risks southern european customers may adversely affect results operations european product sales governmentowned supported customers southern europe specifically greece italy portugal spain historically continue subject significant payment delays due government funding reimbursement practices resulted may continue result days sales outstanding significantly higher countries due average length time accounts receivable remain outstanding december accounts receivable countries totaled approximately billion million past due greater days million past due greater days follows thousands december greater greater days past days past due due italy spain portugal greece total result fiscal debt crises countries number days invoices past due continued increase line experienced pharmaceutical companies also selling directly hospitals historically receivable balances certain publiclyowned hospitals accumulate period time subsequently settled large lump sum payments significant changes occur reimbursement practices european governments government funding becomes unavailable may able collect amounts due us customers results operations would adversely affected example greek government settled substantially outstanding receivables subject bond settlement zerocoupon bonds trade discount face table contents value december received total million bonds allowance doubtful accounts adequate cover exposure related discount bonds spain italy portugal actively pursuing collection overdue receivables taking action necessary enforce legal right payment revenues gross margin could reduced imports countries products available lower prices prices products based local market economics competition sometimes differ country country sales countries relatively higher prices may reduced products imported countries lower price markets cases pharmaceutical products sold steeply discounted prices developing world reexported european countries could resold much higher prices happens products particularly truvada viread agreed make available substantially reduced prices countries participating gilead access program atripla merck distributes substantially reduced prices hiv infected patients developing countries agreement revenues would adversely affected addition established partnerships thirteen indian generic manufacturers distribute highquality lowcost generic versions tenofovir disoproxil fumarate developing world countries including india generic versions medications licenses reexported united states europe markets outside countries revenues would adversely affected addition purchases products countries selling prices relatively low resale countries selling prices relatively high may adversely impact revenues gross margin may cause sales fluctuate quarter quarter example european union required permit products purchased one country sold another country purchases products countries selling prices relatively low resale countries selling prices relatively high affect inventory level held wholesalers cause relative sales levels various countries fluctuate quarter quarter reflect actual consumer demand given quarter quarterly fluctuations may impact earnings could adversely affect stock price harm business expensive litigation government investigations reduced may continue reduce earnings november received notice teva submitted anda fda requesting permission manufacture market generic version truvada notice teva alleges two patents associated emtricitabine invalid unenforceable andor infringed tevas manufacture use sale generic version truvada december filed lawsuit teva infringement two emtricitabine patents march received notice teva submitted anda fda requesting permission manufacture market generic version atripla notice teva challenged two emtricitabine patents may filed another lawsuit teva infringement two emtricitabine patents lawsuit consolidated lawsuit filed december january received notice teva submitted anda fda requesting permission manufacture market generic version viread notice teva challenged four tenofovir disoproxil fumarate patents protecting viread january also received notices teva amending andas related atripla truvada notice related truvada teva challenged four patents related tenofovir disoproxil fumarate two additional patents related emtricitabine notice related atripla teva challenged four patents related tenofovir disoproxil fumarate two additional patents related emtricitabine two patents related efavirenz march filed lawsuit teva infringement four viread patents two additional emtricitabine patents march bms merck filed lawsuit teva infringement patents related efavirenz table contents june received notice lupin submitted anda fda requesting permission manufacture market generic version ranexa notice lupin alleges ten patents associated ranexa invalid unenforceable andor infringed lupins manufacture use sale generic version ranexa july filed lawsuit lupin infringement patents ranexa august received notice sigmapharm submitted anda fda requesting permission manufacture market generic version hepsera notice sigmapharm alleges patents associated hepsera invalid unenforceable andor infringed sigmapharms manufacture use sale generic version hepsera september filed lawsuit sigmapharm infringement patents hepsera one patents challenged sigmapharm also challenged ranbaxy pursuant notice received october patent challenged ranbaxy expires july considering options enforcing patent february received notice natco submitted anda fda requesting permission manufacture market generic version tamiflu notice natco alleges one patents associated tamiflu invalid unenforceable andor infringed natcos manufacture use sale generic version tamiflu march roche filed lawsuit natco infringement patent associated tamiflu november received notice teva submitted abbreviated new drug submission ands canadian ministry health requesting permission manufacture market generic version truvada product notice teva alleges three patents associated truvada invalid unenforceable andor infringed tevas manufacture use sale generic version truvada january filed lawsuit teva seeking order prohibition approval ands december received notice teva submitted ands canadian ministry health requesting permission manufacture market generic version atripla product notice teva alleges three patents associated atripla two mercks patents associated atripla invalid unenforceable andor infringed tevas manufacture use sale generic version atripla february filed lawsuit teva seeking order prohibition approval ands predict ultimate outcome actions may spend significant resources enforcing defending patents unsuccessful lawsuits original claims patents may narrowed invalidated patent protection atripla truvada viread hepsera ranexa tamiflu united states atripla viread canada could substantially shortened patents covering products invalidated fda could approve requests manufacture generic version products prior expiration date patents addition june received subpoena united states attorneys office northern district california requesting documents related manufacture related quality distribution practices atripla emtriva hepsera letairis truvada viread complera outcome lawsuits lawsuits may brought us investigation investigations may initiated inherently uncertain adverse developments outcomes result significant expenses monetary damages penalties injunctive relief us could significantly reduce earnings cash flows harm business table contents countries may required grant compulsory licenses products face generic competition products number developing countries government officials interested groups suggested pharmaceutical companies make drugs hiv infection available low cost alternatively governments developing countries could require grant compulsory licenses allow competitors manufacture sell versions products thereby reducing product sales example past certain offices government brazil expressed concern affordability hiv products declared considering issuing compulsory licenses permit manufacture otherwise patented products hiv infection including viread july brazilian patent authority rejected patent application tenofovir disoproxil fumarate active pharmaceutical ingredient viread highest level appeal available us within brazilian patent authority currently patent brazil brazilian government purchased supply tenofovir disoproxil fumarate generic manufacturers result sell hiv products brazil addition concerns cost availability tamiflu related potential avian flu pandemic hn influenza generated international discussions compulsory licensing tamiflu patents example canadian government considered allowing canadian manufacturers manufacture export active ingredient tamiflu eligible developing least developed countries canadas access medicines regime furthermore roche issued voluntary licenses permit thirdparty manufacturing tamiflu example roche granted sublicense shanghai pharmaceutical group co ltd china sublicense indias hetero drugs limited india certain developing countries one compulsory licenses issued permitting generic manufacturing override tamiflu patents roche issue additional voluntary licenses permit thirdparty manufacturing tamiflu developments could reduce royalties receive roches sales tamiflu certain countries permit enforcement patents thirdparty manufacturers able sell generic versions products countries compulsory licenses sales generic versions products could significantly reduce sales adversely affect results operations particularly generic versions products imported territories existing commercial sales changes royalty revenue disproportionately affect pretax income earnings per share gross margins portion revenues derived royalty revenues recognized collaboration agreements third parties royalty revenues impact pretax income earnings per share gross margins disproportionately contributions revenues increase decrease royalty revenue could material could significantly impact operating results example recognized million royalty revenue year ended december related royalties received sales tamiflu f hoffmannla roche ltd together hoffmannla roche inc roche although royalty revenue represented approximately total revenues represented approximately pretax income period roches tamiflu sales unpredictable variability due strong relationship global pandemic planning efforts tamiflu royalties increased sharply first quarter primarily result pandemic planning initiatives worldwide tamiflu royalties since second quarter decreased due declining pandemic planning initiatives worldwide may face significant liability resulting products may covered insurance successful claims could materially reduce earnings testing manufacturing marketing use commercial products well product candidates development involve substantial risk product liability claims claims may made directly consumers healthcare providers pharmaceutical companies others recent years coverage availability table contents costeffective product liability insurance decreased may unable maintain sufficient coverage product liabilities may arise addition cost defend lawsuits pay damages product liability claims may exceed coverage unable maintain adequate coverage claims exceed coverage financial condition ability clinically test product candidates market products adversely impacted addition negative publicity associated claims regardless merit may decrease future demand products impair financial condition business disruptions natural manmade disasters may harm future revenues worldwide operations could subject business interruptions stemming natural manmade disasters may selfinsured corporate headquarters palo alto locations together house majority research development activities san dimas oceanside manufacturing facilities located california seismically active region carry earthquake insurance significant recovery time could required resume operations financial condition operating results could materially adversely affected event major earthquake changes effective income tax rate could reduce earnings various factors may favorable unfavorable effects income tax rate factors include limited interpretations existing tax laws changes tax laws rates portion nondeductible pharmaceutical excise tax accounting stock options sharebased payments mergers acquisitions future levels rd spending changes accounting standards changes mix earnings various tax jurisdictions operate changes overall levels pretax earnings resolution federal state foreign income tax audits impact income tax provision resulting mentioned factors may significant could negative impact net income income tax returns audited federal state foreign tax authorities currently examination internal revenue service tax years various state foreign jurisdictions differing interpretations tax laws regulations result significant disputes may arise tax authorities involving issues timing amount deductions allocations income among various tax jurisdictions resolution one exposures reporting period could material impact results operations period fail attract retain highly qualified personnel may unable successfully develop new product candidates conduct clinical trials commercialize product candidates future success depend large part continued ability attract retain highly qualified scientific technical management personnel well personnel expertise clinical testing governmental regulation commercialization face competition personnel companies universities public private research institutions government entities organizations competition qualified personnel biopharmaceutical field intense limited pool qualified potential employees recruit may able attract retain quality personnel acceptable terms unsuccessful recruitment retention efforts business may harmed item b unresolved staff comments applicable item properties lease facilities foster city palo alto fremont san dimas california house manufacturing warehousing rd activities addition also lease facilities branford connecticut princeton new jersey durham north carolina seattle washington house administrative rd activities table contents international headquarters include commercial medical administrative facilities located leased london area united kingdom manufacturing facility cork ireland primarily use solid dose tablet manufacturing antiviral products well product packaging activities also lease facility cork used shared services lease facilities dublin area ireland house distribution activities manufacturing facility edmonton alberta canada primarily use conduct process research scaleup clinical development candidates manufacturing active pharmaceutical ingredients investigational commercial products chemical development activities improve existing commercial manufacturing processes also manufacturing facility oceanside california designed equipped produce biologic compounds toxicological phase phase clinical studies use facility process development manufacture gs investigational monoclonal antibody candidate development treatment certain cancers fibrotic diseases another antibody currently preclinical testing leased additional facilities house commercial medical administrative activities australia austria belgium canada france germany greece hong kong ireland italy netherlands poland portugal spain south korea sweden switzerland turkey united kingdom also lease office shanghai china provide sourcing manufacturing support primarily related commercial purchases active pharmaceutical ingredients believe existing properties including owned leased sites good condition suitable conduct business believe capital resources sufficient purchase lease construct additional facilities required meet expected longterm growth needs item legal proceedings november received notice teva pharmaceuticals teva submitted abbreviated new drug application anda us food drug administration fda requesting permission manufacture market generic version truvada notice teva alleges two patents associated emtricitabine owned emory university licensed exclusively us invalid unenforceable andor infringed tevas manufacture use sale generic version truvada december filed lawsuit us district court new york teva infringement two emtricitabine patents march received notice teva submitted anda fda requesting permission manufacture market generic version atripla notice teva challenged two emtricitabine patents may filed another lawsuit us district court new york teva infringement two emtricitabine patents lawsuit consolidated lawsuit filed december january received notice teva submitted anda fda requesting permission manufacture market generic version viread notice teva challenged four tenofovir disoproxil fumarate patents protecting viread january also received notices teva amending andas related atripla truvada notice related atripla teva challenged four patents related tenofovir disoproxil fumarate two additional patents related emtricitabine two patents related efavirenz notice related truvada teva challenged four patents related tenofovir disoproxil fumarate two additional patents related emtricitabine march filed lawsuit teva infringement four viread patents two additional emtricitabine patents march bristolmyers squibb company merck co inc filed lawsuit teva infringement patents related efavirenz june received notice lupin limited lupin submitted anda fda requesting permission manufacture market generic version ranexa notice lupin alleges ten table contents patents associated ranexa invalid unenforceable andor infringed lupins manufacture use sale generic version ranexa july filed lawsuit us district court new jersey lupin infringement patents ranexa august received notice sigmapharm labs sigmapharm submitted anda fda requesting permission manufacture market generic version hepsera notice sigmapharm alleges patents associated hepsera invalid unenforceable andor infringed sigmapharms manufacture use sale generic version hepsera september filed lawsuit us district court new jersey sigmapharm infringement patents hepsera one patents challenged sigmapharm also challenged ranbaxy inc ranbaxy pursuant notice received october patent challenged ranbaxy expires july option filing lawsuit time believe ranbaxy infringing patent february received notice natco pharma ltd natco submitted anda fda requesting permission manufacture market generic version tamiflu notice natco alleges one patents associated tamiflu invalid unenforceable andor infringed natcos manufacture use sale generic version tamiflu march f hoffmannla roche ltd filed lawsuit us district court new jersey natco infringement patent associated tamiflu november received notice teva submitted abbreviated new drug submission ands canadian ministry health requesting permission manufacture market generic version truvada product notice teva alleges three patents associated truvada invalid unenforceable andor infringed tevas manufacture use sale generic version truvada january filed lawsuit canadian federal court teva seeking order prohibition approval ands december received notice teva submitted ands canadian ministry health requesting permission manufacture market generic version atripla product notice teva alleges three patents associated atripla two mercks patents associated atripla invalid unenforceable andor infringed tevas manufacture use sale generic version atripla february filed lawsuit canadian federal court teva seeking order prohibition approval ands predict ultimate outcome actions may spend significant resources enforcing defending patents unsuccessful lawsuits original claims patents may narrowed invalidated patent protection atripla truvada viread hepsera ranexa tamiflu united states atripla truvada canada could substantially shortened patents covering products invalidated fda could approve requests manufacture generic version products prior expiration date patents june received subpoena united states attorneys office northern district california requesting documents related manufacture related quality distribution practices atripla emtriva hepsera letairis truvada viread complera cooperating continue cooperate governmental inquiry estimate possible loss range losses determined given early stage inquiry party various legal actions arose ordinary course business believe legal actions material adverse impact consolidated business financial position results operations item mine safety disclosures applicable table contents part ii item market registrants common equity related stockholder matters issuer purchases equity securities common stock traded nasdaq global select market symbol gild following table sets forth high low intraday sale prices per share common stock nasdaq global select market periods indicated prices represent quotations among dealers without adjustments retail markups markdowns commissions may represent prices actual transactions high low first quarter second quarter third quarter fourth quarter first quarter second quarter third quarter fourth quarter february shares common stock outstanding held approximately stockholders record paid cash dividends common stock since inception expect retain earnings primarily use operation expansion business therefore anticipate paying cash dividends near future effort continue return value stockholders minimize dilution stock issuances january board directors board authorized threeyear billion stock repurchase program commenced september upon completion may stock repurchase program intend use additional authorization repurchase shares time time offset dilution created shares issued employee stock plans repurchase shares december repurchased million common stock january stock repurchase program spent total billion repurchase retire million shares common stock average purchase price per share see item note consolidated financial statements included annual report information regarding stock repurchase programs table contents performance graph following graph compares total stockholder returns past five years two indices standard poors stock index labeled sp index nasdaq biotechnology index labeled nbi index total return index assumes reinvestment dividends paid companies included indices calculated december year composite member sp index nbi index intend use indices comparators stock performance purposes following graph going forward composite member sp index required applicable regulations use index comparator believe nbi index relevant comparator since composed peer companies linesofbusiness similar stockholder return shown graph necessarily indicative future performance make endorse predictions future stockholder returns comparison cumulative total return investment past five years section soliciting material deemed filed sec incorporated reference filings securities act exchange act whether made date hereof irrespective general incorporation language filing shows cumulative return investment assuming investment common stock nbi index sp index december table contents issuer purchases equity securities effort continue return value stockholders minimize dilution stock issuances january board authorized threeyear billion stock repurchase program commenced september upon completion may stock repurchase program intend use additional authorization repurchase shares time time offset dilution created shares issued employee stock plans repurchase shares december repurchased million common stock january stock repurchase program spent total billion repurchase retire million shares common stock average purchase price per share see item note consolidated financial statements included annual report information regarding stock repurchase programs table summarizes stock repurchase activity three months ended december thousands except per share amounts total number maximum fair value shares purchased shares may yet total number average price paid part publicly purchased shares purchased per share announced programs program october october november november december december total difference total number shares purchased total number shares purchased part publicly announced programs due shares common stock withheld us employee restricted stock awards order satisfy applicable tax withholding obligations table contents item selected financial data gilead sciences inc selected consolidated financial data thousands except per share data year ended december consolidated statement income data total revenues total costs expenses income operations provision income taxes net income attributable gilead net income per share attributable gilead common stockholdersbasic shares used per share calculationbasic net income per share attributable gilead common stockholdersdiluted shares used per share calculationdiluted december consolidated balance sheet data cash cash equivalents marketable securities working capital total assets longterm obligations convertible senior notes unsecured senior notes retained earnings total stockholders equity recorded million impairment charges research development rd expense related certain inprocess research development iprd assets acquired cgi pharmaceuticals inc see item notes consolidated financial statements included annual report recorded million impairment charges rd expense related certain iprd assets acquired cv therapeutics inc cv therapeutics see item notes consolidated financial statements included annual report completed acquisition assets navitas assets llc related cicletanine business aggregate purchase price million allocated purchased iprd table contents gilead sciences inc selected consolidated financial datacontinued completed acquisition cv therapeutics recognized consideration transferred billion primarily recorded intangible assets see item note consolidated financial statements included annual report issued billion principal amount senior unsecured notes registered offerings see item note consolidated financial statements included annual report issued billion principal amount convertible senior notes private placement see item note consolidated financial statements included annual report table contents item managements discussion analysis financial condition results operations following managements discussion analysis financial condition results operations mda intended help reader understand results operations financial condition mda provided supplement read conjunction audited consolidated financial statements accompanying notes consolidated financial statements disclosures included annual report including disclosures item risk factors consolidated financial statements prepared accordance us generally accepted accounting principles presented us dollars management overview gilead sciences inc gilead us incorporated delaware june researchbased biopharmaceutical company discovers develops commercializes innovative medicines areas unmet medical need new discovery experimental drug candidate seek improve care patients suffering lifethreatening diseases around world gileads primary areas focus include human immunodeficiency virus hivaids liver diseases hepatitis b virus hbv hepatitis c virus hcv serious cardiovascularmetabolic respiratory conditions headquartered foster city california operations north america europe asia pacific continue seek add existing portfolio products internal discovery clinical development programs product acquisition inlicensing strategy product portfolio comprised atripla truvada viread emtriva compleraeviplera hepsera ambisome letairis ranexa cayston vistide addition also sell distribute certain products corporate partners royaltypaying collaborative agreements example f hoffmannla roche ltd together hoffmannla roche inc roche markets tamiflu glaxosmithkline inc gsk markets hepsera viread certain territories outside united states gsk also markets volibris outside united states astellas pharma us inc markets ambisome united states canada astellas us llc markets lexiscan injection united states rapidscan pharma solutions inc markets rapiscan certain territories outside united states menarini international operations luxembourg sa markets ranexa certain territories outside united states japan tobacco inc japan tobacco markets truvada viread emtriva japan business highlights continued advance pipeline internal programs across therapeutic areas augmented efforts strategic investments acquisitions inlicensing opportunities collaborations liver disease area acquisition pharmasset inc pharmasset early marks significant opportunity continue developing bestinclass drugs believe combination existing internal research programs recent partnerships acquisitions drive research development efforts accelerate product pipeline continue bring innovative therapies individuals around world living unmet medical needs summary key accomplishments received marketing approval began launching compleraeviplera second singletablet regimen treatment hiv united states canada certain countries european union submitted new drug application nda quad singletablet regimen elvitegravir cobicistat emtricitabine tenofovir disoproxil fumarate treatment hiv six weeks phase studies concluded obtained us food drug administration fda agreement revision letairis label subsequently changed sales trajectory product table contents progressed gs investigational nucleotide reverse transcriptase inhibitor completed collaborative agreements hiv field set stage third generation singletablet regimens accelerated timeline develop first alloral hcv regimen result pharmasset acquisition completed arresto biosciences inc arresto calistoga pharmaceuticals inc calistoga acquisitions acquired oceanside california facility biologics manufacturing support advancing clinical studies oncology new potential product offerings new drug applications area hiv continued efforts expand product offerings singletablet regimens launch compleraeviplera submission quad regulatory approval united states europe august received fda approval complera treatment hiv infection treatmentnave adults complera combines three antiretroviral medications one daily tabletour truvada fixeddose combination emtricitabine tenofovir disoproxil fumarate edurant rilpivirine marketed tibotec pharmaceuticals tibotec november received marketing approval product europe product marketed eviplera october submitted nda fda marketing approval quad treatment hiv infection adults subsequently fda accepted nda set target review date august prescription drug user fee act pdufa fda indicated panel convened may provide expert advice application submitted marketing authorisation application quad treatment hiv infection adults european medicines agency november december announced phase clinical trials pharmacoenhancing boosting agent cobicistat met week primary object non inferiority cobicistat increases blood levels certain hiv medicines allow one pill oncedaily dosing study indicated weeks treatment percent patients taking regimen cobicistatboosted atazanavir plus truvada achieved comparable results patients taking ritonavirboosted atazanavir plus truvada also december announced phase clinical trial results showing elvitegravir integrase inhibitor evaluated treatment hiv infection noninferior integrase inhibitor raltegravir two years therapy treatmentexperienced patients results study indicate elvitegravir potential become new oncedaily treatment option hiv developed resistance therapies acquisitions january completed acquisition arresto million plus potential future payments based achievement certain sales levels arresto privatelyheld developmentstage biotechnology company based palo alto california focused developing antibodies potential treatment fibrotic diseases cancer lead product acquisition gs humanized monoclonal antibody mab targeting human lysyl oxidaselike loxl protein addition ongoing phase studies gs liver fibrosis myelofibrosis colorectal cancer pancreatic cancer phase study conducted evaluate gs patients idiopathic pulmonary fibrosis april acquired calistoga million plus potential payments million based achievement certain milestones calistoga privatelyheld biotechnology company based seattle washington focused development medicines treat cancer inflammatory diseases table contents portfolio proprietary compounds acquisition selectively targeted isoforms phosphoinositide kinase pik calistogas lead product candidate gs firstinclass specific inhibitor pik delta isoform pik delta preferentially expressed leukocytes involved variety inflammatory autoimmune diseases hematological cancers november entered agreement acquire pharmasset billion acquisition financed cash hand bank debt senior unsecured notes acquisition completed january pharmasset clinicalstage pharmaceutical company located princeton new jersey committed discovering developing commercializing novel drugs treat viral infections pharmassets primary focus development oral therapeutics treatment hcv pharmassets research development rd efforts focused nucleosidetide analogs class compounds act alternative substrates viral polymerase thus inhibiting viral replication inlicensing collaborations june entered agreement tibotec development commercialization new fixeddose combination product containing cobicistat tibotecs protease inhibitor prezista darunavir indicated treatment hiv prezista currently coadministered ritonavir combination antiretroviral agents october entered agreement boehringer ingelheim bi worldwide rights research development commercialization bis novel noncatalytic site integrase inhibitors hiv includes lead compound bi evaluated phase doseescalation study assess bioavailability pharmacokinetics healthy volunteers also october entered agreement globeimmune inc license development commercialization therapeutic vaccine products use conjunction viread oral therapies treatment chronic hbv infection also october entered agreement bristolmyers squibb company bms licensing development commercialization fixeddose combination containing bmss protease inhibitor reyataz atazanavir sulfate cobicistat currently studying atazanavir cobicistat phase studies hiv treatmentnave patients november entered agreement tibotec development commercialization singletablet regimen combining tibotecs prezista emtriva gs cobicistat financial highlights spite challenging macroeconomic environment continued grow business achieved total product sales billion increase growth product sales primarily driven growth antiviral franchise sales increased billion compared prior year sales products comprised primarily ambisome ranexa letairis reached billion increase compared prior year total revenues grew billion product sales growth partially offset decline royalty revenues collaborations corporate partners million decrease primarily due lower tamiflu royalties pandemic planning initiatives worldwide declined gross margin decreased primarily due annual selling price adjustment percentage share atripla paid partner rd expenses billion billion increase million increase due primarily costs related clinical studies impact higher headcount table contents expenses associated acquisitions collaborations ongoing growth business selling general administrative sga expenses billion billion increase million increase due primarily increased expenses associated ongoing growth business pharmaceutical excise tax resulting us healthcare reform increased bad debt provision due slower collections certain southern european countries net income billion decrease billion due primarily investments made existing clinical programs acquisitions inlicensing collaboration agreements lower tamiflu royalties roche result declining pandemic planning initiatives worldwide diluted earnings per share increased incorporates impact share repurchases throughout year financing activity cash cash equivalents marketable securities increased billion total billion december primary sources cash cash equivalents marketable securities operating cash flows billion billion proceeds issuance senior unsecured notes billion raised december partially fund pharmasset acquisition key uses cash year included billion repurchases common stock stock repurchase programs million repayment convertible senior notes due million acquisition activities completed may billion stock repurchase program commenced share repurchases threeyear billion stock repurchase program authorized board directors january spent total billion cash repurchase retire million shares common stock average purchase price per share subsequent events january raised billion bank debt partially fund acquisition pharmasset acquired pharmasset billion cash tender offer subsequent merger closed january pharmassets lead compound nucleotide analog hcvinfected individuals across genotypes known gs expect receive significant amount data clinical trials evaluating gs february announced data indicates gs ribavirin treatment genotype patients prior null response interferoncontaining regimen weeks sufficient cure disease currently conducting additional phase studies hcv infected genotype patients including treatmentnave patients results expect end first quarter second quarter early third quarter outlook operating objectives include increasing market share commercial products continuing strengthen pipeline internally developed andor externally inlicensed purchased opportunities strengthening key alliances rd standpoint continue execute pipeline development particular focus innovative hiv singletablet regimens patients progression hcv molecules clinic new initiatives oncology inflammation expect publicly announce additional data sets related development gs treatment hcv affect cost duration development efforts gs table contents commercial standpoint number internal external initiatives intended promote continued growth franchises hiv area scientific arguments diagnose treat patients earlier strong reasons use singletablet regimens compelling medically practically extension ryan white treatment act provide stable funding aids drug assistance programs adaps united states continue roll compleraeviplera around world subject fda approval quad bring third singletablet regimen individuals us living hiv launched truvadarilpivirine singletablet regimen treatment hiv complera united states canada eviplera united kingdom austria expect continued uptake complera united states canada launch eviplera throughout europe quad reviewed fda pdufa date august assuming approval expect launch product september expect quad contribute incremental revenue hiv franchise hbv area continue support educational promotional activities focused us asian communities highlighting need screen diagnose link patients care cardiovascular area continue efforts raise awareness gilead pulmonary arterial hypertension cardiology communities believe help grow revenues letairis ranexa mindful conditions current macroeconomic environment could affect ability achieve goals factors could affect business include future changes healthcare reform united states continuation worsening global economic conditions patent expirations competitive products launch generic competitors continued government pricing pressures internationally potential volatility foreign currency exchange rates continue monitor conditions adjust business processes appropriate mitigate risks business believe successes experienced enabled us continue build financially sound business model allow us continue expand commercial rd activities maintain quality compliance continue grow business remain focused profitable revenue growth prudent expense management believe enable solid execution operating objectives critical accounting policies estimates judgments discussion analysis financial condition results operations based consolidated financial statements prepared accordance us generally accepted accounting principles preparation financial statements requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosures ongoing basis evaluate estimates including related revenue recognition intangible assets allowance doubtful accounts prepaid royalties clinical trial accruals tax provision stockbased compensation base estimates historical experience various market specific relevant assumptions believe reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources actual results may differ significantly estimates believe following critical accounting policies reflect significant judgments estimates used preparation consolidated financial statements table contents revenue recognition product sales recognize revenues product sales persuasive evidence arrangement exists delivery customer occurred price fixed determinable collectability reasonably assured record estimated reductions revenues government rebates medicaid reimbursements customer incentives cash discounts prompt payment distributor fees expected returns expired products estimates deducted gross product sales time revenues recognized reductions gross product sales government rebates significantly impact reported net product sales based upon certain estimates require complex significant judgment management government rebates estimate reductions revenues governmentmanaged medicaid programs well certain qualifying federal state foreign government programs reimbursement portions retail price prescriptions filled covered programs reductions settled either us invoiced directly chargebacks wholesalers government rebates invoiced directly us recorded accrued government rebates consolidated balance sheets qualified programs purchase products wholesalers lower contractual government price wholesalers charge back us difference acquisition cost lower contractual government price record allowances accounts receivable although may pay rebates countries outside united states date payments made foreign governments represented significant portion total government rebates government programs united states estimate sales allowances based contractual terms historical utilization rates new information regarding changes programs regulations guidelines would impact amount actual rebates expectations regarding future utilization rates programs channel inventory data obtained major us wholesalers accordance inventory management agreements us government rebates billion billion million respectively representing total gross product sales respectively deducted gross product sales believe methodology use estimate sales allowances government price reductions reasonable appropriate given current facts circumstances however actual results may differ based current information available us actual government rebates claimed periods varied approximately estimates recorded periods december accrued us government rebates million million respectively accrued government rebates allowance government chargebacks million million respectively recorded accounts receivable following table summarizes aggregate activity us government rebates allowance accrued liabilities accounts balance deducted balance beginning charged end year expense accruals year year ended december government rebates allowances accrued liabilities activity related sales activity related sales prior total year ended december government rebates allowances accrued liabilities activity related sales activity related sales prior total table contents intangible assets conjunction business combinations completed recorded intangible assets primarily related marketed products iprd projects goodwill part recognition measurement assets acquired liabilities assumed business combination identifiable intangible assets related marketed products iprd projects measured respective fair values acquisition date believe fair values assigned acquired intangible assets based reasonable estimates assumptions given available facts circumstances acquisition dates discounted cash flow models used valuing intangible assets models require use significant estimates assumptions including limited estimates revenues operating profits related products product candidates probability success unapproved product candidates considering stages development time resources needed complete development approval product candidates life potential commercialized products associated risks including inherent difficulties uncertainties developing product candidate obtaining fda regulatory approvals risks related viability potential alternative treatments future target markets goodwill represents excess consideration transferred estimated fair values assets acquired liabilities assumed business combination goodwill intangible assets determined indefinite useful lives amortized required tested impairment least annually test goodwill indefinitelived intangible assets impairment annual basis annual tests become aware events occurring changes circumstances would indicate reduction fair values assets carrying amounts december billion indefinitelived intangible assets consisting billion goodwill resulting various business combinations million intangible assets related iprd projects acquired arresto calistoga intangible assets finite useful lives amortized estimated useful lives reviewed impairment facts circumstances suggest carrying value assets may recoverable amortizing intangible asset related ranexa product acquired cv therapeutics estimated useful life using amortization rate derived forecasted future product sales ranexa product sales forecasts prepared annually determined using best estimates future activity upon considering factors historical expected future patient usage uptake products introduction complimentary combination therapies products future product launch plans previously unanticipated significant change occurs sales forecasts prospectively update rate used amortize intangible asset related ranexa may increase future cost goods sold record amortization expense amortizing intangible asset related lexiscan product also acquired cv therapeutics estimated useful life cost goods sold straightline basis given current lexiscan revenues consist royalties received collaboration partner lack ongoing access visibility partners future sales forecasts make reasonable estimate amortization rate using forecasted product sales approach december million net unamortized finitelived intangible assets consisting primarily intangible assets related marketed products acquired cv therapeutics judgment regarding existence impairment indicators based historical projected future operating results extent manner use acquired assets legal regulatory factors events overall business strategy market economic trends events occur future cause us conclude impairment indicators exist certain intangible assets impaired financial condition results operations may adversely impacted table contents fourth quarter recorded million impairment charges related certain iprd assets acquired cv therapeutics future plans develop deemed future use us market participants charges related gs adentri tecadenoson programs recorded rd expense majority impairment charge related gs program product candidate phase clinical studies treatment diabetes hypertriglyceridemia terminated fourth quarter due unfavorable results pharmacokinetics pharmacodynamics tests demonstrated limited effectiveness compound patients given results believe alternative future uses us market participants fourth quarter recorded million impairment charges related certain iprd assets acquired cgi impairment charges result changes anticipated market share related syk compound allowance doubtful accounts also maintain allowance doubtful accounts estimated losses resulting inability customers make required payments allowance based analysis several factors including limited contractual payment terms historical payment patterns customers individual customer circumstances analysis days sales outstanding geographic region review local economic environment potential impact government funding reimbursement practices financial condition customers economic environment operate deteriorate resulting inability make payments additional allowances may required believe allowance doubtful accounts adequate however significant deterioration factors could materially change expectations may result increase allowance doubtful accounts prepaid royalties capitalize royalties prepaid cost specifically related emtricitabine royalties paid emory university emory hiv indication based present value future royalty obligation would expect pay emory assuming certain expected future levels product sales incorporating emtricitabine present value future royalty obligation derived using weightedaverage cost capital review periodically expected future sales levels products indicators might require writedown net recoverable value asset change estimated life prepaid royalty potential indicators impairment include launch significant product competitor significant deviations recognized product sales compared forecast product safety issues recalls amortize prepaid royalties based effective royalty rate derive forecasted future hiv product sales incorporating emtricitabine product sales forecasts prepared annually determined using best estimates future activity upon considering factors historical expected future patient usage uptake products introduction complimentary combination therapies products future product launch plans previously unanticipated significant change occurs sales forecasts including introduction competing product us one competitors hiv market emtricitabine prospectively update royalty rate used amortize prepaid royalties may increase future cost goods sold record amortization expense december prepaid royalty asset relating emtricitabine royalties paid emory million million respectively amortization expense relating prepaid royalty asset million million million years ended december respectively clinical trial accruals record accruals estimated clinical study costs clinical studies performed thirdparty contract research organizations cros costs significant component rd expenses table contents incurred cro costs million million million respectively accrue costs clinical studies performed cros service periods specified contracts adjust estimates required based upon ongoing review level effort costs actually incurred cros validate accruals quarterly vendors perform detailed reviews activities related significant contracts based upon results validation processes assess appropriateness accruals make adjustments deem necessary ensure expenses reflect actual effort incurred cros generally significant portion total clinical trial costs associated start activities trial patient enrollment extensively outsource clinical trial activities usually perform small portion startup activities inhouse result cros typically perform total startup activities trials including document preparation site identification screening preparation prestudy visits training program management startup costs usually occur within months contract executed milestone event driven nature remaining clinical activities related costs patient monitoring administration generally occur ratably throughout life individual contract study contracts negotiated fixed per unit prices vary length three months single dose phase clinical study two years complex phase clinical study average length contracts upper end range order provide longterm safety efficacy data support commercial launches atripla truvada viread compleraeviplera hepsera emtriva letairis ranexa material cro contracts terminable us upon written notice generally liable actual effort expended cro certain noncancelable expenses incurred point termination amounts paid advance relating uncompleted services refunded us contract terminated contracts may include additional termination payments become due payable terminate contract additional termination payments recorded becomes probable contract terminated december differences actual estimated activity levels particular study material however management receive complete accurate information vendors underestimates activity levels associated study given point time may record additional potentially significant rd expenses future periods tax provision estimate income tax provision including deferred tax assets liabilities based significant management judgment evaluate realization portion deferred tax assets quarterly basis record valuation allowance reduce deferred tax assets amounts likely realized consider future taxable income ongoing tax planning strategies historical financial performance assessing need valuation allowance expect realize deferred tax assets previously recorded valuation allowance reduce valuation allowance period determination first made future effective income tax rate may affected factors changes tax laws regulations rates changing interpretation existing laws regulations impact accounting stockbased compensation changes international organization changes overall levels income tax record liabilities related uncertain tax positions accordance guidance clarifies accounting uncertainty income taxes recognized enterprises financial statements prescribing minimum recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return believe uncertain tax positions currently pending material adverse effect consolidated financial statements although adverse resolution one uncertain tax positions period could material impact results operations period table contents december total federal state foreign unrecognized tax benefits million million respectively total unrecognized tax benefits million million december respectively recognized would reduce effective tax rate period recognition december believe reasonably possible unrecognized tax benefits significantly change next months expect clarification irs tax authorities around uncertain tax positions file federal state foreign income tax returns many jurisdictions united states abroad federal income tax purposes statute limitations open onwards certain acquired entities statute limitations open years inception due utilization net operating losses credits carried prior years california income tax purposes statute limitations open onwards income tax returns audited federal state foreign tax authorities currently examination irs tax years various state foreign jurisdictions differing interpretations tax laws regulations result significant disputes may arise tax authorities involving issues timing amount deductions allocations income among various tax jurisdictions periodically evaluate exposures associated tax filing positions stockbased compensation measure sharebased payments employees directors including grants stock options based relative fair values fair values awards granted stock option plans employee stock purchase plan estimated grant purchase dates using blackscholes option valuation model blackscholes option valuation model developed use estimating fair value traded options vesting restrictions fully transferable addition option valuation models require input highly subjective assumptions including expected stock price volatility expected award life fair value restricted stock units rsus equal closing price common stock grant date rsus vest ratably annual basis five years grant date awards granted prior four years grant date awards granted also grant performancebased restricted stock units valued using monte carlo valuation method vest upon achievement specified market performance goals relative pre determined peer group actual number common shares ultimately issued calculated multiplying number performance units payout percentage ranging performance awards vest committee subcommittee board determined achieved specified market performance goals stockbased compensation recognized expense requisite service periods consolidated statements income using graded vesting expense attribution approach unvested stock options granted prior january using straightline expense attribution approach stock options granted adoption new guidance sharebased payments employees directors january stockbased compensation expenses related stock options recognized adoption new guidance based awards ultimately expected vest gross expense reduced estimated forfeitures guidance requires forfeitures estimated time grant revised necessary subsequent periods actual forfeitures differ estimates estimated forfeitures based historical experience prior adoption guidance pro forma information required disclosed included forfeitures occurred result guidance adopted january recognize tax benefit stockbased compensation additional paidin capital apic incremental tax benefit realized tax attributes currently available us utilized addition elected account indirect benefits stockbased compensation research tax credit extraterritorial income deduction consolidated statements income rather apic years ended december recognized stockbased compensation expenses million million million respectively operating expenses table contents capitalized million million million respectively inventory december million million million stockbased compensation costs included inventory respectively december unrecognized stockbased compensation expenses million related unvested stock options expect expense estimated weightedaverage period years unrecognized stock based compensation expenses million related rsus expect expense estimated weighted average period years results operations total revenues total revenues billion billion billion included total revenues product sales royalty revenues contract revenues increases total revenues driven growth product sales total product sales billion increase total product sales billion driven primarily antiviral franchise resulting continued growth sales atripla truvada increase product sales also reflected sales growth nonantiviral products primarily ambisome ranexa letairis cayston reached billion mark compared million increase product sales partially offset decline tamiflu royalties roche due declining pandemic planning initiatives worldwide total product sales increased compared billion primarily driven growth atripla truvada sales product sales united states increased compared primarily driven continued sales growth antiviral franchise introduction complera partially offset ongoing impact us healthcare reform increase also reflected sales growth nonantiviral franchises ranexa sales contributed million product sales increase compared letairis sales contributed million product sales increase compared cayston contributed million product sales increase compared product sales europe increased compared primarily driven sales growth antiviral franchise increase partially offset impact price reductions due part austerity measures certain european countries antiviral product sales europe totaled billion increase compared billion driven primarily sales atripla truvada foreign currency exchange net hedges unfavorable impact european product sales compared significant percentage product sales continues denominated foreign currencies face exposure adverse movements foreign currency exchange rates used foreign currency exchange forward option contracts hedge percentage forecasted international sales primarily denominated euro foreign currency exchange net hedges favorable impact million revenues compared unfavorable impact million revenues compared expect total product sales continue grow expect realize full year impact related newest product compleraeviplera expect launch quad united states september table contents product sales following table summarizes period period changes product sales thousands change change antiviral products atripla truvada viread hepsera compleraeviplera emtriva total antiviral products ambisome letairis ranexa total product sales antiviral products antiviral product sales increased compared compared atripla atripla sales increased compared driven primarily sales growth europe united states atripla sales increased compared driven primarily sales growth united states europe benefited launch atripla france second quarter atripla sales include efavirenz component gross margin zero efavirenz portion atripla sales approximately billion billion million respectively atripla sales accounted total antiviral product sales respectively truvada truvada sales increased compared driven primarily sales growth europe united states truvada sales increased compared driven primarily sales growth united states europe truvada sales accounted total antiviral product sales respectively antiviral products antiviral product sales include product sales viread hepsera compleraeviplera emtriva decreased compared due primarily decrease hepsera sales partially offset launch compleraeviplera following fda approval august european commission approval november antiviral product sales decreased compared due primarily decreases hepsera sales partially offset sales growth viread ambisome sales ambisome increased compared driven primarily sales growth latin america canada europe sales ambisome increased compared driven primarily sales growth certain markets outside united states partially offset unfavorable foreign table contents currency exchange impact ambisome product sales united states canada relate solely sales ambisome astellas pharma us inc recorded manufacturing cost letairis sales letairis increased compared compared driven primarily sales growth new patient enrollments increased following fdas approval march remove liver toxicity language boxed warning ranexa sales ranexa increased compared compared driven primarily sales growth royalty revenues following table summarizes period period changes royalty revenues thousands change change royalty revenues historically significant source royalty revenues sales tamiflu roche recognize royalties tamiflu sales roche quarter following quarter tamiflu sales recognized roche royalty revenues declined compared due primarily lower tamiflu royalties roche royalty revenues increased compared driven primarily increase royalty revenues include royalties gsk hepsera royalties astellas us llc lexiscan royalties japan tobacco truvada partially offset lower tamiflu royalties roche tamiflu royalties since second quarter decreasing due declining pandemic planning initiatives worldwide tamiflu royalties roche contributed million million million total royalty revenues respectively cost goods sold product gross margin following table summarizes period period changes product sales thousands cost goods sold thousands product gross margin change change total product sales cost goods sold product gross margin product gross margin decrease compared due primarily annual selling price adjustment percentage share atripla paid partner product gross margin consistent product gross margin expect product gross margin lower compared due primarily product mix expect higher proportion atripla sales partially offset increase product gross margin related full year impact sales compleraeviplera anticipated launch quad september table contents research development expenses manage rd expenses identifying research development activities anticipate performed given period prioritizing efforts based scientific data probability successful development market potential available human capital resources similar considerations continually review rd pipeline status development necessary reallocate resources among rd portfolio believe best support future growth business following table summarizes period period changes rd expenses thousands change change research development rd expenses summarized consist primarily personnel costs including salaries benefits stockbased compensation clinical studies performed cros materials supplies licenses fees milestone payments collaboration arrangements overhead allocations consisting various support facilitiesrelated costs following table provides breakout rd expenses major cost type thousands clinical studies outside services personnel expenses impairment restructuring charges total rd expenses increased million compared due primarily million increase clinical studies outside services related study progression liver disease hiv new investments oncology inflammation new inlicense agreements milestones ongoing collaborations million increase personnel expenses due higher headcount increase expenses including research process development manufacturing support clinical studies ongoing growth business partially offset decrease impairment charges rd expenses increased million compared due primarily impairment charges million recorded related iprd assets acquired cv therapeutics million clinical studies expenses related increased hiv research activities million compensation benefits expenses majority impairment charge related gs program product candidate phase clinical studies treatment diabetes hypertriglyceridemia terminated fourth quarter due unfavorable results pharmacokinetics pharmacodynamics tests demonstrated limited effectiveness compound patients given results believe alternative future uses us market participants increase rd expenses partially offset million due timing certain clinical studies million lower rd expense reimbursement related collaboration tibotec expect rd expenses increase levels due continued investment internal collaborative rd efforts anticipate product candidates progress advanced phases clinical studies well adding clinical development programs pipeline table contents selling general administrative expenses following table summarizes period period changes sga expenses thousands change change selling general administrative sga expenses comprised primarily compensation benefits associated sales marketing finance human resources legal administrative personnel facilities overhead costs outside marketing advertising legal expenses general administrative costs sga expenses increased million compared due primarily increased contract legal professional services million pharmaceutical excise tax million resulting us healthcare reform increased compensation benefits expenses million result higher headcount support expanding commercial activities promotional costs million driven expanding sales marketing activities bad debt provisions million associated slower collections southern european countries sga expenses increased million compared due primarily increased compensation benefits expenses million result higher headcount support expanding commercial activities increased contract professional services expenses million driven primarily expanding sales marketing activities million related facilities equipment expenses expect sga expenses increase levels due increased investments supporting continued growth franchises increase us pharmaceutical excise tax believe appropriate sga infrastructure support growth business restructuring expenses second quarter approved communicated plan close research operations durham north carolina consolidate liver disease research activities foster city california believe plan allow employees collaborate effectively advance programs liver disease area recorded total million million restructuring expenses sga rd expenses respectively related employee severance facilitiesrelated expenses plan december closed operations durham incurred expect incur additional significant costs connection plan second quarter approved plan realize certain synergies result cv therapeutics acquisition realigning cardiovascular operations eliminating redundancies recorded million million restructuring expenses sga rd expenses respectively related employee severance relocation lease termination costs facilitiesrelated expenses recorded million restructuring expenses sga related facilitiesrelated expenses total costs incurred plan million million sga rd expenses respectively incurred expect incur additional significant costs connection plan interest income net recorded interest income net million million million respectively increase interest income net compared driven primarily favorable net foreign currency exchange impact increase interest income partially offset increase costs related hedging activities increase interest income net compared driven primarily decreased costs related hedging activities table contents expect interest income decrease spent cash cash equivalents marketable securities partially fund pharmasset acquisition closed january interest expense interest expense million million million respectively increase interest expense compared due primarily issuance convertible senior notes billion july issuance senior unsecured notes billion march issuance senior unsecured notes billion december bridge financing associated acquisition pharmasset increase partially offset maturity convertible senior notes due may aggregate principal balance million increase interest expense compared due primarily issuance senior convertible notes billion july expect interest expense increase due additional debt issued connection acquisition pharmasset included billion senior unsecured notes issued december billion bank debt raised subsequent december provision income taxes provision income taxes million billion million respectively effective tax rate differed us federal statutory rate due primarily tax credits certain operating earnings nonus subsidiaries considered indefinitely invested outside united states partially offset state taxes nondeductible pharmaceutical excise tax provide us income taxes undistributed earnings foreign operations intended permanently reinvested effective tax rate differed us federal statutory rate due primarily tax credits certain operating earnings nonus subsidiaries considered indefinitely invested outside united states partially offset state taxes effective tax rate differed us federal statutory rate due primarily tax credits resolution certain tax positions tax authorities certain operating earnings nonus subsidiaries considered indefinitely invested outside united states partially offset state taxes revaluation certain state tax assets related integration cv therapeutics liquidity capital resources believe existing capital resources supplemented cash flows generated operating activities adequate satisfy capital needs foreseeable future cash cash equivalents marketable securities increased significantly fourth quarter issued senior unsecured notes total net proceeds billion fund billion acquisition pharmasset closed january additional information describing cash cash equivalents marketable securities working capital primary sources uses cash table contents following table summarizes cash cash equivalents marketable securities working capital cash flow activities end periods presented thousands december cash cash equivalents marketable securities working capital year ended december cash provided used operating activities investing activities financing activities cash cash equivalents marketable securities cash cash equivalents marketable securities totaled billion december increase billion december increase primarily attributable issuance senior unsecured notes total net proceeds billion cash provided operations billion increase partially offset billion used repurchases common stock stock repurchase programs million used repay convertible senior notes due may million used recent acquisitions arresto calistoga net proceeds related senior unsecured notes issued december used fund acquisition pharmasset january cash cash equivalents marketable securities totaled billion december increase billion december increase primarily attributable net cash provided operations billion net proceeds billion issuance convertible senior notes partially offset billion used repurchase common stock stock repurchase programs working capital working capital billion december increase billion working capital december primarily attributable increase billion cash cash equivalents shortterm marketable securities resulting billion issuance senior unsecured notes december sales longterm marketable securities anticipation acquisition pharmasset decrease million current portion longterm debt obligations net due primarily repayment convertible senior notes due may working capital billion december increase million working capital december increase primarily attributable increase million cash cash equivalents shortterm marketable securities increase million accounts receivable net primarily driven increased product sales increase million inventories due primarily purchase efavirenz estimated net selling price bms table contents increase partially offset increase million current portion convertible senior notes net longterm obligations due reclassification convertible senior notes due may current liabilities cash provided operating activities cash provided operating activities billion primarily related net income billion adjusted noncash items million depreciation amortization expenses million stockbased compensation expenses million deferred income taxes million net cash inflow related changes operating assets liabilities partially offset million excess tax benefits stock option exercises reclassified cash used financing activities cash provided operating activities billion primarily related net income billion adjusted noncash items million depreciation amortization expenses million stockbased compensation expenses million iprd impairment expenses million tax benefits employee stock plans partially offset million net cash outflow related changes operating assets liabilities million excess tax benefits stock option exercises reclassified cash used financing activities cash provided operating activities billion primarily related net income billion adjusted noncash items million stockbased compensation expenses million amortization expenses cash provided used investing activities cash provided investing activities billion consisting net proceeds billion related sales marketable securities connection acquisition pharmasset partially offset million used acquisitions arresto calistoga million capital expenditures cash used investing activities billion driven net use billion purchases marketable securities million used acquisition cgi million capital expenditures cash used investing activities billion driven cash used acquisition cv therapeutics billion net cash acquired net use million purchases marketable securities million capital expenditures year capital expenditures included purchase office building approximately acres land located foster city california cash provided used financing activities cash provided financing activities billion driven primarily issuance billion senior unsecured notes billion raised december partially fund pharmasset acquisition net issuance costs million proceeds issuances common stock employee stock plans cash proceeds partially offset billion used repurchase common stock stock repurchase programs including commissions million used repay convertible senior notes due may cash used financing activities billion driven primarily billion used repurchase common stock stock repurchase programs million used purchase note hedges related convertible senior notes due may may cash outflows partially offset billion net proceeds issuance notes million proceeds sale warrants related notes million proceeds issuances common stock employee stock plans table contents cash used financing activities billion driven primarily million used repurchase common stock stock repurchase program million used extinguish convertible senior notes assumed acquisition cv therapeutics cash outflows partially offset proceeds million issuances common stock employee stock plans completed may threeyear billion stock repurchase program time initiated purchases january threeyear billion stock repurchase program completed program repurchased retired total million shares common stock average purchase price per share december remaining authorized amount stock repurchases may made repurchase program billion longterm debt eligible borrow aggregate billion revolving credit loans amended restated credit agreement credit agreement also included subfacility swingline loans letters credit december million letters credit outstanding billion credit agreement january fully repaid outstanding obligations credit agreement time credit agreement terminated january conjunction acquisition pharmasset entered fiveyear billion revolving credit facility credit agreement fiveyear revolving credit agreement million shortterm revolving credit facility credit agreement shortterm revolving credit agreement billion term loan facility term loan credit agreement borrowed aggregate principal amount billion follows million five year revolving credit agreement million shortterm revolving credit agreement billion term loan credit agreement upon close acquisition three credit agreements contain customary representations warranties affirmative negative financial maintenance covenants events default loans bear interest either eurodollar rate plus applicable margin ii base rate plus applicable margin defined applicable credit agreement may reduce commitments may prepay loans agreements whole part time without premium penalty fiveyear revolving credit agreement inclusive million swing line loan subfacility million letter credit subfacility five year revolving credit agreement terminate amounts owing thereunder shall due payable january shortterm revolving credit agreement terminate amounts owing thereunder shall due payable january however may request maturity date extended january principal repayment installments term loan credit agreement due payable specified term loan credit agreement final principal installment payment due payable january december issued senior unsecured notes registered offering aggregate principal amount billion partially fund acquisition pharmasset notes pay interest fixed annual rates ranging convertible senior notes due may matured repaid aggregate principal balance million also paid million cash related conversion spread matured notes represent conversion value excess principal amount received million cash related convertible note hedges warrants related convertible senior notes due may expired august table contents march issued senior unsecured notes due april registered offering aggregate principal amount billion notes pay interest fixed annual rate believe existing capital resources supplemented cash generated operations adequate satisfy capital needs foreseeable future future capital requirements depend many factors including limited following commercial performance current future products progress scope rd efforts including preclinical studies clinical trials cost timing outcome regulatory reviews expansion sales marketing capabilities administrative expenses possibility acquiring additional manufacturing capabilities office facilities possibility acquiring companies new products establishment additional collaborative relationships companies costs associated defense settlement adverse results litigation government investigations may future require additional funding could form proceeds equity debt financings funding required assure available us favorable terms balance sheet arrangements balance sheet arrangements contractual obligations contractual obligations consist debt obligations operating leases capital commitments purchase obligations active pharmaceutical ingredients inventoryrelated items clinical trials contracts following table summarizes significant enforceable legally binding obligations future commitments obligations related contracts likely continue regardless fact certain obligations may cancelable december thousands payments due period less one contractual obligations total year years years years longterm debt operating lease obligations capital commitments purchase obligations clinical trials total longterm debt obligations include future interest payments based fixed rates convertible senior notes due may may may respectively longterm debt obligations also include future interest payments based fixed rates senior unsecured notes due december december april december december respectively december aggregate carrying values convertible notes senior unsecured notes billion billion respectively table contents december firm capital project commitments approximately million primarily relating facilities improvement projects december firm purchase commitments related active pharmaceutical ingredients certain inventoryrelated items amounts include minimum purchase requirements actual purchases expected significantly exceed amounts addition committed make potential future milestone payments third parties part licensing collaboration development arrangements payments agreements generally become due payable upon achievement certain developmental regulatory andor commercial milestones achievement milestones neither probable reasonably estimable contingencies recorded consolidated balance sheets included table december several clinical studies various clinical trial phases significant clinical trial expenditures cros although material contracts cros cancelable historically cancelled contracts amounts reflect commitments based existing contracts reflect future modifications terminations existing contracts anticipated potential new contracts total gross unrecognized tax benefit liabilities million december believe reasonably possible unrecognized tax benefits significantly change next months expect clarification irs tax authorities around uncertain tax positions unrecognized tax benefits included longterm income taxes payable noncurrent deferred tax assets consolidated balance sheet included table recent accounting pronouncements may financial accounting standards board fasb issued amendments existing standard fair value measurement achieve common guidance us generally accepted accounting principles international financial reporting standards addition amended standard revises certain requirements measuring fair value disclosure around fair value measurement require additional fair value measurements intended establish valuation standards affect valuation practices outside financial reporting updated standard effective us beginning first quarter early adoption permitted adoption amendments material impact consolidated financial statements june fasb issued update existing standard comprehensive income make presentation items within comprehensive income oci prominent updated standard prohibits current presentation oci statement stockholders equity instead provides public companies option presenting oci continuous statement comprehensive income two separate consecutive statements additionally update requires reclassification adjustments displayed face financial statements oci reported december fasb issued another update indefinitely deferred specific requirement presenting reclassification adjustments oci net income oci face financial statements deferral period existing requirements presentation reclassification adjustments must continue followed updated standard effective us beginning first quarter upon adoption updated standard impact presentation consolidated financial statements however impact financial position results operations september fasb issued new accounting guidance intended simplify goodwill impairment testing entities allowed perform qualitative assessment goodwill impairment determine whether quantitative assessment necessary guidance effective goodwill impairment tests performed interim annual periods fiscal years beginning december standard effective us beginning first quarter adoption guidance material impact consolidated financial statements table contents december fasb issued new standard address disclosure requirements around offsetting financial derivative instruments related arrangements enable users financial statements understand effect arrangements companys financial position update requires companies disclose net gross amounts relevant assets liabilities offset notes financial statements updated standard effective us beginning first quarter applied retrospectively comparative periods presented believe adoption standard material impact consolidated financial statements table contents item quantitative qualitative disclosures market risk foreign currency exchange risk operations include manufacturing sales activities united states canada ireland well sales activities countries outside united states including europe asia pacific result financial results could significantly affected factors changes foreign currency exchange rates weak economic conditions foreign markets distribute products operating results exposed changes foreign currency exchange rates us dollar various foreign currencies significant euro us dollar strengthens currencies relative value sales made respective foreign currency decreases conversely us dollar weakens currencies relative amounts sales increase overall net receiver foreign currencies therefore benefit weaker us dollar adversely affected stronger us dollar relative foreign currencies transact significant amounts business significant percentage product sales denominated foreign currencies enter foreign currency exchange forward option contracts partially mitigate impact changes currency exchange rates net cash flows foreign currency denominated sales also hedge certain monetary assets liabilities denominated foreign currencies reduces eliminate exposure currency fluctuations date transaction recorded date cash collected paid general market risks contracts offset corresponding gains losses transactions hedged following table summarizes notional amounts weightedaverage currency exchange rates fair values open foreign currency exchange forward contracts december foreign currency exchange option contracts outstanding december contracts maturities months less weightedaverage rates stated terms amount us dollars per foreign currency fair values represent estimated settlement amounts december notional amounts fair values us dollars thousands foreign currency exchange forward contracts december december weighted weighted average average notional settlement notional settlement currency amount price fair value amount price fair value euro british pound canadian dollar australian dollar swiss franc danish krone swedish krone norwegian krone new zealand dollar turkish lira polish zloty total table contents interest rate risk portfolio availableforsale marketable securities fixed variable rate liabilities create exposure interest rate risk respect investment portfolio adhere investment policy requires us limit amounts invested securities based credit rating maturity industry group investment type issuer except securities issued us government goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return following table summarizes expected maturities average interest rates interestgenerating assets interestbearing liabilities december dollars thousands total fair years ending december value december thereafter total assets availableforsale debt securities average interest rate liabilities longterm debt average interest rate april issued convertible senior notes due may private placement pursuant rule securities act amended notes issued par bear interest rates may converted shares common stock subject certain circumstances july issued convertible senior notes due may may private placement pursuant rule securities act amended notes due may may issued par bear interest rates respectively may converted shares common stock subject certain circumstances march issued senior unsecured notes due april registered offering notes pay interest fixed annual rate december issued senior unsecured notes due december registered offering notes pay interest fixed annual rates ranging connection funding billion acquisition pharmasset liquidated approximately billion investment portfolio late proceeds sales reinvested money market funds totaled billion december interest rate risk money market funds low excluded balance table interest rate sensitive instruments continue invest existing portfolio securities similar profile however amounts invested generally smaller shorter investment horizon credit risk december held approximately million auction rate securities within availableforsale longterm marketable securities auction rate securities comprised less total table contents cash cash equivalents marketable securities december began observing failed auctions auction rate securities underlying assets comprised student loans auction rate securities including subject failed auctions currently rated aaa consistent high quality rating required investment policy supported federal government part federal family education loan program overcollateralized auction rate securities reset every seven days maturity dates ranging annual interest rates ranging december auction rate securities continued earn interest auctions continue fail securities invested may unable liquidate auction rate securities par need desire access funds invested securities however based expected operating cash flows well access funds credit facility believe able hold securities recovery auction market related securities may final maturity result anticipate current illiquidity auction rate securities material effect cash requirements working capital december held greek governmentissued bonds estimated fair value approximately million within availableforsale long term marketable securities greek government agreed settle majority aged outstanding accounts receivable zerocoupon bonds currently bonds trade infrequently open market substantial discount face value believe able hold securities maturity result anticipate illiquidity securities material effect cash requirements working capital light volatility developments seen financial markets continue review cash equivalents marketable securities carefully strive invest prudently believe maintaining primary goals investment policy safety preservation principal diversification risk well liquidity helped protect us many risks credit markets allowing us continue meet operating cash flow requirements well execute strategic opportunities also subject credit risk accounts receivable related product sales accounts receivable balance december billion compared billion december majority trade accounts receivable arises product sales united states europe december accounts receivables southern europe specifically greece italy portugal spain totaled approximately billion million greater days past due million greater days past due item financial statements supplementary data financial statements required item set forth beginning annual report incorporated herein reference item changes disagreements accountants accounting financial disclosure applicable item controls procedures evaluation disclosure controls procedures evaluation december carried supervision participation management including chief executive officer chief financial officer effectiveness disclosure controls procedures defined rule ae securities exchange act table contents amended exchange act controls procedures company designed ensure information required disclosed company reports files submits exchange act recorded processed summarized reported within time periods specified securities exchange commissions rules forms information accumulated communicated companys management including chief executive officer chief financial officer appropriate allow timely decisions regarding required disclosure based upon evaluation chief executive officer chief financial officer concluded disclosure controls procedures effective december b managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting term defined rule af exchange act internal control system designed provide reasonable assurance regarding preparation fair presentation financial statements external purposes accordance generally accepted accounting principles internal control systems matter well designed inherent limitations provide reasonable assurance objectives internal control system met supervision participation management including chief executive officer chief financial officer conducted evaluation effectiveness internal control financial reporting based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission coso based evaluation concluded internal control financial reporting effective december independent registered public accounting firm ernst young llp audited consolidated financial statements included annual report issued report effectiveness internal control financial reporting december report audit internal control financial reporting appears c changes internal control financial reporting management including chief executive officer chief financial officer evaluated changes internal control financial reporting occurred quarter ended december concluded change quarter materially affected reasonably likely materially affect internal control financial reporting completed implementation new enterprise resource planning erp system fourth quarter implementation undertaken response identified deficiency weakness internal controls financial reporting undertaken establish scalable foundation core business processes item b information applicable table contents report independent registered public accounting firm board directors stockholders gilead sciences inc audited gilead sciences incs internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso criteria gilead sciences incs management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying managements report internal control financial reporting responsibility express opinion companys internal control financial reporting based audit conducted audit accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk performing procedures considered necessary circumstances believe audit provides reasonable basis opinion companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate opinion gilead sciences inc maintained material respects effective internal control financial reporting december based coso criteria also audited accordance standards public company accounting oversight board united states consolidated financial statements gilead sciences inc report dated february expressed unqualified opinion thereon ernst young llp redwood city california february table contents part iii item directors executive officers corporate governance information required item concerning directors executive officers incorporated reference sections definitive proxy statement filed securities exchange commission pursuant regulation connection annual meeting stockholders proxy statement headings nominees qualification nominees board committees meetings executive officers section beneficial ownership reporting compliance written code ethics applies directors employees including executive officers including without limitation principal executive officer principal financial officer principal accounting officer controller persons performing similar functions code ethics available website httpwwwgileadcom investors section corporate governance changes waivers code ethics disclosed website intend satisfy disclosure requirement item form k regarding amendment waiver provision code ethics disclosing information website item executive compensation information required item incorporated reference sections proxy statement headings executive compensation compensation committee interlocks insider participation compensation committee report compensation nonemployee board members item security ownership certain beneficial owners management related stockholder matters information required item incorporated reference sections proxy statement headings security ownership certain beneficial owners management securities authorized issuance equity compensation plans item certain relationships related transactions director independence information required item incorporated reference sections proxy statement headings nominees certain relationships related party transactions item principal accountant fees services information required item incorporated reference section proxy statement heading principal accountant fees services table contents part iv item exhibits financial statement schedules following documents filed part annual report index list consolidated financial statements report independent registered public accounting firm audited consolidated financial statements consolidated balance sheets consolidated statements income consolidated statements stockholders equity consolidated statements cash flows notes consolidated financial statements schedule ii included report schedules omitted required required information included financial statements notes thereto exhibits following exhibits filed herewith incorporated reference exhibit exhibit footnote number description document agreement plan merger among registrant apex merger sub inc cv therapeutics inc dated march agreement plan merger among registrant cougar merger sub inc cgi pharmaceuticals inc dated june agreement plan merger among registrant arroyo merger sub inc arresto biosciences inc dated december agreement plan merger among registrant gilead biopharmaceutics ireland corporation gilead sciences limited calistoga pharmaceuticals inc shareholder representative services llc stockholders agent dated february amendment agreement plan merger among registrant gilead biopharmaceutics ireland corporation hot springs acquisition corp calistoga pharmaceuticals inc shareholder representative services llc stockholders agent entered march agreement plan merger among registrant merger sub pharmasset inc dated november restated certificate incorporation registrant amended may certificate designation series junior participating preferred stock registrant certificate amendment certificate designation series junior participating preferred stock registrant amended restated bylaws registrant amended restated may reference made exhibit exhibit exhibit exhibit amended restated rights agreement registrant chasemellon shareholder services llc dated october table contents exhibit exhibit footnote number description document first amendment amended restated rights agreement registrant mellon investor services llc formerly known chasemellon shareholder services llc dated october second amendment amended restated rights agreement registrant mellon investor services llc formerly known chasemellon shareholder services llc dated may indenture related convertible senior notes due registrant wells fargo bank national association trustee including form convertible senior note due dated april indenture related convertible senior notes due registrant wells fargo bank national association trustee including form convertible senior note due dated july indenture related convertible senior notes due registrant wells fargo bank national association trustee including form convertible senior note due dated july indenture dated march registrant wells fargo national association trustee first supplemental indenture dated march registrant wells fargo national association trustee form note included exhibit second supplemental indenture dated december registrant wells fargo national association trustee form note included exhibit form note included exhibit form note included exhibit form note included exhibit confirmation otc convertible note hedge related notes dated april amended restated april registrant bank america na confirmation otc warrant transaction dated april amended restated april registrant bank america na warrants expiring confirmation otc convertible note hedge related notes dated july registrant goldman sachs co confirmation otc convertible note hedge related notes dated july registrant jpmorgan chase bank national association confirmation otc convertible note hedge related notes dated july registrant goldman sachs co confirmation otc convertible note hedge related notes dated july registrant jpmorgan chase bank national association confirmation otc warrant transaction dated july registrant goldman sachs co warrants expiring confirmation otc warrant transaction dated july registrant jpmorgan chase bank national association warrants expiring table contents exhibit exhibit footnote number description document confirmation otc warrant transaction dated july registrant goldman sachs co warrants expiring confirmation otc warrant transaction dated july registrant jpmorgan chase bank national association warrants expiring confirmation otc additional convertible note hedge related notes dated august registrant goldman sachs co confirmation otc additional convertible note hedge related notes dated august registrant jpmorgan chase bank national association confirmation otc additional convertible note hedge related notes dated august registrant goldman sachs co confirmation otc additional convertible note hedge related notes dated august registrant jpmorgan chase bank national association confirmation otc additional warrant transaction dated august registrant goldman sachs co warrants expiring confirmation otc additional warrant transaction dated august registrant jpmorgan chase bank national association warrants expiring confirmation otc additional warrant transaction dated august registrant goldman sachs co warrants expiring confirmation otc additional warrant transaction dated august registrant jpmorgan chase bank national association warrants expiring amendment confirmation otc convertible note hedge related notes dated august registrant goldman sachs co amendment confirmation otc convertible note hedge related notes dated august registrant jpmorgan chase bank national association amendment confirmation otc convertible note hedge related notes dated august registrant goldman sachs co amendment confirmation otc convertible note hedge related notes dated august registrant jpmorgan chase bank national association amendment confirmation otc additional convertible note hedge related notes dated august registrant goldman sachs co amendment confirmation otc additional convertible note hedge related notes dated august registrant jpmorgan chase bank national association amendment confirmation otc additional convertible note hedge related notes dated august registrant goldman sachs co amendment confirmation otc additional convertible note hedge related notes dated august registrant jpmorgan chase bank national association year revolving credit facility credit agreement among registrant gilead biopharmaceutics ireland corporation borrowers bank america na administrative agent swing line lender lc issuer certain lenders parties thereto barclays capital syndication agent goldman sachs bank usa jpmorgan chase bank na royal bank canada wells fargo bank na codocumentation agents dated january table contents exhibit exhibit footnote number description document shortterm revolving credit facility credit agreement among registrant gilead biopharmaceutics ireland corporation borrowers bank america na administrative agent certain lenders parties thereto barclays capital syndication agent goldman sachs bank usa jpmorgan chase bank na royal bank canada wells fargo bank na codocumentation agents dated january term loan facility credit agreement among registrant borrower bank america na certain lenders parties thereto barclays capital syndication agent goldman sachs bank usa jpmorgan chase bank na royal bank canada wells fargo bank na codocumentation agents dated january parent guaranty agreement year revolving credit facility dated january registrant parent guaranty agreement shortterm revolving credit facility dated january registrant gilead sciences inc stock option plan amended january form option agreements used stock option plan gilead sciences inc nonemployee directors stock option plan amended january form option agreement used gilead sciences inc nonemployee directors stock option plan gilead sciences inc equity incentive plan amended may form employee stock option agreement used equity incentive plan grants prior february form employee stock option agreement used equity incentive plan grants made february april form employee stock option agreement used equity incentive plan grants commencing may form employee stock option agreement used equity incentive plan grants commencing february form employee stock option agreement used equity incentive plan subsequent year grants form nonemployee director stock option agreement used equity incentive plan grants prior form nonemployee director option agreement used equity incentive plan initial grants made form nonemployee director option agreement used equity incentive plan annual grants made may form nonemployee director option agreement used equity incentive plan annual grants commencing may form restricted stock unit issuance agreement used equity incentive plan annual grants nonemployee directors commencing may form restricted stock award agreement used equity incentive plan annual grants certain nonemployee directors form performance share award agreement used equity incentive plan grants made table contents exhibit exhibit footnote number description document form performance share award agreement used equity incentive plan grants made form performance share award agreement used equity incentive plan grants made form performance share award agreement used equity incentive plan grants made form performance share award agreement used equity incentive plan form restricted stock unit issuance agreement used equity incentive plan grants made prior may form restricted stock unit issuance agreement used equity incentive plan grants commencing may form restricted stock unit issuance agreement used equity incentive plan servicebased vesting executive officers commencing november form restricted stock unit issuance agreement used equity incentive plan gilead sciences inc employee stock purchase plan amended restated november gilead sciences inc international employee stock purchase plan adopted november gilead sciences inc deferred compensation planbasic plan document gilead sciences inc deferred compensation planadoption agreement addendum gilead sciences inc deferred compensation plan gilead sciences inc deferred compensation plan amended restated october gilead sciences inc severance plan amended december gilead sciences inc corporate bonus plan amended restated gilead sciences inc code section bonus plan base salaries named executive officers offer letter dated april registrant robin washington form indemnity agreement entered registrant directors executive officers form employee proprietary information invention agreement entered registrant certain officers key employees form employee proprietary information invention agreement entered registrant certain officers key employees revised september amended restated collaboration agreement among registrant gilead holdings llc bristolmyers squibb company er squibb sons llc bristolmyers squibb gilead sciences llc dated september commercialization agreement gilead sciences limited bristolmyers squibb company dated december table contents exhibit exhibit footnote number description document amendment agreement dated october registrant institute organic chemistry biochemistry iocb rega stichting vzw rega together following exhibits license agreement dated december registrant iocb rega license agreement license agreement dated october registrant iocb rega october license agreement license agreement dated december registrant iocb rega december license agreement amendment agreement registrant iocbrega dated december amending license agreement december license agreement sixth amendment agreement license agreement iocbrega registrant dated august amending october license agreement december license agreement development license agreement among registrant f hoffmannla roche ltd hoffmannla roche inc dated september first amendment supplement dated november development licensing agreement registrant f hoffmannla roche ltd hoffmanla roche inc dated september second amendment dated december development licensing agreement registrant f hoffmannla roche ltd hoffmanla roche inc dated september exclusive license agreement registrant successor triangle pharmaceuticals inc glaxo group limited wellcome foundation limited glaxo wellcome inc emory university dated may royalty sale agreement among registrant emory university investors trust custodial services ireland limited solely capacity trustee royalty pharma dated july amended restated license agreement registrant emory university investors trust custodial services ireland limited solely capacity trustee royalty pharma dated july license agreement japan tobacco inc registrant dated march first amendment license agreement japan tobacco inc registrant dated may second amendment license agreement japan tobacco inc registrant dated may third amendment license agreement japan tobacco inc registrant dated july fourth amendment license agreement japan tobacco inc registrant dated july license agreement registrant successor myogen inc abbott deutschland holding gmbh dated october license agreement registrant successor cv therapeutics inc syntex usa inc dated march first amendment license agreement registrant successor cv therapeutics inc syntex usa inc dated july amendment license agreement registrant successor cv therapeutics inc syntex usa inc dated november table contents exhibit exhibit footnote number description document amendment license agreement registrant successor cv therapeutics inc roche palo alto llc successor interest merger syntex usa inc dated june amendment license agreement registrant successor cv therapeutics inc roche palo alto llc successor interest merger syntex usa inc dated december license collaboration agreement among registrant gilead sciences limited tibotec pharmaceuticals dated july second amendment license collaboration agreement among registrant gilead sciences limited tibotec pharmaceuticals dated july master clinical commercial supply agreement gilead world markets limited registrant patheon inc dated january tenofovir disoproxil fumarate manufacturing supply agreement gilead sciences limited pharmachem technologies grand bahama ltd dated july addendum tenofovir disoproxil fumarate manufacturing supply agreement gilead sciences limited pharmachem technologies grand bahama ltd dated may addendum tenofovir disoproxil fumarate manufacturing supply agreement gilead sciences limited pharmachem technologies grand bahama ltd dated december addendum tenofovir disoproxil fumarate manufacturing supply agreement gilead sciences limited pharmachem technologies grand bahama ltd dated february tenofovir disoproxil fumarate manufacturing supply agreement gilead sciences limited ampac fine chemicals llc dated november restated amended toll manufacturing agreement gilead sciences limited registrant nycomed gmbh formerly altana pharma oranienburg gmbh dated november emtricitabine manufacturing supply agreement gilead sciences limited evonik degussa gmbh formerly known degussa ag dated june amendment emtricitabine manufacturing supply agreement gilead sciences limited evonik degussa gmbh formerly known degussa ag dated april purchase sale agreement escrow instructions electronics imaging inc registrant dated october subsidiaries registrant consent independent registered public accounting firm power attorney reference made signature certification chief executive officer required rule aa rule da securities exchange act amended certification chief financial officer required rule aa rule da securities exchange act amended certifications chief executive officer chief financial officer required rule ab rule db section chapter title united states code usc table contents exhibit exhibit footnote number description document following materials registrants annual report year ended december formatted extensible business reporting language xbrl includes consolidated balance sheets december ii consolidated statements income years ended december iii consolidated statements stockholders equity years ended december iv consolidated statements cash flows years ended december v notes consolidated financial statements filed exhibit registrants current report form k filed march incorporated herein reference filed exhibit registrants quarterly report form q quarter ended june incorporated herein reference filed exhibit registrants annual report fiscal year ended december incorporated herein reference filed exhibit registrants quarterly report form q quarter ended march incorporated herein reference filed exhibit registrants current report form k filed november incorporated herein reference filed exhibit registrants current report form k filed may incorporated herein reference filed exhibit registrants current report form k filed november incorporated herein reference filed exhibit registrants current report form k filed may incorporated herein reference filed exhibit registrants current report form k filed october incorporated herein reference filed exhibit registrants current report form k filed october incorporated herein reference filed exhibit registrants registration statement form filed june incorporated herein reference filed exhibit registrants current report form k filed april incorporated herein reference filed exhibit registrants current report form k filed august incorporated herein reference filed exhibit registrants current report form k filed april incorporated herein reference filed exhibit registrants current report form k filed december incorporated herein reference filed exhibit registrants quarterly report form q quarter ended june incorporated herein reference filed exhibit registrants quarterly report form q quarter ended september incorporated herein reference filed exhibit registrants current report form k filed january incorporated herein reference filed exhibit registrants registration statement form filed january incorporated herein reference filed exhibit registrants registration statement form amended incorporated herein reference filed exhibit registrants annual report fiscal year ended december incorporated herein reference table contents filed exhibit registrants current report form k filed may incorporated herein reference filed exhibit registrants current report form ka filed february incorporated herein reference filed exhibit registrants annual report fiscal year ended december incorporated herein reference filed exhibit registrants quarterly report form q quarter ended june incorporated herein reference filed exhibit registrants annual report fiscal year ended december incorporated herein reference filed exhibit registrants annual report fiscal year ended december incorporated herein reference filed exhibit registrants quarterly report form q quarter ended march incorporated herein reference filed exhibit registrants current report form k first filed december incorporated herein reference filed exhibit registrants quarterly report form q quarter ended march incorporated herein reference filed exhibit registrants registration statement form filed december incorporated herein reference filed exhibit registrants annual report fiscal year ended december incorporated herein reference filed exhibit registrants annual report fiscal year ended december incorporated herein reference information included registrants current report form k filed february incorporated herein reference filed exhibit registrants quarterly report form q quarter ended june incorporated herein reference filed exhibit registrants quarterly report form q quarter ended september incorporated herein reference filed exhibit registrants annual report fiscal year ended march incorporated herein reference filed exhibit registrants annual report fiscal year ended december incorporated herein reference filed exhibit registrants annual report fiscal year ended december incorporated herein reference filed exhibit triangle pharmaceuticals incs quarterly report form qa filed november incorporated herein reference filed exhibit registrants quarterly report form q quarter ended september incorporated herein reference filed exhibit registrants quarterly report form q quarter ended march incorporated herein reference filed exhibit registrants quarterly report form q quarter ended september incorporated herein reference filed exhibit myogen incs registration statement form amended originally filed august incorporated herein reference filed exhibit cv therapeutics incs registration statement form amended originally filed april incorporated herein reference filed exhibit cv therapeutics incs quarterly report form q quarter ended june incorporated herein reference filed exhibit registrants quarterly report form q quarter ended september incorporated herein reference table contents filed exhibit registrants annual report fiscal year ended december incorporated herein reference filed exhibit registrants current report form k filed august incorporated herein reference agreement plan merger merger agreement contains representations warranties registrant cougar merger sub inc cgi pharmaceuticals inc made solely specific dates representations warranties made solely purposes merger agreement may subject important qualifications limitations agreed registrant cougar merger sub inc cgi pharmaceuticals inc moreover representations warranties may accurate complete specified date may subject standard materiality provided merger agreement used purpose allocating risk among registrant cougar merger sub inc cgi pharmaceuticals inc rather establishing matters facts agreement plan merger arresto merger agreement contains representations warranties registrant arroyo merger sub inc arresto biosciences inc made solely specific dates representations warranties made solely purposes arresto merger agreement may subject important qualifications limitations agreed registrant arroyo merger sub inc arresto biosciences inc moreover representations warranties may accurate complete specified date may subject standard materiality provided arresto merger agreement used purpose allocating risk among registrant arroyo merger sub inc arresto biosciences inc rather establishing matters facts agreement plan merger calistoga merger agreement contains representations warranties registrant gilead biopharmaceutics ireland corporation gilead sciences limited calistoga pharmaceuticals inc made solely specific dates representations warranties made solely purposes calistoga merger agreement may subject important qualifications limitations agreed registrant gilead biopharmaceutics ireland corporation gilead sciences limited calistoga pharmaceuticals inc moreover representations warranties may accurate complete specified date may subject standard materiality provided calistoga merger agreement used purpose allocating risk among registrant gilead biopharmaceutics ireland corporation gilead sciences limited calistoga pharmaceuticals inc rather establishing matters facts agreement plan merger pharmasset merger agreement contains representations warranties registrant merger sub pharmasset inc made solely specific dates representations warranties made solely purposes pharmasset merger agreement may subject important qualifications limitations agreed registrant merger sub pharmasset moreover representations warranties may accurate complete specified date may subject standard materiality provided pharmasset merger agreement used purpose allocating risk among registrant merger sub pharmasset rather establishing matters facts management contract compensatory plan arrangement certification accompanies relates deemed filed securities exchange commission incorporated reference filing registrant securities act amended securities exchange act amended whether made date irrespective general incorporation language contained filing furnished herewith certain confidential portions exhibit omitted means marking portions asterisk mark exhibit filed separately secretary sec without mark pursuant registrants application requesting confidential treatment rule b securities exchange act amended table contents gilead sciences inc consolidated financial statements years ended december contents report independent registered public accounting firm audited consolidated financial statements consolidated balance sheets consolidated statements income consolidated statements stockholders equity consolidated statements cash flows notes consolidated financial statements table contents report independent registered public accounting firm board directors stockholders gilead sciences inc audited accompanying consolidated balance sheets gilead sciences inc december related consolidated statements income stockholders equity cash flows three years period ended december audits also included financial statement schedule listed index item financial statements schedule responsibility companys management responsibility express opinion financial statements schedule based audits conducted audits accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements audit also includes assessing accounting principles used significant estimates made management well evaluating overall financial statement presentation believe audits provide reasonable basis opinion opinion financial statements referred present fairly material respects consolidated financial position gilead sciences inc december consolidated results operations cash flows three years period ended december conformity us generally accepted accounting principles also opinion related financial statement schedule considered relation basic financial statements taken whole presents fairly material respects information set forth therein also audited accordance standards public company accounting oversight board united states gilead sciences incs internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission report dated february expressed unqualified opinion thereon ernst young llp redwood city california february table contents gilead sciences inc consolidated balance sheets thousands except per share amounts december assets current assets cash cash equivalents shortterm marketable securities accounts receivable net allowances december december inventories deferred tax assets prepaid taxes prepaid expenses current assets total current assets property plant equipment net noncurrent portion prepaid royalties noncurrent deferred tax assets longterm marketable securities intangible assets noncurrent assets total assets liabilities stockholders equity current liabilities accounts payable accrued government rebates accrued compensation employee benefits income taxes payable accrued liabilities deferred revenues current portion convertible senior notes net longterm obligations total current liabilities longterm deferred revenues longterm debt net longterm income taxes payable longterm obligations commitments contingencies note stockholders equity preferred stock par value per share shares authorized none outstanding common stock par value per share shares authorized shares issued outstanding december respectively additional paidin capital accumulated comprehensive income retained earnings total gilead stockholders equity noncontrolling interest total stockholders equity total liabilities stockholders equity see accompanying notes table contents gilead sciences inc consolidated statements income thousands except per share amounts year ended december revenues product sales royalty revenues contract revenues total revenues costs expenses cost goods sold research development selling general administrative total costs expenses income operations interest income net interest expense income provision income taxes provision income taxes net income net loss attributable noncontrolling interest net income attributable gilead net income per share attributable gilead common stockholdersbasic shares used per share calculationbasic net income per share attributable gilead common stockholdersdiluted shares used per share calculationdiluted see accompanying notes table contents gilead sciences inc consolidated statements stockholders equity thousands gilead stockholders equity common stock additional accumulated total paidin comprehensive retained noncontrolling stockholders shares amount capital income loss earnings interest equity balance december distributions noncontrolling interest net income loss unrealized gain availableforsale securities net tax foreign currency translation adjustment unrealized loss cash flow hedges net tax comprehensive income issuances employee stock purchase plan stock option exercises net tax benefits employee stock plans stockbased compensation assumption stock options connection acquisition repurchases common stock balance december contributions noncontrolling interest net income loss unrealized gain availableforsale securities net tax foreign currency translation adjustment unrealized gain cash flow hedges net tax comprehensive income issuances employee stock purchase plan stock option exercises net tax benefits employee stock plans stockbased compensation purchases convertible note hedges sale warrants deferred tax assets convertible note hedges equity portion convertible notes net issuance costs repurchases common stock balance december distributions noncontrolling interest net income loss unrealized loss availableforsale securities net tax foreign currency translation adjustment unrealized gain cash flow hedges net tax comprehensive income issuances employee stock purchase plan stock option exercises net tax benefits employee stock plans stockbased compensation repurchases common stock balance december see accompanying notes table contents gilead sciences inc consolidated statements cash flows thousands year ended december operating activities net income adjustments reconcile net income net cash provided operating activities depreciation expense amortization expense stockbased compensation expenses inprocess research development impairment excess tax benefits stockbased compensation tax benefits employee stock plans deferred income taxes noncash transactions changes operating assets liabilities accounts receivable net inventories prepaid expenses assets accounts payable income taxes payable accrued liabilities deferred revenues net cash provided operating activities investing activities purchases marketable securities proceeds sales marketable securities proceeds maturities marketable securities acquisitions net cash acquired capital expenditures net cash provided used investing activities financing activities proceeds issuances senior notes net issuance costs proceeds issuances convertible notes net issuance costs proceeds sale warrants purchases convertible note hedges proceeds credit facility repayments credit facility proceeds issuances common stock repurchases common stock extinguishment longterm debt repayments longterm obligations excess tax benefits stockbased compensation contributions distributions noncontrolling interest net cash provided used financing activities effect exchange rate changes cash net change cash cash equivalents cash cash equivalents beginning period cash cash equivalents end period supplemental disclosure cash flow information interest paid income taxes paid see accompanying notes table contents gilead sciences inc notes consolidated financial statements organization summary significant accounting policies overview gilead sciences inc gilead us incorporated delaware june researchbased biopharmaceutical company discovers develops commercializes innovative medicines areas unmet medical need new discovery experimental drug candidate seek improve care patients suffering lifethreatening diseases around world gileads primary areas focus include human immunodeficiency virus hivaids liver diseases hepatitis b virus hbv hepatitis c virus hcv serious cardiovascularmetabolic respiratory conditions headquartered foster city california operations north america europe asia pacific continue seek add existing portfolio products internal discovery clinical development programs product acquisition inlicensing strategy product portfolio comprised atripla truvada viread emtriva compleraeviplera hepsera ambisome letairis ranexa cayston vistide addition also sell distribute certain products corporate partners royaltypaying collaborative agreements example f hoffmannla roche ltd together hoffmannla roche inc roche markets tamiflu glaxosmithkline inc gsk markets hepsera viread certain territories outside united states gsk also markets volibris outside united states astellas pharma us inc markets ambisome united states canada astellas us llc markets lexiscan injection united states rapidscan pharma solutions inc markets rapiscan certain territories outside united states menarini international operations luxembourg sa markets ranexa certain territories outside united states japan tobacco inc japan tobacco markets truvada viread emtriva japan basis presentation accompanying consolidated financial statements include accounts gilead whollyowned subsidiaries joint ventures bristol myers squibb company bms primary beneficiary record noncontrolling interest consolidated financial statements reflect bmss interest joint ventures intercompany transactions eliminated consolidated financial statements include results companies acquired us date acquisition applicable reporting periods significant accounting policies estimates judgments preparation consolidated financial statements conformity us gaap requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosures ongoing basis management evaluates estimates including critical accounting policies estimates related revenue recognition intangible assets allowance doubtful accounts prepaid royalties clinical trial accruals tax provision stockbased compensation base estimates historical experience various market specific relevant assumptions believe reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources actual results may differ significantly estimates table contents gilead sciences inc notes consolidated financial statementscontinued revenue recognition product sales recognize revenue product sales persuasive evidence arrangement exists delivery customer occurred price fixed determinable collectability reasonably assured upon recognition revenue product sales provisions made government rebates medicaid reimbursements customer incentives cash discounts prompt payment distributor fees expected returns expired products appropriate items deducted gross product sales government rebates estimate reductions revenues governmentmanaged medicaid programs well certain qualifying federal state foreign government programs based contractual terms historical utilization rates new information regarding changes programs regulations guidelines would impact amount actual rebates expectations regarding future utilization rates programs us product sales channel inventory data obtained major us wholesalers accordance inventory management agreements government rebates invoiced directly us recorded accrued government rebates consolidated balance sheets qualified programs purchase products wholesalers lower contractual government price wholesalers charge back us difference acquisition cost lower contractual government price record allowances accounts receivable cash discounts estimate cash discounts based contractual terms historical utilization rates expectations regarding future utilization rates distributor fees inventory management agreements significant us wholesalers pay wholesalers fee primarily compliance certain contractually determined covenants maintenance agreed upon inventory levels distributor fees based contractually determined fixed percentage sales product returns provide customers general right product return permit returns product damaged defective received customer case product sold united states certain countries outside united states product expired accept returns product expire within six months prior expired one year expiration dates estimates expected returns expired products based primarily ongoing analysis historical return patterns royalty revenues royalty revenue sales lexiscan ambisome astellas us llc astellas pharma us inc respectively recognized month following month corresponding sales occur royalty revenue sales products generally recognized received generally quarter following quarter corresponding sales occur table contents gilead sciences inc notes consolidated financial statementscontinued contract revenues revenue nonrefundable upfront license fees milestone payments development collaboration obligation supply product recognized performance occurs obligations completed accordance specific terms obligations arrangements revenue recognized obligation fulfilled ratably development manufacturing period revenue associated substantive atrisk milestones recognized based upon achievement milestones defined respective agreements advance payments received excess amounts earned classified deferred revenue consolidated balance sheets shipping handling costs shipping handling costs incurred inventory purchases product shipments recorded cost goods sold consolidated statements income research development expenses major components research development rd expenses consist personnel costs including salaries benefits stockbased compensation clinical studies performed contract research organizations cros materials supplies licenses fees milestone payments collaboration arrangements overhead allocations consisting various support facilities related costs charge rd costs including clinical study costs expense incurred clinical study costs significant component rd expenses clinical studies performed thirdparty cros monitor levels performance significant contract including extent patient enrollment activities communications cros accrue costs clinical studies performed cros service periods specified contracts adjust estimates required based upon ongoing review level effort costs actually incurred cros validate accruals quarterly vendors perform detailed reviews activities related significant contracts based upon results validation processes assess appropriateness accruals make adjustments deem necessary ensure expenses reflect actual effort incurred cros material cro contracts terminable us upon written notice generally liable actual effort expended cro certain noncancelable expenses incurred point termination amounts paid advance related uncompleted services refunded us contract terminated contracts may include additional termination payments become due payable terminate contract additional termination payments recorded becomes probable contract terminated advertising expenses expense costs advertising including promotional expenses incurred advertising expenses million million million net income per share attributable gilead common stockholders basic net income per share attributable gilead common stockholders calculated based weightedaverage number shares common stock outstanding period diluted net income per share attributable gilead common stockholders calculated based weightedaverage number shares common stock outstanding dilutive securities outstanding period potential dilutive shares common stock resulting assumed exercise outstanding stock options restricted stock units performance shares assumed exercise warrants relating convertible senior notes due table contents gilead sciences inc notes consolidated financial statementscontinued may may notes may may notes may may notes may may notes collectively convertible notes determined treasury stock method principal amount convertible notes settled cash conversion spread relating convertible notes included calculation diluted net income per share attributable gilead common stockholders common stock resulting assumed settlement conversion spread convertible notes dilutive effect average market price common stock period exceeds conversion prices may notes may notes may notes may notes respectively may may notes matured result considered impact period outstanding net income per share calculations august warrants related may notes expired result considered impact period outstanding net income per share calculations average market prices common stock exceeded conversion prices may may notes dilutive effects included accompanying table average market prices common stock exceed conversion prices may notes may notes therefore notes dilutive effect net income per share periods warrants relating may notes may notes may notes may notes dilutive effect average market price common stock period exceeds warrants exercise prices respectively average market prices common stock exceed warrants exercise prices relating convertible notes therefore warrants dilutive effect net income per share periods stock options purchase approximately million million million weightedaverage shares common stock outstanding respectively included computation diluted net income per share attributable gilead common stockholders effect antidilutive following table reconciliation numerator denominator used calculation basic diluted net income per share attributable gilead common stockholders thousands year ended december numerator net income attributable gilead denominator weightedaverage shares common stock outstanding used calculation basic net income per share attributable gilead common stockholders effect dilutive securities stock options equivalents conversion spread related may notes conversion spread related may notes weightedaverage shares common stock outstanding used calculation diluted net income per share attributable gilead common stockholders table contents gilead sciences inc notes consolidated financial statementscontinued stockbased compensation sharebased payments employees directors recognized consolidated statements income based fair values benefit tax deductions excess recognized compensation cost reported consolidated statements cash flows financing activity calculated pool excess tax benefits recorded part additional paidin capital apic cash cash equivalents consider highly liquid investments insignificant interest rate risk original maturity three months less purchase date cash equivalents may enter overnight repurchase agreements repos purchase securities obligation resell following day securities purchased agreements resell recorded face value reported cash cash equivalents investment policy may enter repos major banks authorized dealers provided repos collateralized us government securities fair value least fair value securities sold us eligible instruments investment policy included cash equivalents include commercial paper money market funds bank obligations marketable nonmarketable securities determine appropriate classification marketable securities consist primarily debt securities include auction rate securities variable rate demand obligations time purchase reevaluate designation balance sheet date marketable securities considered availableforsale carried estimated fair values reported either cash equivalents shortterm marketable securities longterm marketable securities unrealized gains losses availableforsale securities excluded net income reported accumulated comprehensive income loss separate component stockholders equity interest income net includes interest dividends amortization purchase premiums discounts realized gains losses sales securities otherthantemporary declines fair value securities cost securities sold based specific identification method regularly review investments otherthantemporary declines fair value review includes consideration cause impairment including creditworthiness security issuers number securities unrealized loss position severity duration unrealized losses whether intent sell securities whether likely required sell securities recovery amortized cost basis determine decline fair value investment accounting basis decline otherthan temporary reduce carrying value security hold record loss amount decline result entering collaborations time time may hold investments nonpublic companies record nonmarketable securities cost noncurrent assets less amounts otherthantemporary impairment regularly review securities indicators impairment investments nonmarketable securities material periods presented concentrations risk subject credit risk portfolio cash equivalents marketable securities investment policy limit amounts invested securities credit rating maturity industry group investment type issuer except securities issued us government exposed significant concentrations credit risk financial instruments goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return table contents gilead sciences inc notes consolidated financial statementscontinued also subject credit risk accounts receivable related product sales majority trade accounts receivable arises product sales united states europe december accounts receivable southern europe specifically greece italy portugal spain totaled approximately billion million greater days past due million greater days past due date experienced significant losses respect collection accounts receivable believe allowance doubtful accounts adequate december certain raw materials components utilize operations obtained single suppliers certain raw materials utilize operations made one facility since suppliers key components raw materials must named new drug application nda filed us food drug administration fda product significant delays occur qualification new supplier required delivery material suppliers interrupted reason may unable ship commercial products supply product candidates clinical trials accounts receivable trade accounts receivable recorded net allowances wholesaler chargebacks related government rebate programs cash discounts prompt payment doubtful accounts sales returns estimates wholesaler chargebacks government rebates cash discounts sales returns based contractual terms historical trends expectations regarding utilization rates programs estimates allowance doubtful accounts determined based existing contractual payment terms historical payment patterns customers individual customer circumstances analysis days sales outstanding geographic region review local economic environment potential impact government funding reimbursement practices historically amounts uncollectible accounts receivable written insignificant consistent managements expectations inventories inventories recorded lower cost market cost determined firstin firstout basis periodically review composition inventories order identify obsolete slowmoving otherwise unsaleable items unsaleable items observed alternate uses inventory record writedown net realizable value period impairment first recognized prepaid royalties prepaid royalties capitalized cost initially equivalent present value future royalty obligation would expect pay licensor expected future levels product sales incorporating related technology review periodically expected future sales levels products indicators might require writedown net recoverable value asset change estimated life prepaid royalty amortize prepaid royalties cost goods sold remaining life underlying patent based effective royalty rate derived forecasted future product sales incorporating related technology review effective royalty rate least annually prospectively adjust effective rate based significant new facts circumstances may arise review prepaid royalties primarily comprised emtricitabine royalties paid emory university emory hiv indication royalty pharma purchased royalty interest owned emory terms transaction royalty pharma paid respectively total purchase price million emory exchange elimination emtricitabine royalties due table contents gilead sciences inc notes consolidated financial statementscontinued emory worldwide net sales products containing emtricitabine result transaction capitalized prepaid royalties share million purchase price million december unamortized prepaid royalty asset million million respectively million million million amortized cost goods sold respectively property plant equipment property plant equipment stated cost less accumulated depreciation amortization depreciation amortization recognized using straightline method repairs maintenance costs expensed incurred estimated useful lives years follows description estimated useful life buildings improvements laboratory manufacturing equipment office computer equipment leasehold improvements shorter useful life lease term office computer equipment includes capitalized software unamortized capitalized software costs million million consolidated balance sheets december respectively leasehold improvements capitalized leased equipment amortized shorter lease term assets useful life amortization capitalized leased equipment included depreciation expense capitalized interest construction inprogress included property plant equipment interest capitalized significant goodwill intangible assets goodwill represents excess consideration transferred estimated fair value assets acquired liabilities assumed business combination intangible assets indefinite useful lives related purchased inprocess research development iprd projects measured respective fair values acquisition date amortize goodwill intangible assets indefinite useful lives test goodwill indefinitelived intangible assets impairment annual basis annual tests become aware events occurring changes circumstances would indicate reduction fair value assets carrying amounts intangible assets related iprd projects considered indefinitelived completion abandonment associated rd efforts period assets considered indefinitelived amortized tested impairment annual basis well annual tests become aware events occurring changes circumstances would indicate reduction fair value iprd projects respective carrying amounts development complete generally occurs regulatory approval market product obtained associated assets would deemed finitelived would amortized based respective estimated useful lives point time intangible assets finite useful lives primarily related purchased marketed products acquisition cv therapeutics inc cv therapeutics amortized estimated useful lives intangible assets finite useful lives reviewed impairment facts circumstances suggest carrying value assets may recoverable amortize intangible asset related ranexa table contents gilead sciences inc notes consolidated financial statementscontinued acquired cv therapeutics estimated useful life cost goods sold using amortization rate derived forecasted future product sales ranexa product sales forecasts prepared annually determined using best estimates future activity consider factors historical expected future patient usage uptake products introduction complimentary combination therapies products future product launch plans previously unanticipated significant change occurs sales forecasts prospectively update rate used amortize intangible asset related ranexa may increase future cost goods sold record amortization expense amortize intangible asset related lexiscan also acquired cv therapeutics estimated useful life cost goods sold straightline basis given current lexiscan revenues consist royalties received collaboration partner lack ongoing access visibility partners future sales forecasts make reasonable estimate amortization rate using forecasted product sales approach impairment longlived assets carrying value longlived assets reviewed regular basis existence facts circumstances internally externally may suggest impairment specific potential indicators impairment include significant decrease fair value asset significant change extent manner asset used significant physical change asset significant adverse change legal factors business climate affects value asset adverse action assessment fda another regulator accumulation costs significantly excess amount originally expected acquire construct asset operating cash flow losses combined history operating cash flow losses projection forecast demonstrates continuing losses associated income producing asset indication impairment test recoverability comparing estimated undiscounted future cash flows expected result use asset asset group eventual disposition carrying amount asset asset group excess carrying value asset asset group estimated fair value recognized impairment loss foreign currency translation transactions contracts adjustments resulting translating financial statements foreign subsidiaries us dollars excluded determination net income recorded accumulated comprehensive income loss separate component stockholders equity net foreign currency exchange transaction gains losses included interest income net consolidated statements income net transaction losses totaled million million million respectively hedge portion foreign currency exposures related outstanding monetary assets liabilities well forecasted product sales using foreign currency exchange forward option contracts general market risk related contracts offset corresponding gains losses hedged transactions credit risk associated contracts driven changes interest currency exchange rates result varies time working major banks closely monitoring current market conditions limit risk counterparties contracts may unable perform also limit risk loss entering contracts permit net settlement maturity therefore overall risk loss event counterparty default limited amount unrecognized gains outstanding contracts ie contracts positive fair value date default enter derivative contracts trading purposes hedge net investment foreign subsidiaries table contents gilead sciences inc notes consolidated financial statementscontinued fair value financial instruments financial instruments consist principally cash cash equivalents marketable securities accounts receivable foreign currency exchange forward option contracts accounts payable shortterm longterm debt cash cash equivalents marketable securities foreign currency exchange contracts hedge accounts receivable forecasted sales reported respective fair values consolidated balance sheets carrying value fair value convertible notes billion billion respectively december carrying value fair value convertible notes billion billion respectively december march issued senior unsecured notes due april april notes registered offering aggregate principal amount billion carrying value fair value april notes million billion respectively december december issued senior unsecured notes due december december notes december december notes december december notes december december notes aggregate principal amount billion carrying value fair value notes billion billion respectively december fair values convertible notes senior unsecured notes based quoted market values remaining financial instruments reported consolidated balance sheets amounts approximate current fair values income taxes income tax provision computed liability method deferred tax assets liabilities determined based difference financial statement tax basis assets liabilities using enacted tax rates effect year differences expected reverse significant estimates required determining provision income taxes estimates based interpretations existing tax laws regulations various factors may favorable unfavorable effects income tax rate factors include limited interpretations existing tax laws changes tax laws rates portion nontax deductible pharmaceutical excise tax required pay result enactment us healthcare reform legislation accounting stock options sharebased payments mergers acquisitions future levels rd spending changes accounting standards changes mix earnings various tax jurisdictions operate changes overall levels pretax earnings resolution federal state foreign income tax audits impact income tax provision resulting mentioned factors may significant could negative impact consolidated net income record liabilities related uncertain tax positions accordance guidance clarifies accounting uncertainty income taxes recognized enterprises financial statements prescribing minimum recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return believe uncertain tax positions currently pending material adverse effect consolidated financial statements although adverse resolution one uncertain tax positions period could material impact results operations period recent accounting pronouncements may financial accounting standards board fasb issued amendments existing standard fair value measurement achieve common guidance us generally accepted accounting principles table contents gilead sciences inc notes consolidated financial statementscontinued international financial reporting standards addition amended standard revises certain requirements measuring fair value disclosure around fair value measurement require additional fair value measurements intended establish valuation standards affect valuation practices outside financial reporting updated standard effective us beginning first quarter adoption amendments material impact consolidated financial statements june fasb issued update existing standard comprehensive income make presentation items within comprehensive income oci prominent updated standard prohibits current presentation oci statement stockholders equity instead provides public companies option presenting oci continuous statement comprehensive income two separate consecutive statements additionally update requires reclassification adjustments displayed face financial statements oci reported december fasb issued another update indefinitely deferred specific requirement presenting reclassification adjustments oci net income oci face financial statements deferral period existing requirements presentation reclassification adjustments must continue followed updated standard effective us beginning first quarter upon adoption updated standard impact presentation consolidated financial statements however impact financial position results operations september fasb issued new accounting guidance intended simplify goodwill impairment testing entities allowed perform qualitative assessment goodwill impairment determine whether quantitative assessment necessary guidance effective goodwill impairment tests performed interim annual periods fiscal years beginning december standard effective us beginning first quarter adoption guidance material impact consolidated financial statements december fasb issued new standard address disclosure requirements around offsetting financial derivative instruments related arrangements enable users financial statements understand effect arrangements companys financial position update requires companies disclose net gross amounts relevant assets liabilities offset notes financial statements updated standard effective us beginning first quarter applied retrospectively comparative periods presented believe adoption standard material impact consolidated financial statements fair value measurements determine fair value financial nonfinancial assets liabilities using fair value hierarchy establishes three levels inputs may used measure fair value follows level inputs include quoted prices active markets identical assets liabilities level inputs include observable inputs level inputs quoted prices similar assets liabilities quoted prices identical similar assets liabilities markets active inputs observable corroborated observable market data substantially full term asset liability review trading activity pricing investments measurement date sufficient quoted pricing identical securities available use market pricing observable market inputs similar securities obtained various thirdparty data providers inputs either represent quoted prices similar assets active markets derived observable market data table contents gilead sciences inc notes consolidated financial statementscontinued level inputs include unobservable inputs supported little market activity significant fair value underlying asset liability level assets liabilities include whose fair value measurements determined using pricing models discounted cash flow methodologies similar valuation techniques well significant management judgment estimation following table summarizes assets liabilities recorded fair value respective fair value classification level input within fair value hierarchy defined thousands december december level level level total level level level total assets debt securities us treasury securities money market funds certificates deposit us government agencies fdic guaranteed securities municipal debt securities nonus government securities corporate debt securities residential mortgage assetbacked securities student loanbacked securities total debt securities equity securities derivatives liabilities contingent consideration derivatives following table provides rollforward assets measured using level inputs thousands year ended december balance beginning period total realized unrealized gains losses included interest income net comprehensive income loss net sales marketable securities transfers level balance end period table contents gilead sciences inc notes consolidated financial statementscontinued policy recognize transfers level classification actual date event change circumstances caused transfer assets measured fair value using level inputs comprised auction rate securities greek governmentissued bonds within availableforsale investment portfolio underlying assets auction rate securities consist student loans although auction rate securities would typically measured using level inputs failure auctions lack market activity liquidity experienced since beginning required securities measured using level inputs fair value auction rate securities determined using discounted cash flow model considered projected cash flows issuing trusts underlying collateral expected yields projected cash flows estimated based underlying loan principal bonds outstanding payout formulas weightedaverage life cash flows projected considered collateral composition securities related historical projected prepayments underlying student loans weightedaverage expected life two seven years discount rates used discounted cash flow model based market conditions comparable similar term assetbacked fixed income securities adjusted illiquidity discount resulted annual discount rate auction rate securities reset every seven days maturity dates ranging annual interest rates ranging december auction rate securities continued earn interest although continued failed auctions well lack market activity liquidity believe otherthantemporary impairments securities december intend sell securities likely required sell securities recovery amortized cost basis greek government agreed settle majority aged outstanding accounts receivable zerocoupon bonds expected trade discount face value december received total million bonds million received year ended december included transfers level estimated fair value greek zerocoupon bonds using level inputs due current lack market activity liquidity discount rates used fair value model bonds based credit default swap rates ability intent hold bonds maturity therefore believe otherthantemporary impairments investments december december auction rate securities recorded longterm marketable securities consolidated balance sheet december greek governmentissued bonds recorded shortterm longterm marketable securities consolidated balance sheet contingent consideration liabilities measured fair value using level inputs increased million december million december result acquisitions arresto biosciences inc arresto january calistoga pharmaceuticals inc calistoga april estimated fair value contingent consideration liabilities acquisitions based present value total earnout amount giving consideration probability technical regulatory success achieve milestone events expected dates evaluate changes fair values contingent consideration liabilities end period see note description acquisitions table contents gilead sciences inc notes consolidated financial statementscontinued availableforsale securities following table summary availableforsale debt equity securities recorded cash cash equivalents marketable securities consolidated balance sheets estimated fair values availableforsale securities generally based prices obtained commercial pricing services thousands gross gross amortized unrealized unrealized estimated cost gains losses fair value december debt securities us treasury securities money market funds certificates deposit us government agencies fdic guaranteed securities municipal debt securities nonus government securities corporate debt securities residential mortgage assetbacked securities student loanbacked securities total debt securities equity securities total december debt securities us treasury securities money market funds certificates deposit us government agencies fdic guaranteed securities municipal debt securities nonus government securities corporate debt securities residential mortgage assetbacked securities student loanbacked securities total debt securities equity securities total following table summarizes classification availableforsale debt equity securities consolidated balance sheets thousands december december cash cash equivalents shortterm marketable securities longterm marketable securities total table contents gilead sciences inc notes consolidated financial statementscontinued following table summarizes portfolio availableforsale debt securities contractual maturity thousands december december amortized cost fair value amortized cost fair value less one year greater one year less five years greater five years less ten years greater ten years total following table summarizes gross realized gains losses related sales marketable securities thousands year ended december gross realized gains sales gross realized losses sales cost securities sold determined based specific identification method table contents gilead sciences inc notes consolidated financial statementscontinued following table summarizes availableforsale debt securities continuous unrealized loss position deemed otherthan temporarily impaired thousands less months months greater total gross gross gross unrealized estimated unrealized estimated unrealized estimated losses fair value losses fair value losses fair value december debt securities us treasury securities us government agencies fdic guaranteed securities municipal debt securities nonus government securities corporate debt securities certificates deposit residential mortgage assetbacked securities student loanbacked securities total december debt securities us treasury securities certificates deposit us government agencies fdic guaranteed securities municipal debt securities nonus government securities corporate debt securities residential mortgage assetbacked securities student loanbacked securities total december approximately respectively total number securities unrealized loss position gross unrealized losses greek governmentissued bonds reflect higher discount rate used valuation securities compared implied interest rates securities resulting primarily lack market activity liquidity underlying securities gross unrealized losses auction rate securities also reflect higher discount rate used valuation securities based review securities believe otherthantemporary impairments securities december intend sell securities likely required sell securities recovery amortized cost basis table contents gilead sciences inc notes consolidated financial statementscontinued derivative financial instruments operate foreign countries exposes us market risk associated foreign currency exchange rate fluctuations us dollar various foreign currencies significant euro order manage risk hedge portion foreign currency exposures related outstanding monetary assets liabilities well forecasted product sales using foreign currency exchange forward option contracts general market risk related contracts offset corresponding gains losses hedged transactions credit risk associated contracts driven changes interest currency exchange rates result varies time working major banks closely monitoring current market conditions limit risk counterparties contracts may unable perform also limit risk loss entering contracts permit net settlement maturity therefore overall risk loss event counterparty default limited amount unrecognized gains outstanding contracts ie contracts positive fair value date default enter derivative contracts trading purposes hedge net investment foreign subsidiaries hedge exposure foreign currency exchange rate fluctuations certain monetary assets liabilities foreign subsidiaries denominated nonfunctional currency derivative instruments use hedge exposure designated hedges result changes fair value recorded interest income net consolidated statements income hedge exposure foreign currency exchange rate fluctuations forecasted product sales denominated nonfunctional currency derivative instruments use hedge exposure designated cash flow hedges maturity dates months less upon executing hedging contract quarterly thereafter assess prospective hedge effectiveness using regression analysis calculates change cash flow result hedge instrument monthly basis assess retrospective hedge effectiveness using dollar offset approach exclude time value effectiveness testing recognize changes time value hedge interest income net effective component hedge recorded unrealized gain loss hedging instrument accumulated oci within stockholders equity hedged forecasted transaction occurs hedge dedesignated unrealized gains losses reclassified product sales majority gains losses related hedged forecasted transactions reported accumulated oci december reclassified product sales within months notional amounts foreign currency exchange contracts outstanding billion billion december respectively table contents gilead sciences inc notes consolidated financial statementscontinued following table summarizes information fair values derivative instruments consolidated balance sheets thousands december asset derivatives liability derivatives fair classification value classification fair value derivatives designated hedges foreign currency exchange contracts current assets accrued liabilities foreign currency exchange contracts noncurrent assets longterm obligations total derivatives designated hedges derivatives designated hedges foreign currency exchange contracts current assets accrued liabilities total derivatives designated hedges total derivatives december asset derivatives liability derivatives classification fair value classification fair value derivatives designated hedges foreign currency exchange contracts current assets accrued liabilities foreign currency exchange contracts noncurrent assets longterm obligations total derivatives designated hedges derivatives designated hedges foreign currency exchange contracts current assets accrued liabilities total derivatives designated hedges total derivatives table contents gilead sciences inc notes consolidated financial statementscontinued following table summarizes effect foreign currency exchange contracts consolidated statements income thousands year ended december derivatives designated hedges net gains recognized oci effective portion net gains losses reclassified accumulated oci product sales effective portion net gains losses recognized interest income net ineffective portion amounts excluded effectiveness testing derivatives designated hedges net gains recognized interest income net material amounts recorded interest income net years ended december result discontinuance cash flow hedges acquisitions calistoga pharmaceuticals inc february entered agreement acquire calistoga million plus potential payments million based achievement certain milestones transaction closed april time calistoga became whollyowned subsidiary calistoga privatelyheld biotechnology company based seattle washington focused development medicines treat cancer inflammatory diseases acquisition provided us portfolio proprietary compounds selectively target isoforms phosphoinositide kinase pik lead product candidate gs firstinclass specific inhibitor pik delta isoform pik delta preferentially expressed leukocytes involved variety inflammatory autoimmune diseases hematological cancers acquisition accounted business combination calistogas results operations since april included consolidated statement income significant acquisitiondate fair value total consideration transferred acquire calistoga million consisted cash paid prior closing million contingent consideration million following table summarizes fair values assets acquired liabilities assumed april thousands iprd goodwill net liabilities assumed total consideration transferred table contents gilead sciences inc notes consolidated financial statementscontinued iprd intangible assets associated iprd projects relate gs product candidate management determined estimated acquisitiondate fair value intangible assets related iprd million estimated fair value determined using income approach discounts expected future cash flows present value estimated fair value using present value discount rate considers estimated weightedaverage cost capital companies profiles substantially similar calistoga well acquirers estimated weightedaverage cost capital believe appropriate given unique characteristics acquisition included competitive bidding process rate comparable estimated internal rate return acquisition represents rate market participants would use value intangible assets projected cash flows iprd projects based key assumptions estimates revenues operating profits related project considering stage development time resources needed complete development approval product candidate life potential commercialized product associated risks including inherent difficulties uncertainties developing product candidate obtaining marketing approval fda regulatory agencies risks related viability potential alternative treatments future target markets intangible assets related iprd projects considered indefinitelived completion abandonment associated rd efforts goodwill excess consideration transferred fair values assigned assets acquired liabilities assumed million represents goodwill amount resulting calistoga acquisition management believes goodwill mainly represents synergies expected combining research development operations well acquiring calistogas assembled workforce intangible assets qualify separate recognition consider calistoga acquisition material business combination therefore disclosed pro forma results operations required material business combinations arresto biosciences inc december entered agreement acquire arresto million plus potential future payments based achievement certain sales targets transaction closed january time arresto became whollyowned subsidiary arresto privatelyheld developmentstage biotechnology company based palo alto california focused developing antibodies potential treatment fibrotic diseases cancer lead product acquisition arresto gs humanized monoclonal antibody mab targeting human lysyl oxidaselike loxl protein addition ongoing phase study gs patients advanced solid tumors time acquisition phase study also initiated evaluate gs patients idiopathic pulmonary fibrosis acquisition accounted business combination arrestos results operations since january included consolidated statement income significant acquisitiondate fair value total consideration transferred acquire arresto million consisted cash paid prior closing million contingent consideration million table contents gilead sciences inc notes consolidated financial statementscontinued following table summarizes fair values assets acquired liabilities assumed january thousands iprd goodwill deferred tax assets deferred tax liabilities net liabilities assumed total consideration transferred iprd intangible assets associated iprd projects relate gs product candidate management determined estimated acquisitiondate fair value intangible assets related iprd million estimated fair value determined using income approach discounts expected future cash flows present value estimated fair value using present value discount rate based estimated weightedaverage cost capital companies profiles substantially similar arresto comparable estimated internal rate return acquisition represents rate market participants would use value intangible assets projected cash flows iprd projects based key assumptions estimates revenues operating profits related project considering stage development time resources needed complete development approval product candidate life potential commercialized product associated risks including inherent difficulties uncertainties developing product candidate obtaining marketing approval fda regulatory agencies risks related viability potential alternative treatments future target markets intangible assets related iprd projects considered indefinitelived completion abandonment associated rd efforts goodwill excess consideration transferred fair values assigned assets acquired liabilities assumed million represents goodwill amount resulting arresto acquisition management believes goodwill mainly represents synergies expected combining research development operations well acquiring arrestos assembled workforce intangible assets qualify separate recognition consider arresto acquisition material business combination therefore disclosed pro forma results operations required material business combinations cgi pharmaceuticals inc june entered agreement acquire cgi pharmaceuticals inc cgi million cash consisting million upfront payment million contingent consideration payable based achievement clinical development milestones transaction closed july time cgi became whollyowned subsidiary cgi privatelyheld development stage pharmaceutical company based branford connecticut primarily focused small molecule chemistry protein kinase biology lead preclinical compound cgis library proprietary small molecule kinase inhibitors targets spleen tyrosine kinase syk could unique applications treatment serious inflammatory diseases including rheumatoid arthritis table contents gilead sciences inc notes consolidated financial statementscontinued cgi acquisition accounted business combination results operations cgi since july included consolidated statements income significant acquisitiondate fair value total consideration transferred acquire cgi million consisted cash paid prior closing million contingent consideration million following table summarizes fair values assets acquired liabilities assumed july thousands iprd goodwill deferred tax assets deferred tax liabilities net liabilities assumed total consideration transferred iprd intangible assets associated iprd projects relate preclinical syk product candidate management estimated acquisitiondate fair value intangible assets related iprd million estimated fair value determined using income approach discounts expected future cash flows present value estimated fair value using present value discount rate based estimated weightedaverage cost capital companies profiles substantially similar cgi comparable estimated internal rate return cgis operations represents rate market participants would use value intangible assets projected cash flows iprd project based key assumptions estimates revenues operating profits related project considering stage development time resources needed complete development approval product candidate life potential commercialized product associated risks including inherent difficulties uncertainties developing drug compound obtaining marketing approval fda regulatory agencies risks related viability potential alternative treatments future target markets intangible assets related iprd projects considered indefinitelived completion abandonment associated rd efforts fourth quarter recorded million impairment charges rd expense related syk iprd asset acquired cgi impairment charges result changes anticipated market share related syk compound goodwill excess consideration transferred fair values assigned assets acquired liabilities assumed million represents goodwill amount resulting cgi acquisition management believes goodwill mainly represents synergies expected combining research development operations well acquiring cgis assembled workforce intangible assets qualify separate recognition cv therapeutics inc april acquired cv therapeutics cash tender offer terms agreement plan merger entered march cv therapeutics publiclyheld table contents gilead sciences inc notes consolidated financial statementscontinued biopharmaceutical company based palo alto california primarily focused discovery development commercialization small molecule drugs treatment cardiovascular metabolic pulmonary diseases cv therapeutics two marketed products ranexa treatment chronic angina lexiscan injection use pharmacologic stress agent radionuclide mpi patients unable undergo adequate exercise stress cv therapeutics also several product candidates clinical development treatment cardiovascular metabolic pulmonary diseases cv therapeutics acquisition accounted business combination results operations cv therapeutics since april included consolidated statements income acquisition date determined april date acquired approximately outstanding shares common stock cv therapeutics obtained effective control company acquisition completed two days later april time cv therapeutics became whollyowned subsidiary aggregate consideration transferred acquire cv therapeutics billion consisted cash paid common stock equity instruments prior closing billion fair value vested stock options assumed million accordance merger agreement number gilead stock options restricted stock units assumed cv therapeutics stock options restricted stock units converted determined based option conversion ratio conversion ratio calculated taking per share acquisition price dividing average closing price common stock five consecutive trading days immediately preceding including closing date april per share fair value stock options assumed calculated using blackscholes valuation model following assumptions market price per share closing price common stock acquisition date expected term ranging years riskfree interest rate ranging expected volatility ranging dividend yield fair value restricted stock units assumed calculated using acquisitiondate closing price per share common stock included fair value vested stock options assumed us million consideration transferred acquisition assume vested restricted stock units estimated fair value unvested stock options restricted stock units assumed us million included consideration transferred recognized stockbased compensation expenses remaining future vesting period awards table contents gilead sciences inc notes consolidated financial statementscontinued following table summarizes assets acquired liabilities assumed april thousands intangible assetsmarketed products intangible assetsiprd goodwill deferred tax assets deferred tax liabilities assetsliabilities cash cash equivalents marketable securities accounts receivable inventories prepaids current assets property plant equipment assets accounts payable accrued current liabilities convertible senior notes liabilities total net liabilities total consideration transferred intangible assets substantial portion assets acquired consisted intangible assets related cv therapeutics two marketed products ranexa lexiscan cv therapeutics iprd projects management determined estimated acquisitiondate fair values intangible assets related marketed products iprd projects million million respectively million intangible assets related marketed products million related ranexa million related lexiscan determined intangible assets finite useful lives amortized respective useful lives estimated periods associated product patents expire periods intangible assets expected contribute future cash flows related products amortizing intangible asset related ranexa estimated useful life using amortization rate derived forecasted future product sales ranexa amortizing intangible asset related lexiscan estimated useful life straightline basis given current lexiscan revenues consist royalties received collaboration partner lack ongoing access visibility partners future sales forecasts make reasonable estimate amortization rate using forecasted product sales approach weightedaverage amortization period intangible assets approximately ten years million intangible assets related iprd projects million related gs product candidate phase clinical studies treatment diabetes hypertriglyceridemia remaining balance intangible assets related iprd projects represented various inprocess projects single project comprising significant portion total value intangible assets related iprd projects considered indefinitelived completion abandonment associated rd efforts period assets considered indefinitelived amortized table contents gilead sciences inc notes consolidated financial statementscontinued tested impairment annual basis annual tests become aware events occurring changes circumstances would indicate reduction fair value iprd projects respective carrying amounts fourth quarter recorded million impairment charges related certain iprd assets acquired cv therapeutics future plans develop deemed future use us market participants charges related gs adentri tecadenoson programs recorded rd expense majority impairment charge related gs program terminated fourth quarter due unfavorable results pharmacokinetics pharmacodynamics tests demonstrated limited effectiveness compound patients given results believe alternative future uses us market participants first quarter million purchased iprd project cv therapeutics completed reclassified finite lived intangible asset currently amortized estimated useful life december million iprd assets acquired cv therapeutics remaining consolidated balance sheet deferred tax assets deferred tax liabilities million deferred tax assets resulting acquisition primarily related federal state net operating loss tax credit carryforwards million deferred tax liabilities resulting acquisition primarily related difference book basis tax basis intangible assets related marketed products iprd projects concluded likely realize benefit deferred tax assets related certain state net operating loss carryforwards result valuation allowance million recorded related deferred tax assets presentation purposes million deferred tax liabilities noncurrent nature netted noncurrent deferred tax assets consolidated balance sheet result impairment charges recorded fourth quarter reduced deferred tax liabilities related iprd projects million convertible senior notes result acquisition assumed convertible notes cv therapeutics consisting senior subordinated convertible notes due senior subordinated convertible notes due senior subordinated convertible debentures due convertible notes recognized fair values acquisition date may offered repurchase convertible notes consideration par value plus accrued interest required terms respective convertible note agreements following occurrence change control fundamental change defined agreements december convertible notes extinguished goodwill excess consideration transferred fair values assigned assets acquired liabilities assumed million represents goodwill amount resulting acquisition management believes goodwill mainly represents synergies economies scale expected combining operations cv therapeutics none goodwill expected deductible income tax purposes recorded goodwill intangible asset consolidated balance sheet acquisition date goodwill tested impairment annual basis annual tests become aware events occurring changes circumstances would indicate reduction fair value goodwill carrying amount table contents gilead sciences inc notes consolidated financial statementscontinued restructuring second quarter implemented plan close research operations durham north carolina consolidate liver disease research activities foster city california restructuring plan includes consolidation liver disease rd organization exit certain facilities recorded total million million sga expenses rd expenses respectively related employee severance facilities related expenses plan december closed operations durham incurred expect incur additional significant costs connection plan second quarter approved plan realize certain synergies result cv therapeutics acquisition realigning cardiovascular operations eliminating redundancies restructuring plan included consolidation realignment cardiovascular rd organization exit certain facilities termination certain contractual obligations recorded facilitiesrelated expenses million sga expense comparatively recorded million million restructuring expenses sga rd expenses respectively recorded million million sga rd expenses respectively expenses primarily related employee severance relocation lease termination costs facilitiesrelated expenses total costs incurred plan million million sga rd expenses respectively incurred expect incur additional costs connection plan following table summarizes restructuring liabilities accrued changes amounts period restructuring plan related cardiovascular operations thousands employee severance termination facilities benefits related costs balance december costs incurred period costs paid settled period balance december costs incurred period costs paid settled period balance december costs incurred period costs paid settled period balance december inventories inventories summarized follows thousands december raw materials work process finished goods total table contents gilead sciences inc notes consolidated financial statementscontinued december joint ventures formed gilead bms see note included consolidated financial statements held million million inventory respectively efavirenz active pharmaceutical ingredient purchased bms bmss estimated net selling price efavirenz property plant equipment property plant equipment summarized follows thousands december property plant equipment net buildings improvements including leasehold improvements laboratory manufacturing equipment office computer equipment capitalized leased equipment construction progress subtotal less accumulated depreciation amortization including relating capitalized leased equipment respectively subtotal land total september completed purchase clinical biologics manufacturing facility certain process development assets located oceanside california paid total purchase price million cash including transaction costs accounted transaction asset acquisition purchase price allocated based fair value acquired tangible assets consisted primarily property plant equipment intangible assets following table summarizes carrying amount intangible assets thousands december goodwill finitelived intangible assets indefinitelived intangible assets total table contents gilead sciences inc notes consolidated financial statementscontinued goodwill following table summarizes changes carrying amount goodwill thousands balance december goodwill resulting acquisition arresto goodwill resulting acquisition calistoga balance december finitelived intangible assets following table summarizes finitelived intangible assets thousands december december gross carrying accumulated gross carrying accumulated amount amortization amount amortization intangible asset ranexa intangible asset lexiscan total amortization expense related intangible assets million million years ended december respectively recorded cost goods sold consolidated statement income amortization expense related intangible assets million year ended december recorded primarily cost goods sold consolidated statement income weightedaverage amortization period intangible assets approximately ten years december estimated future amortization expense associated intangible assets five succeeding fiscal years follows thousands fiscal year amount total indefinitelived intangible assets december indefinitelived intangible assets million consisted million million purchased iprd acquisitions arresto calistoga respectively fourth quarter recorded million impairment charges related certain iprd assets acquired cgi impairment charges result changes anticipated market share related syk compound million purchased iprd project cv therapeutics completed reclassified finitelived intangible asset currently amortized estimated useful life table contents gilead sciences inc notes consolidated financial statementscontinued december indefinitelived intangible assets million consisted million million purchased iprd acquisitions cgi cv therapeutics respectively fourth quarter recorded million impairment charges rd expense related certain iprd assets acquired cv therapeutics future plans develop deemed future use us market participants majority impairment charge related gs program product candidate phase clinical studies treatment diabetes hypertriglyceridemia terminated due unfavorable results pharmacokinetics pharmacodynamics tests demonstrated limited effectiveness compound patients given results believe alternative future uses us market participants collaborative arrangements time time result entering strategic collaborations may hold investments nonpublic companies review interests investee companies consolidation andor appropriate disclosure based applicable guidance contractual terms provide us control entity may require us consolidate entity entities consolidated controlled means majority voting interest referred variable interest entities vies assess whether primary beneficiary vie based power direct activities vie significantly impact vies economic performance obligation absorb losses right receive benefits vie could potentially significant vie december determined certain investee companies vies however respect joint ventures bms primary beneficiary therefore consolidate investees bristolmyers squibb company north america entered collaboration arrangement bms united states develop commercialize singletablet regimen containing truvada bmss sustiva efavirenz sell atripla collaboration structured joint venture operates limited liability company named bristolmyers squibb gilead sciences llc consolidate ownership interests joint venture thus sharing product revenue costs reflect respective economic interests bms gilead based proportions net selling price atripla attributable efavirenz truvada since net selling price truvada may change time relative net selling price efavirenz bmss respective economic interests joint venture may vary annually bms share marketing sales efforts parties providing equivalent sales force efforts levels agreed annually bms gilead since second quarter except limited number activities jointly managed parties longer coordinate detailing promotional activities united states parties begun reduce joint promotional efforts canada launch complera anticipation launch quad parties continue collaborate activities manufacturing regulatory compliance pharmacovigilance responsible accounting financial reporting tax reporting manufacturing product distribution joint venture parties provide respective bulk active pharmaceutical ingredients joint venture approximate market values joint venture received approval fda sell atripla united states also bms amended joint ventures collaboration agreement allow joint venture sell atripla canada joint venture received approval health canada sell atripla canada december joint venture held efavirenz active pharmaceutical ingredient purchased bms bmss estimated net selling price efavirenz us market amounts table contents gilead sciences inc notes consolidated financial statementscontinued included inventories consolidated balance sheets december total assets held joint venture billion billion respectively consisted primarily cash cash equivalents accounts receivable including intercompany receivables gilead inventories december total liabilities held joint venture billion million respectively consisted primarily accounts payable including intercompany payables gilead accrued expenses asset liability amounts reflect impact intercompany eliminations included consolidated balance sheets although primary beneficiary joint venture legal structure joint venture limits recourse creditors general credit assets europe gilead sciences limited whollyowned subsidiary ireland bms entered collaboration arrangement commercialize distribute atripla european union iceland liechtenstein norway switzerland collectively european territory parties formed limited liability company consolidate manufacture atripla distribution european territory using efavirenz purchases bms bmss estimated net selling price efavirenz european territory responsible product distribution inventory management warehousing local subsidiaries primary responsibility order fulfillment collection receivables customer relations handling sales returns territories copromote atripla bms starting except limited number activities jointly managed parties longer coordinate detailing promotional activities region also responsible accounting financial reporting tax reporting collaboration european commission approved atripla sale european union december efavirenz purchased bms bmss estimated net selling price efavirenz european territory included inventories consolidated balance sheets parties also formed limited liability company hold marketing authorization atripla europe primary responsibility regulatory activities share marketing sales efforts bms major market countries parties agreed provide equivalent sales force efforts revenue cost sharing based relative ratio respective net selling prices truvada efavirenz pari gmbh result acquisition corus pharma inc corus assumed rights february development agreement corus pari gmbh pari development cayston development inhalation delivery device product terms agreement obligated pay pari services rendered subject achievement specific milestones obligated pay certain milestone payments pari addition make royalty payments based net sales cayston agreement also provided us right reduce royalty rate payable pari paid pari million reduce royalty rate agreement cayston yet approved commercialization time payment recorded payment rd expenses consolidated statement income entered commercialization agreement pari provides supply manufacture inhalation delivery device accessories use cayston terms agreement obligated pay royalties future net sales products pursuant development agreement table contents gilead sciences inc notes consolidated financial statementscontinued received marketing approval fda cayston treatment improve respiratory symptoms cystic fibrosis patients p aeruginosa cayston conditionally approved europe canada received full approvals roche entered development license agreement agreement roche develop commercialize therapies treat prevent viral influenza tamiflu antiviral oral formulation treatment prevention influenza codeveloped us roche agreement roche exclusive right manufacture sell tamiflu worldwide subject obligation pay us percentage net revenues roche generates tamiflu sales turn subject reduction certain defined manufacturing costs entered first amendment supplement agreement roche amended agreement provided formation joint manufacturing committee review roches manufacturing capacity tamiflu global plans manufacturing tamiflu us commercial committee evaluate commercial plans strategies tamiflu united states joint supervisory committee evaluate roches overall commercial plans tamiflu global basis case consisting representatives roche us amended agreement also option provide specialized sales force supplement roches marketing efforts united states tamiflu royalties payable us net sales tamiflu sold roche remain amended agreement follows first million worldwide net sales given calendar year b next million worldwide net sales calendar year c worldwide net sales excess million calendar year amended agreement revised provision agreement relating calculation royalty payments given calendar quarter roche pay royalties based actual royalty rates applicable quarter addition amended agreement royalties payable roche us longer subject cost goods sold adjustment provided agreement recorded total million million million tamiflu royalties respectively result acquisition cv therapeutics assumed rights agreement cv therapeutics roche exclusive worldwide license ranexa license agreement paid initial license fee obligated make certain payments roche upon receipt first second product approvals ranexa following major market countries france germany italy united states united kingdom received fda approval ranexa treatment chronic angina paid million roche accordance agreement received marketing authorization european medicines agency ema ranexa treatment chronic angina european union member states paid million roche related approval amount capitalized noncurrent asset consolidated balance sheet amortized useful patent life approximately years expiring entered amendment agreement roche related ranexa amendment provided us exclusive worldwide commercial rights ranexa potential indications humans terms amendment made upfront payment roche obligated make royalty payments roche worldwide net product sales licensed products addition obligated make additional milestone payments upon achievement certain regulatory approvals table contents gilead sciences inc notes consolidated financial statementscontinued japan tobacco inc japan tobacco granted us exclusive rights develop commercialize elvitegravir novel hiv integrase inhibitor countries world excluding japan japan tobacco retained rights agreement responsible seeking regulatory approval territories required use diligent efforts commercialize product treatment hiv infection bear costs expenses associated commercialization efforts terms agreement incurred upfront license fee million included rd expenses future alternative use technology recorded million rd expenses related milestone incurred result dosing first patient phase clinical study recorded million rd expenses related milestone paid related dosing first patient phase clinical study october submitted nda fda marketing approval oncedaily singletablet quad regimen elvitegravir cobicistat tenofovir disoproxil fumarate emtricitabine december fda accepted nda review fda set target review date quad august prescription drug user fee act also december announced submitted marketing authorization application ema marketing approval singletablet regimen recorded million rd expenses december related milestones incurred connection filings obligated make additional payments upon achievement milestones well pay royalties future product sales arising collaboration glaxosmithkline inc granted gsk right commercialize hepsera oral antiviral treatment chronic hbv asia latin america certain territories agreement retained rights hepsera united states canada europe australia new zealand turkey gsk received exclusive rights develop hepsera solely treatment chronic hbv territories significant include china japan south korea taiwan gsk full responsibility development commercialization hepsera territories terms agreement received upfront license payment million received aggregate million milestone payments related commercial approvals hepsera various countries received aggregate million milestone payments gsk achievement gsk four consecutive quarters hepsera gross sales exceeding million achievement certain drug status china upfront license fee milestone payments recorded deferred revenue total million million amortized contract revenue respectively terminated supply agreement gsk allow gsk assume manufacturing supply obligations hepsera use gsk territories result termination supply agreement recognized remaining million balance deferred revenue contract revenue terms agreement gsk also required pay us royalties net sales gsk generates sales hepsera epivirhbvzeffix gsks hepatitis product gsk territories recorded million million million royalty revenues respectively entered agreement gsk commercialize viread treatment chronic hbv five countries asia agreement retain exclusive rights commercialization viread chronic hbv hong kong singapore south korea taiwan china gsk exclusive commercialization rights viread chronic hbv company pay royalties sales viread chronic hbv respective asian territories table contents gilead sciences inc notes consolidated financial statementscontinued granted gsk exclusive right commercialize tenofovir disoproxil fumarate chronic hbv japan gsk required pay us royalties sales tenofovir disoproxil fumarate chronic hbv territory result acquisition myogen inc myogen assumed rights march license distribution supply agreements myogen gsk terms license agreement gsk exclusive rights market ambrisentan active pharmaceutical ingredient letairis name volibris pulmonary arterial hypertension territories outside united states received upfront payment million subject achievement specific milestones eligible receive total additional milestone payments million addition receive royalties based net sales volibris gsk territories gsk option negotiate us exclusive sublicense additional therapeutic uses volibris gsk territories term license agreement continue conduct bear expense clinical development activities believe required obtain maintain regulatory approvals letairis volibris united states canada european economic area party may conduct additional development activities territories expense parties may agree jointly develop ambrisentan new indications licensed field party pay share external costs associated joint development significant milestone payments received date include milestone payment million gsk validation ema marketing authorization application volibris million milestone payment related european commission marketing authorization approval volibris received million milestone payment achievement gsk four consecutive quarters volibris net sales exceeding million milestone upfront license payments recorded deferred revenue recognized contract revenue remaining period performance obligations agreement approximately six years recognized million million million contract revenue respectively astellas us llc astellas pharma us inc astellas applicable result acquisition cv therapeutics assumed rights july collaboration agreement cv therapeutics astellas us llc develop market second generation pharmacologic mpi stress agents agreement astellas received exclusive north american rights lexiscan backup compound received fda approval lexiscan use pharmacologic stress agent mpi studies patients unable undergo adequate exercise stress terms agreement product marketed astellas launched united states recognized million million million royalty revenues respectively astellas related sales lexiscan since agreement astellas pharma us inc related rights market ambisome terms agreement astellas responsible promotion ambisome united states canada exclusive marketing rights ambisome rest world subject obligation pay royalties astellas connection sales significant markets asia receive royalties astellas sales ambisome unites states canada connection agreement recorded royalty revenues million million million respectively tibotec pharmaceuticals entered license collaboration agreement tibotec pharmaceuticals tibotec whollyowned subsidiary johnson johnson develop commercialize fixeddose combination table contents gilead sciences inc notes consolidated financial statementscontinued truvada tibotecs nonnucleoside reverse transcriptase inhibitor rilpivirine combination approved united states european union sold trade name complera united states eviplera european union license collaboration agreement tibotec granted exclusive license compleraeviplera administration adults oncedaily oral dosage form worldwide excluding certain middle income developing world countries japan neither party restricted combining drug products drugs accordance terms agreement reimburse million approximately million development costs incurred tibotec rilpivirine december recorded million approximately million million approximately million million approximately million respectively reimbursable rd expenses incurred tibotec development rilpivirine responsible manufacturing compleraeviplera lead role registration distribution commercialization combination product licensed countries tibotec exercised right codetail combination product countries gilead selling party price combination product expected sum prices truvada rilpivirine components cost rilpivirine purchased us tibotec combination product approximate market price rilpivirine less specified percentage thirty percent amended agreement include distribution compleraeviplera rest world distribute product north america europe latin america australia new zealand tibotec distribute product regions including japan russia longterm obligations financing arrangements following table summarizes carrying amount borrowings various financing arrangements thousands december may convertible senior notes may convertible senior notes may convertible senior notes may convertible senior notes december senior unsecured notes december senior unsecured notes april senior unsecured notes december senior unsecured notes december senior unsecured notes total debt net less current portion may convertible senior notes total longterm debt net may convertible senior notes april issued million may notes million may notes private placement pursuant rule securities act amended may may table contents gilead sciences inc notes consolidated financial statementscontinued notes matured repaid aggregate principal balance million also paid million cash related conversion spread may notes represents conversion value excess principal amount received million cash convertible note hedges related may notes warrants related may notes expired august may notes may notes issued par bear interest rates respectively debt issuance costs million recorded noncurrent assets amortized interest expense contractual terms may notes may notes initial conversion rate may notes shares per principal amount may notes represents initial conversion price approximately per share initial conversion rate may notes shares per principal amount may notes represents initial conversion price approximately per share conversion rates subject customary antidilution adjustments may notes may notes may converted subject adjustment following circumstances calendar quarter beginning september closing price common stock least trading days last consecutive trading day period previous quarter applicable conversion price per share make specified distributions holders common stock specified corporate transactions occur last month prior maturity applicable notes upon conversion holder would receive amount cash equal lesser principal amount note ii conversion value note conversion value exceeds principal amount may also deliver option cash common stock combination cash common stock conversion value excess principal amount may notes may notes converted connection change control may required provide make whole premium form increase conversion rate subject stated maximum amount addition event change control holders may require us purchase portion notes purchase price equal principal amount plus accrued unpaid interest december ifconverted value may notes would exceed principal amount notes million concurrent issuance may notes may notes purchased convertible note hedges private transactions cost million tax deductible life notes also sold warrants private transactions received net proceeds million sale warrants convertible note hedges warrants intended reduce potential economic dilution upon future conversions notes effectively increasing conversion price per share may notes per share may notes net cost million convertible note hedge warrant transactions recorded stockholders equity consolidated balance sheets convertible note hedges cover subject customary antidilution adjustments million shares common stock strike prices initially correspond initial conversion prices may notes may notes subject adjustments similar applicable conversion price related notes market value per share common stock time conversion may notes may notes strike price applicable convertible note hedges entitled receive counterparties transactions shares common stock extent made corresponding election respect related convertible notes cash combination cash shares common stock option excess market value common stock strike price convertible note hedges convertible note hedges terminate upon maturity may notes may notes none may notes may notes remain outstanding due conversion otherwise million shares common stock underlying warrants subject table contents gilead sciences inc notes consolidated financial statementscontinued customary antidilution adjustments warrants strike prices per share warrants expiring per share warrants expiring exercisable respective expiration dates market value common stock time exercise applicable warrants exceeds respective strike prices required net settle cash shares common stock option respective counterparties value warrants excess warrant strike prices contemporaneously closing sale may notes may notes portion net proceeds notes issuance proceeds warrant transactions used repurchase million shares common stock million current accounting guidance bifurcated conversion option may notes may notes debt instrument classified conversion option equity accreting resulting debt discount interest expense contractual terms may notes may notes following table summarizes information equity liability components may notes may notes thousands carrying value net carrying amount unamortized discount equity component liability component liability component december december december may convertible senior notes may convertible senior notes total may convertible senior notes years ended december recognized million million million respectively interest expense related contractual coupon rates amortization debt discount may notes may notes effective interest rates liability components may notes may notes respectively may convertible senior notes july issued billion may notes billion may notes private placement pursuant rule securities act amended may notes may notes issued par bear interest rates respectively debt issuance costs primarily comprised million bankers fees majority recorded noncurrent assets amortized interest expense contractual terms may notes may notes aggregate principal amount may notes may notes sold reflects full exercise initial purchasers option purchase additional notes cover overallotments initial conversion rate may notes shares per principal amount represents initial conversion price approximately per share initial conversion rate may notes shares per principal amount represents initial conversion price approximately per share conversion rates subject customary antidilution adjustments may notes may notes may converted prior april april respectively following circumstances calendar quarter commencing table contents gilead sciences inc notes consolidated financial statementscontinued september closing price common stock least trading days whether consecutive period consecutive trading days ending last trading day preceding calendar quarter greater applicable conversion price applicable trading day five business day period measurement period ten consecutive trading days trading day period trading price per principal amount notes less product last reported sale price common stock applicable conversion rate trading day upon occurrence specified corporate transactions distribution certain stock rights cash amounts assets shareholders occurrence change control april case may notes april case may notes holders may convert notes time regardless foregoing circumstances generally upon conversion holder would receive amount cash equal lesser principal amount note ii conversion value note measured indenture governing relevant notes conversion value exceeds principal amount may also deliver option cash common stock combination cash common stock conversion value excess principal amount may notes may notes converted connection change control may required provide make whole premium form increase conversion rate subject stated maximum amount addition event change control holders may require us purchase portion notes purchase price equal principal amount plus accrued unpaid interest december ifconverted value may notes may notes would exceed principal amounts notes concurrent issuance may notes may notes purchased convertible note hedges private transactions cost million tax deductible life notes also sold warrants private transactions received net proceeds million sale warrants convertible note hedges warrants intended reduce potential economic dilution upon future conversions may notes may notes effectively increasing conversion price per share may notes per share may notes net cost million convertible note hedge warrant transactions recorded stockholders equity consolidated balance sheets convertible note hedges cover subject customary antidilution adjustments million shares common stock strike prices initially correspond initial conversion prices may notes may notes subject adjustments similar applicable conversion price related notes market value per share common stock time conversion may notes may notes strike price applicable convertible note hedges entitled receive counterparties transactions shares common stock extent made corresponding election respect related convertible notes cash combination cash shares common stock option excess market value common stock strike price convertible note hedges convertible note hedges terminate upon maturity may notes may notes none may notes may notes remain outstanding due conversion otherwise million shares common stock underlying warrants subject customary antidilution adjustments warrants strike prices per share warrants expiring per share warrants expiring exercisable respective expiration dates market value common stock time exercise applicable warrants exceeds respective strike prices required net settle cash shares common stock option respective counterparties value warrants excess warrant strike prices used net proceeds issuance convertible notes repurchase shares common stock repay existing indebtedness table contents gilead sciences inc notes consolidated financial statementscontinued current accounting guidance bifurcated conversion option may notes may notes debt instrument classified conversion option equity accreting resulting debt discount interest expense contractual terms may notes may notes following table summarizes information equity liability components may notes may notes thousands carrying value net carrying amount unamortized discount equity component liability component liability component december december december may convertible senior notes may convertible senior notes total may convertible senior notes years ended december recognized million million respectively interest expense related contractual coupon rates amortization debt discount may notes may notes effective interest rate liability components may notes may notes respectively april senior unsecured notes march issued april notes registered offering aggregate principal amount billion april notes mature april pay interest fixed annual rate debt issuance costs incurred connection issuance debt totaled approximately million amortized interest expense contractual term april notes april notes may redeemed option time time time redemption price equal greater principal amount notes redeemed ii sum determined independent investment banker present values remaining scheduled payments principal interest notes redeemed exclusive interest accrued date redemption discounted redemption date semiannual basis treasury rate plus basis points plus case accrued unpaid interest notes redeemed date redemption time january may redeem notes whole part principal amount notes redeemed plus accrued unpaid interest date redemption addition event occurrence change control downgrade rating april notes investment grade rating standard poors ratings services moodys investors service inc holders may require us purchase portion notes price equal principal amount plus accrued unpaid interest used net proceeds general corporate purposes include repayment existing indebtedness repurchases common stock december senior unsecured notes december issued december notes december notes december notes december notes registered offering million million billion billion respectively aggregate principal amount billion notes mature december table contents gilead sciences inc notes consolidated financial statementscontinued pay interest fixed annual rates respectively debt issuance costs incurred connection issuance debt totaled approximately million amortized interest expense contractual term respective notes notes may redeemed option time time time redemption price equal greater principal amount notes redeemed ii sum determined independent investment banker present values remaining scheduled payments principal interest notes redeemed exclusive interest accrued date redemption discounted redemption date semiannual basis treasury rate plus basis points case december notes december notes basis points case december notes december notes plus case accrued unpaid interest notes redeemed date redemption time date three months prior maturity date december notes may redeem notes whole part principal amount notes redeemed plus accrued unpaid interest date redemption time date six months prior maturity date december notes may redeem notes whole part principal amount notes redeemed plus accrued unpaid interest date redemption event occurrence change control downgrade rating series notes investment grade rating standard poors ratings services moodys investors service inc holders series notes may require us purchase portion notes series price equal aggregate principal amount notes repurchased plus accrued unpaid interest plan use net proceeds fund acquisition pharmasset inc pharmasset announced november completed january see note credit facilities amended restated credit agreement along whollyowned subsidiary gilead biopharmaceutics ireland corporation may borrow aggregate billion revolving credit loans credit agreement also includes subfacility swingline loans letters credit loans credit agreement bear interest interest rate either libor plus margin ranging basis points basis points base rate described credit agreement may reduce commitments may prepay loans credit agreement whole part time without penalty subject certain conditions credit agreement terminate december unpaid borrowings thereunder shall due payable time april connection acquisition cv therapeutics borrowed million credit agreement partially fund acquisition december repaid million credit agreement may borrowed million credit agreement fund stock repurchases august repaid million borrowed credit agreement using proceeds convertible senior notes issued july december million letters credit outstanding billion credit agreement required comply certain covenants credit agreement december compliance covenants subsequently january fully repaid outstanding obligations terminated credit agreement table contents gilead sciences inc notes consolidated financial statementscontinued commitments contingencies lease arrangements entered various longterm noncancelable operating leases equipment facilities lease facilities foster city fremont palo alto san dimas california branford connecticut princeton new jersey seattle washington dublin cork areas ireland london area united kingdom also operating leases sales marketing administrative facilities europe canada asia pacific leases expire various dates many leases containing options renew certain facility leases also contain rent escalation clauses significant lease related facility seattle washington expires year term lease provides us three consecutive rights extend term lease contains annual three percent rent escalation clause lease also requires us pay additional amounts operating expenses maintenance also leases three corporate aircraft varying terms renewal options upon expiration lease terms lease expense operating leases approximately million million million years ended december respectively aggregate noncancelable future minimum rental payments operating leases follows thousands thereafter legal proceedings june received subpoena united states attorneys office northern district california requesting documents related manufacture related quality distribution practices atripla emtriva hepsera letairis truvada viread complera cooperating continue cooperate governmental inquiry estimate possible loss range losses determined given early stage inquiry party various legal actions arose ordinary course business believe legal actions material adverse impact consolidated business financial position results operations commitments normal course business enter various firm purchase commitments primarily related active pharmaceutical ingredients certain inventory related items december commitments next five years approximately million million million million million amounts related active pharmaceutical ingredients represent minimum purchase requirements actual payments purchases related active pharmaceutical ingredients billion million billion years ended december respectively table contents gilead sciences inc notes consolidated financial statementscontinued stockholders equity stock repurchase programs repurchased retired million shares common stock average purchase price per share aggregate purchase price million open market transactions billion stock repurchase program approved board october also received million shares common stock accelerated share repurchase agreement completed march december completed stock repurchases october stock repurchase program january board authorized program repurchase common stock amount billion open market private block transactions pursuant rule b plans privately negotiated purchases means completed plan may time board authorized threeyear billion stock repurchase program december repurchased billion common stock may program remaining authorized amount stock repurchases may made program billion spent total billion repurchase retire million shares common stock average purchase price per share january board authorized threeyear billion stock repurchase program initiated purchases program september upon completion may stock repurchase program december repurchased million common stock january stock repurchase program remaining authorized amount stock repurchases may made plan billion spent total billion repurchase retire million shares common stock average purchase price per share use par value method accounting stock repurchases par value method common stock first charged par value shares involved excess cost shares acquired par value allocated apic based estimated average sales price per issued share excess amounts charged retained earnings result stock repurchases reduced common stock apic aggregate million charged million retained earnings result stock repurchases reduced common stock apic aggregate million charged billion retained earnings result stock repurchases reduced common stock apic aggregate million charged billion retained earnings preferred stock shares authorized preferred stock issuable series board authorized determine designation powers preferences rights series designated shares series junior participating preferred stock potential issuance november rights agreement computershare limited amended rights plan preferred stock outstanding december rights plan rights plan provides distribution preferred stock purchase right dividend share common stock purchase rights currently exercisable certain conditions involving acquisition proposed acquisition person group common stock purchase rights permit holders holder purchase common stock discount market price time upon payment specified exercise price per purchase right addition event table contents gilead sciences inc notes consolidated financial statementscontinued certain business combinations purchase rights permit purchase common stock acquirer discount market price time certain conditions purchase rights may redeemed board whole part price per purchase right purchase rights voting privileges attached automatically trade common stock october october may board approved amendments rights plan first amendment provided among things increase exercise price right plan extension term plan november october second amendment provides among things increase exercise price right plan extension term rights plan october third amendment clarifying amendment entered connection increase designated number shares series junior participating preferred stock potential issuance rights plan may equity incentive plan may stockholders approved adopted gilead sciences inc equity incentive plan plan replaced existing equity plans prior plans remaining shares available future grants prior plans transferred plan additionally awards granted prior plans expire otherwise terminate without exercised shares common stock reserved awards added back pool available shares common stock plan plan broad based incentive plan provides grant equitybased awards including stock options restricted stock units restricted stock awards performance awards employees directors consultants plan authorized issue maximum shares fullvalue awards restricted stock restricted stock units performance shares performance units extend settled common stock phantom shares term plan plan authorizes issuance total shares common stock december shares remain available future grant plan stock options plan provides option grants designated either nonqualified incentive stock options prior january granted nonqualified incentive stock options stock options granted january nonqualified stock options plan employee stock options granted prior generally vest five years stock options granted starting generally vest four years options exercisable period exceed contractual term ten years date stock options issued granted prices less fair market value common stock grant date stock option exercises settled common stock plans previously authorized available pool shares connection acquisition cv therapeutics assumed cv therapeutics equity incentive plan amended restated nonemployee directors stock option plan amended restated equity incentive plan amended restated nonstatutory incentive plan amended restated employee commencement incentive plan amended restated collectively cv therapeutics plans majority options issued outstanding cv therapeutics plans april converted options purchase approximately million shares common stock remain subject original terms conditions shares available future grant cv therapeutics plans table contents gilead sciences inc notes consolidated financial statementscontinued connection acquisition arresto assumed arresto equity incentive plan arresto plan options issued outstanding arresto plan converted options purchase common stock effective january number converted options purchase common stock significant shares available future grant arresto plan following table summarizes activity stock option plans option grants presented table exercise prices less fair value underlying common stock grant date shares thousands year ended december weighted weighted weighted average average average shares exercise price shares exercise price shares exercise price outstanding beginning year granted assumed forfeited expired exercised outstanding end year exercisable end year weightedaverage grant date fair value options granted year total intrinsic value options exercised years ended december million million million respectively total fair value stock options vested years ended december million million million respectively december number options outstanding expected vest net estimated future option forfeitures weighted average exercise price per share aggregate intrinsic value million weightedaverage remaining contractual life years aggregate intrinsic value stock options outstanding stock options exercisable december million million respectively december weightedaverage remaining contractual life options outstanding options exercisable years respectively december million unrecognized compensation cost related stock options expected recognized estimated weightedaverage period years performance awards plan grant performancebased restricted stock units vest upon achievement specified market performance goals relative predetermined peer group actual number common shares ultimately issued calculated multiplying number performance units payout percentage ranging performance awards vest committee subcommittee board determined achieved specified market performance goals january granted performancebased unit awards performance shares table contents gilead sciences inc notes consolidated financial statementscontinued performance shares performance shares respectively awards vest single threeyear performance measurement vesting period performance share awards fair value performance share grant estimated grant date using monte carlo valuation methodology weightedaverage grant date fair values performance shares per share respectively recognized million million million stockbased compensation expenses respectively related performance shares december million unrecognized compensation costs related performance shares expected recognized estimated weightedaverage period years also granted performancebased restricted stock units certain employees plan vesting awards subject achievement specified performance goals number awards issued date significant restricted stock units grant restricted stock units rsus certain employees part annual employee equity compensation review program well new hire employees nonemployee members board rsus share awards entitle holder receive freely tradable shares common stock upon vesting generally rsus vest ratably annual basis five years date grant awards granted prior starting january rsus vest four years date grant fair value rsu equal closing price common stock grant date following table summarizes rsu activities related information thousands except per share amounts year ended december weighted weighted weighted average average average grant grant grant date date date fair value fair value fair value shares per share shares per share shares per share outstanding beginning year granted assumed vested forfeited outstanding end year total fair value rsus vested years ended december million million million respectively december million unrecognized compensation cost related nonvested rsus expected recognized weightedaverage period years employee stock purchase plan employee stock purchase plan amended espp employees purchase shares common stock based percentage compensation subject certain limits purchase price per share equal lower fair market value common stock offering date purchase date espp offers twoyear lookback feature well automatic reset feature provides table contents gilead sciences inc notes consolidated financial statementscontinued offering period reset new lowerpriced offering offering price new offering period less current offering period espp purchases settled common stock espps previously authorized available pool shares shares issued espp million total shares common stock reserved issuance espp shares available issuance espp december december million unrecognized compensation cost related espp expected recognized estimated weightedaverage period years stockbased compensation following table summarizes stockbased compensation expenses included consolidated statements income thousands year ended december cost goods sold research development expenses selling general administrative expenses stockbased compensation expense included total costs expenses income tax effect stockbased compensation expense net tax years ended december capitalized million million million stockbased compensation costs inventory respectively million million million remained inventory december respectively stockbased compensation recognized expense requisite service periods consolidated statements income using graded vesting expense attribution approach unvested stock options granted prior january using straightline expense attribution approach stock options granted adoption new guidance sharebased payments employees directors january stockbased compensation expenses related stock options recognized adoption new guidance based awards ultimately expected vest gross expense reduced estimated forfeitures guidance requires forfeitures estimated time grant revised necessary subsequent periods actual forfeitures differ estimates estimated forfeitures based historical experience prior adoption guidance pro forma information required disclosed included forfeitures occurred result guidance adopted january recognize tax benefit stockbased compensation apic incremental tax benefit realized tax attributes currently available us utilized addition elected account indirect benefits stockbased compensation research tax credit extraterritorial income deduction consolidated statements income rather apic valuation assumptions fair values options granted plan purchases espp estimated grant purchase dates using blackscholes option valuation model blackscholes option valuation model developed use estimating fair value traded options vesting restrictions fully table contents gilead sciences inc notes consolidated financial statementscontinued transferable addition option valuation models require input highly subjective assumptions including expected stock price volatility expected award life used following assumptions calculate estimated fair value awards year ended december expected volatility stock options espp expected term years stock options espp riskfree interest rate stock options espp expected dividend yield fair value stock options granted calculated using single option approach use blend historical volatility along implied volatility traded options common stock determine expected volatility expected term stockbased awards represents weightedaverage period awards expected remain outstanding estimate weightedaverage expected term based historical cancellation historical exercise data related stock options well contractual term vesting terms awards riskfree interest rate based upon observed interest rates appropriate term stockbased awards dividend yield based history expectation dividend payouts comprehensive income loss comprehensive income loss comprises net income certain changes stockholders equity excluded net income changes fair value outstanding effective cash flow hedges changes unrealized gains losses availableforsale securities changes cumulative foreign currency translation account comprehensive income loss years ended december included consolidated statements stockholders equity components comprehensive income loss shown net related taxes underlying assets liabilities held jurisdictions expected generate future tax benefit liability following reclassifications recorded connection net realized gains losses sales securities cash flow hedges previously included comprehensive income loss thousands year ended december net unrealized gain loss related availableforsale securities net tax impact respectively net unrealized gain loss related cash flow hedges net tax impact respectively less reclassification adjustments net tax impact respectively comprehensive income loss table contents gilead sciences inc notes consolidated financial statementscontinued balance accumulated comprehensive income loss net taxes reported consolidated balance sheets consists following components thousands december net unrealized gain loss availableforsale securities net unrealized gain cash flow hedges cumulative foreign currency translation adjustment accumulated comprehensive income segment information product sales operate one business segment primarily focuses development commercialization human therapeutics life threatening diseases products included one segment majority products similar economic characteristics including nature products production processes type customers distribution methods regulatory environment product sales consist following thousands year ended december antiviral products atripla truvada viread hepsera compleraeviplera emtriva total antiviral products ambisome letairis ranexa products total product sales table contents gilead sciences inc notes consolidated financial statementscontinued following table summarizes total revenues external customers collaboration partners geographic region thousands product sales productrelated contract revenue attributed countries based shipto location royalty nonproduct related contract revenue attributed countries based location collaboration partner year ended december united states outside united states france united kingdom spain italy germany switzerland european countries countries total revenues outside united states total revenues following table summarizes revenues customers individually accounted total revenues percentage total revenues year ended december cardinal health inc mckesson corp amerisourcebergen corp property plant equipment december net book value property plant equipment united states ireland canada million million million respectively comprised approximately total net book value property plant equipment december net book value property plant equipment united states ireland canada million million million respectively comprised approximately total net book value property plant equipment table contents gilead sciences inc notes consolidated financial statementscontinued income taxes provision income taxes consists following thousands year ended december federal current deferred state current deferred foreign current deferred provision income taxes foreign pretax income billion billion billion respectively cumulative unremitted foreign earnings considered permanently invested outside united states us taxes provided approximately billion billion december respectively residual us tax liability amounts remitted would approximately billion billion december respectively difference provision income taxes amount computed applying us federal statutory income tax rate income provision income taxes follows thousands year ended december income provision income taxes tax federal statutory rate state taxes net federal benefit foreign earnings different rates research credits net unbenefitted stock compensation provision income taxes table contents gilead sciences inc notes consolidated financial statementscontinued deferred income taxes reflect net tax effects temporary differences carrying amounts assets liabilities financial reporting purposes amounts used income tax purposes significant components deferred tax assets liabilities follows thousands december deferred tax assets net operating loss carryforwards stockbased compensation reserves accruals currently deductible deferred revenue depreciation related research credit carryforwards capitalized intangibles net total deferred tax assets valuation allowance valuation allowance total deferred tax assets deferred tax liabilities intangibles unremitted foreign earnings total deferred tax liabilities net deferred tax assets valuation allowance decreased million year ended december increased million million years ended december respectively concluded based standard set forth fasb accounting standards codification related income taxes likely realize benefit deferred tax assets related certain state net operating loss credit carryforwards december us federal net operating loss carryforwards approximately million federal net operating loss carryforwards start expire utilized also federal tax credit carryforwards approximately million start expire utilized addition state net operating loss tax credit carryforwards approximately billion million respectively state net operating loss tax credit carryforwards start expire utilized utilization net operating losses tax credits may subject annual limitation due ownership change limitations provided internal revenue code amended similar state provisions annual limitation may result expiration net operating losses credits utilization file federal state foreign income tax returns many jurisdictions united states abroad federal income tax purposes statute limitations open onwards certain acquired entities statute limitations open years inception due utilization net operating losses credits carried prior years california income tax purposes statute limitations open onwards table contents gilead sciences inc notes consolidated financial statementscontinued income tax returns audited federal state foreign tax authorities currently examination internal revenue service irs tax years various state foreign jurisdictions differing interpretations tax laws regulations result significant disputes may arise tax authorities involving issues timing amount deductions allocations income among various tax jurisdictions periodically evaluate exposures associated tax filing positions december total federal state foreign unrecognized tax benefits million million respectively total unrecognized tax benefits million million december respectively recognized would reduce effective tax rate period recognition continued classify interest penalties related unrecognized tax benefits part income tax provision consolidated statements income december accrued interest penalties related unrecognized tax benefits million million respectively december believe reasonably possible unrecognized tax benefits significantly change next months expect clarification irs tax authorities around uncertain tax positions following rollforward total gross unrecognized tax benefit liabilities years ended december thousands december balance beginning period tax positions related current year additions reductions tax positions related prior years additions reductions settlements lapse statute limitations balance end period deferred compensation plans maintain retirement savings plan eligible employees may defer compensation income tax purposes section k internal revenue code gilead plan gilead plan employees may contribute eligible annual compensation subject irs plan limits make matching contributions gilead plan contributed employees contributions annual maximum match total matching contribution expense gilead plan years ended december million million million respectively maintain deferred compensation plan directors key employees may defer compensation income tax purposes deferred compensation plan nonqualified deferred compensation plan subject qualification requirements section internal revenue code compensation deferred december subject requirements section internal table contents gilead sciences inc notes consolidated financial statementscontinued revenue code plan officers senior grade level employees may contribute annual salaries annual bonus directors may contribute annual retainer fee effective directors may also defer rsu awards amounts deferred participants deposited rabbi trust recorded noncurrent assets consolidated balance sheets beginning directors may also elect receive portion annual cash retainer phantom shares gives participant right receive amount equal value specified number shares specified period time payable shares common stock fractional shares paid cash established plan administrator december phantom shares outstanding participants elect one several distribution dates available plan receive deferred compensation payment subsequent events acquisition pharmasset inc november entered definitive agreement acquire pharmasset billion cash tender offer subsequent merger transaction closed january time pharmasset became whollyowned subsidiary financed transaction approximately billion cash hand billion bank debt billion senior unsecured notes issued december pharmasset clinicalstage pharmaceutical company located princeton new jersey committed discovering developing commercializing novel drugs treat viral infections pharmassets primary focus development oral therapeutics treatment hcv infection pharmassets research development efforts focused nucleosidetide analogs class compounds act alternative substrates viral polymerase thus inhibiting viral replication believe acquisition provide us opportunity complement existing hcv portfolio help advance effort develop alloral regimens treatment hcv pharmassets lead compound nucleotide analog hcvinfected individuals across genotypes known gs gs evaluated phase clinical studies expect receive significant amount data clinical trials evaluating gs february announced data indicates gs ribavirin treatment genotype patients prior null response interferoncontaining regimen weeks sufficient cure disease currently conducting additional phase studies hcv infected genotype patients including treatment nave patients results expect end first quarter second quarter early third quarter currently process valuing assets acquired liabilities assumed business combination upon completion valuation analysis expect provide amounts recognized acquisition date major classes assets acquired liabilities assumed bank debt january conjunction acquisition pharmasset entered fiveyear billion revolving credit facility credit agreement fiveyear revolving credit agreement million shortterm revolving credit facility credit agreement shortterm revolving credit agreement billion term loan facility term loan credit agreement borrowed million fiveyear revolving credit agreement million shortterm revolving credit agreement billion term loan credit agreement upon close acquisition table contents gilead sciences inc notes consolidated financial statementscontinued loans fiveyear revolving credit agreement shortterm revolving credit agreement term loan credit agreement bear interest either eurodollar rate plus applicable margin ii base rate plus applicable margin defined applicable credit agreement may reduce commitments may prepay loans agreements whole part time without premium penalty fiveyear revolving credit agreement inclusive million swing line loan subfacility million letter credit subfacility five year revolving credit agreement terminate amounts owing thereunder shall due payable january shortterm revolving credit agreement terminate amounts owing thereunder shall due payable january however may request maturity date extended january principal repayment installments term loan credit agreement due payable specified term loan credit agreement final principal installment payment due payable january quarterly results operations unaudited following amounts thousands except per share amounts st quarter nd quarter rd quarter th quarter total revenues gross profit product sales net income net income attributable gilead net income per share attributable gilead common stockholdersbasic net income per share attributable gilead common stockholdersdiluted total revenues gross profit product sales net income net income attributable gilead net income per share attributable gilead common stockholdersbasic net income per share attributable gilead common stockholdersdiluted fourth quarter recorded million impairment charges rd expense related certain iprd assets acquired cgi see notes fourth quarter recorded million impairment charges rd expense related certain iprd assets acquired cv therapeutics see notes table contents gilead sciences inc schedule ii valuation qualifying accounts thousands balance additions balance beginning charged end period expense deductions period year ended december accounts receivable allowances valuation allowances deferred tax assets year ended december accounts receivable allowances valuation allowances deferred tax assets year ended december accounts receivable allowances valuation allowances deferred tax assets allowances doubtful accounts sales returns cash discounts chargebacks valuation allowance deferred tax assets includes million million december respectively related acquisitions table contents